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Stroke ranks second as a cause of death worldwide and is a leading cause 
of disability in high-income countries. Treatment of ischemic stroke 
and intracerebral hemorrhage has remained unsatisfactory. Apart 
from stroke unit care, intravenous thrombolysis with recombinant 
tissue-plasminogen activator and aspirin are efficacious in patients 
with ischemic stroke, and there is no treatment for intracerebral 
hemorrhage with proven efficacy. Safe, cheap, and broadly applicable 
therapies for acute stroke are needed.
Over the past years, evidence has accumulated that inflammation plays 
a role in the pathophysiology of acute stroke. Body temperature and 
classic acute-phase reactants are modified by this inflammatory reaction, 
and both may be useful in the prediction of the prognosis after stroke 
and as therapeutic targets. This thesis focuses on body temperature and 
temperature-lowering therapy in acute stroke. A secondary aim is to 
further expand the knowledge on inflammation in relation to prognosis 
and treatment in acute stroke.  
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Safe, cheap, and broadly applicable therapies for acute stroke are urgently needed. 
Stroke ranks second as a cause of death worldwide and is the main cause of disability in 
high-income countries. In the Netherlands alone, more than 37.000 patients are admit-
ted to hospital for acute stroke each year.1 As the incidence of stroke rises exponentially 
with age, the demographic change in world’s population will increase its socio-economic 
impact. 
Strokes are either ischemic or hemorrhagic. Treatment of ischemic stroke and intra-
cerebral hemorrhage has remained unsatisfactory. Stroke unit care has been proven 
effective for all stroke patients, with an absolute risk reduction of death of 3% and long-
term dependency of 5%.2 In patients with ischemic stroke, treatment with recombinant 
tissue-plasminogen activator (rt-PA) reduces the number of patients with poor outcome 
at three months by about 9%3, 4, but the short time window for administration (4.5 hours) 
and the associated bleeding risk restrict treatment with rt-PA to a minority of patients. 
Surgical decompression improves outcome in a very small selected group of patients 
aged up to 60 years who deteriorate because of space-occupying edema within 48 hours 
of stroke onset.5 Aspirin, started within 48 hours of symptom onset, is probably effective 
across the entire range of patients with ischemic stroke, but the benefit is small, with a 
number needed to treat of 79 to prevent death or dependency in a single patient.6 
ETIOLOGY OF STROKE
Ischemic stroke accounts for about 80% of all strokes and results from a transient or 
permanent reduction of cerebral blood flow caused by occlusion of a cerebral artery or 
arteriole. Stroke registries usually fail to identify a definite cause of ischemic stroke in up 
to a third of patients, depending on the quality, completeness, and rapidity of the work-
up, but also on the definition of “cause”.7 The most common causes are atherothrombosis 
and embolism from the heart.8 Atherothrombotic stroke can be subdivided into large 
vessel disease, including the carotid and vertebral arteries, medium vessel disease, and 
small vessel disease of the small penetrating arteries perfusing the brain stem and the 
deep structures of the cerebral hemispheres. The most common sites of atheroma are 
artery branch points, especially in the distribution of the internal carotid artery, curva-
ture and confluence.9 Atherothrombotic stroke is caused by either embolism from the 
carotid or vertebral artery to a distal smaller calibre intracranial vessel or local intracranial 
thrombotic arterial occlusion. In practice, it may be very difficult to differentiate between 
these two, and in many patients various lesions at different sites are found. 
Emboli may arise from the heart, most frequently due to atrial fibrillation. Less com-
mon are recent myocardial infarction, dilated cardiomyopathy, infective endocarditis, 
prosthetic valves, and emboli from the right-sided circulation with subsequent passage 
through a patent foramen ovale.9 Stroke can also rarely result from inadequate cerebral 
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blood flow due to a severe fall in blood pressure, for instance after cardiac arrest, or 
from other rare disorders, syndromes, and diseases such as the moyamoya syndrome, 
moyamoya disease, hypercoagulable disorders, fibromuscular dysplasia, dissection, and 
vasculitis.9 
Hemorrhagic stroke represents about 20% of all strokes and is caused by rupture of a 
blood vessel in the brain. There are two main types of hemorrhagic strokes: intracerebral 
hemorrhage (15%) and subarachnoid hemorrhage (5%). The latter is beyond the scope 
of this thesis. Intracerebral hemorrhages are most frequently caused by hypertension 
or amyloid angiopathy. Other causes of intracerebral hemorrhage include coagulation 
disorders, arteriovenous and other vascular malformations, vasculitis, and primary or 
metastatic brain tumors.9
PATHOPHYSIOLOGY OF ACUTE STROKE
In order to establish new potential treatment targets, detailed knowledge of the natural 
course of the disease is required. In both ischemic stroke and intracerebral hemorrhage, 
a complex cascade of pathophysiological events that evolve over time and space may 
contribute to tissue damage. 
Underlying mechanisms of damage during and following ischemic stroke
The extent of ischemic damage depends on both the severity and duration of cerebral 
ischemia. In the core of the ischemic area, cerebral blood flow is reduced to 0-10 ml/100 
g brain tissue per minute.10 This will result in necrosis of neurons and also of support-
ing cellular elements (glial cells) within a few minutes. The infarct core is surrounded 
by the so-called ischemic penumbra, which may be considered as ischemic tissue that 
is functionally impaired and at risk of infarct, but has the potential to be salvaged by 
reperfusion. In the penumbra, processes including excitotoxicity, radical formation, lipid 
peroxidation, and inflammation may lead to cell damage and cell death.11 
Although there is ample evidence that the penumbra exists in patients with ischemic 
stroke12-14, the extent and temporal dynamics of this area are less well defined and prob-
ably vary between individuals.
Ischemic stroke and inflammation
There is substantial evidence that inflammation is important in the pathophysiology of 
ischemic stroke, particularly after reperfusion. Inflammation plays a pivotal role in tissue 
recovery, but it may also have unfavorable effects. Within a few minutes to hours of re-
duction of cerebral blood flow, proinflammatory genes are upregulated, including those 
for transcription factors, heat shock proteins, cytokines, chemokines and adhesion mol-
13
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ecules.15 Locally produced cytokines including interleukin-6 (IL-6), interleukin-1b (IL-1b), 
and tumor necrosis factor-a (TNF-a), produced by microglia, astrocytes, endothelial cells, 
and neurons, mediate these inflammation processes.16, 17 As a consequence, leucocytes 
are activated, and stimulate the release of chemokines, and upregulation of comple-
mentary adhesion molecules on cerebral microvessels and circulating leucocytes.17 In 
acute ischemic stroke, inflammation may augment tissue damage by disruption of the 
blood-brain barrier, release of cytotoxic agents, activation of the complement system, 
edema resulting from endothelial cell injury and leukocyte-mediated injury, microvas-
cular thrombosis and increased body temperature.18 The inflammatory reaction may last 
for several days. The general hypothesis is that the acute inflammatory reaction is det-
rimental, while the chronic phase inflammation is essential for repair and regeneration.
Underlying mechanisms of damage during and following intracerebral hemorrhage
The pathological consequences of intracerebral hemorrhage include the immediate 
injury and delayed secondary processes. The former results from physical disruption 
of adjacent tissue and mass effect. Mechanical forces during hematoma formation or 
chemical toxicity from the clot might result in necrosis. The hematoma increases in size in 
about a third of the patients during the first 24 hours.19 Early hematoma growth may be a 
dynamic process, with continued bleeding or rebleeding occurring at multiple sites.19
Perihematomal brain edema develops immediately after intracerebral hemorrhage 
and peaks several days later.20 The mechanisms of how edema contributes to tissue dam-
age are not well understood. Previously, swelling of the tissue was thought to lead to 
ischemia of the surrounding brain parenchyma.21 These ischemic areas were believed to 
trigger an inflammatory reaction, producing vasogenic edema. However, more recent 
studies showed that the blood flow to these areas was unchanged.22, 23 It is now thought 
that end-products of coagulation activate the inflammatory cascade which in turn leads 
to vasogenic edema, cytotoxic edema, and disruption of the blood-brain barrier, and 
thereby amplifyies the damage caused by the hematoma.24 It is also possible that the 
hematoma itself actively induces pathways that lead to tissue damage. These pathways 
include thrombin produced during clot formation and iron released from hemoglobin.25, 26
Intracerebral hemorrhage and inflammation
There is growing evidence that inflammation is involved in the pathophysiology of intrace-
rebral hemorrhage as well. In animal studies, intracerebral hemorrhage initiated a microglial 
response, followed by activation of systemic neutrophils and other leucocytes.27 Molecules 
related to adhesion of leucocytes to the endothelium are upregulated. Consequently, 
leucocytes migrate across the blood-brain barrier to the site of injury.27 In addition, the 
complement system may also play a role in tissue injury after intracerebral hemorrhage.28
14
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INFLAMMATORY PARAMETERS AND PROGNOSIS AFTER STROKE
In patients with first-ever stroke, case fatality ranges between 12% within the first seven 
days to 19% in the first three months, and is highest in intracerebral hemorrhage.29, 30 
Between 50% and 70% of patients regain functional independence after a stroke.31
The patient’s age, pre-stroke health status, stroke type and indicators of stroke severity 
(conscious level, lesion volume and severity of neurological impairments) determine the 
likelihood of survival and good functional recovery.32-34 Recurrent stroke33, secondary 
complications related to the stroke including the occurrence of infections35 and venous 
thrombosis36 and physiological parameters such as level of serum glucose, blood pressure, 
and oxygen37-39 have been reported to be related to outcome after stroke. In addition, the 
cause of stroke may affect the prognosis and the likelihood of recurrent events.40, 41
The central role of inflammation in the pathogenesis of neuronal damage following 
acute stroke, suggests a prognostic role of inflammatory parameters such as body tem-
perature and C-reactive protein (CRP). 
Identifying new prognostic factors may have a two-fold aim. It may be useful, both 
for the prediction of functional outcome and stimulating research into the underlying 
pathogenetic mechanisms and development of new, more targeted, medical treatments 
for acute stroke.
MEASURING OUTCOME AFTER ACUTE STROKE
Most phase III stroke trials have used the degree of dependency or death as their main 
outcome measures. Commonly used outcome scales for assessing dependency are the 
modified Rankin Scale (mRS)42 and Barthel Index (BI)43. The BI is an activity of daily living 
scale and measures the degree of disability on 10 different items (see appendix). The 
cumulative score ranges from 0 to 20, with 20 indicating no disability and 0 indicating 
complete dependence. The mRS quantifies dependency using an ordinal hierarchical 
grading from 0 (no symptoms) to 5 (severe disability). Sometimes 6 (death) is added to 
facilitate statistical analysis and interpretation (see appendix).
In previous stroke trials, both the mRS and BI have been collapsed to a binary outcome 
of favorable versus unfavorable. This approach of dichotomizing an ordinal outcome 
scale has several disadvantages. It may not correspond with everyday clinical practice. 
Most treatment strategies tested in acute stroke trials are not expected to be completely 
curative, but to lead to improvement. Therefore, it is also informative to show that treat-
ment moves patients from severe to moderate disability or from moderate disability to 
complete recovery, and not only to demonstrate differences in the numbers of patients 
with a good or poor functional outcome. Furthermore, dichotomization may limit statis-
tical power. Typically, the sample size calculation of a phase III stroke trial assumes that 
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each patient in the placebo group has a 50% probability of poor outcome at 3 months. 
In practice, there will be substantial prognostic heterogeneity because of differences in 
baseline variables between patients. If this is not taken into account, the chance of find-
ing a true treatment effect may be reduced. 
Because of these disadvantages of dichotomization, new approaches to outcome 
analysis have been proposed and tested in acute stroke trials.44-48 These novel outcome 
analyses consider the full range of the ordinal outcome scale and lead to a single and 
meaningful estimate of the treatment effect. One of these new approaches is the so-
called “sliding dichotomy”.46 Analysis by sliding dichotomy allows each patient’s baseline 
prognosis to be taken into account. The outcome of an individual patient is thus regarded 
as favorable or unfavorable depending on what would have been expected based on the 
severity of stroke and other prognostic factors. 
A PROMISING TREATMENT MODALITY IN ACUTE STROKE
The development of therapies for acute stroke has proven to be a difficult and a chal-
lenging task, reflecting the complexity of the pathophysiology and clinical aspects of this 
heterogeneous disorder. 
Subfebrile temperature or fever is present in about a third of patients on the first 
day after stroke onset.49, 50 The pathophysiology of this increase in body temperature is 
not completely understood. On the one hand, increased body temperature may be a 
natural consequence of brain infarction. However, animal studies have suggested that 
high body temperatures may increase the damage induced by cerebral ischemia.51 An 
association between increased body temperature and poor outcome has also been 
shown in patients with acute stroke.49, 50, 52-59 The odds of poor outcome were doubled for 
every degree increase in body temperature measured within 12 hours of stroke onset.50 
Therefore, reduction of body temperature and prevention of fever might be a promising 
approach in treatment to improve functional outcome after stroke. The background and 
existing evidence of this treatment modality will be discussed in Chapter 2. 
Based on the existing evidence, we started the Paracetamol (Acetaminophen) In 
Stroke (PAIS) trial.60 In this trial, we assessed whether early treatment with high-dose 
paracetamol improves functional outcome in patients with acute stroke. The majority of 
the studies described in this thesis are based on the PAIS trial.
16
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AIMS AND OUTLINE OF THE THESIS
This thesis focuses on body temperature and temperature-lowering therapy in acute 
stroke. A secondary aim is to further expand the knowledge on inflammation in relation 
to prognosis and treatment in acute stroke. 
Chapter 2 gives a general review of the literature concerning temperature-lowering 
therapy and discusses the existing evidence in terms of feasibility and effectiveness of 
this treatment strategy in acute stroke. Chapter 3 focuses on the effect of pharmacologi-
cal temperature-lowering therapy by paracetamol in acute stroke. For the PAIS trial, we 
decided to change the planned analysis for the primary outcome measure from a fixed 
dichotomy of the mRS to a sliding dichotomy analysis. Chapter 3.1 describes the protocol 
change. The main results of the PAIS trial are presented in Chapter 3.2. In Chapter 3.3, 
the prognostic role of body temperature in acute stroke is further explored. Besides its 
antipyretic and analgesic properties, high-dose paracetamol may have indirect effects. 
Chapter 3.4 describes the effects of high-dose paracetamol on blood pressure. Chapter 
4.1 evaluates the prognostic value of CRP on clinical outcome in patients with acute 
stroke. Since levels of inflammatory markers may be partially genetically determined, 
we examined haplotypes representing common variations in the CRP gene in relation to 
levels of CRP in acute ischemic stroke in Chapter 4.2
In Chapter 5, a first step into further research in acute stroke aimed at integrating basic 
and clinical science is presented.
The implications of the studies described in this thesis on patient care and future 
research are discussed in Chapter 6. Finally, the results of the studies are summarized in 
Chapter 7. 
17
 G
eneral introduction 
1
REFERENCES
 1.  Vaartjes I. Hart-en vaatziekten in Nederland 2008. Nederlandse Hartstichting, 2008. 
 2.  Govan L, Weir CJ, Langhorne P. Organized Inpatient (Stroke Unit) Care for Stroke. Stroke 2008 Epub.
 3.  Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic 
stroke. N Engl J Med 2008; 359:1317-1329.
 4. Wardlaw JM, Zoppo G, Yamaguchi T et al. Thrombolysis for acute ischaemic stroke. Cochrane 
Database Syst Rev 2003; 3:CD000213.
 5.  Hofmeijer J, Kappelle LJ, Algra A et al. Surgical decompression for space-occupying cerebral 
infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening 
Edema Trial [HAMLET]): a multicenter, open, randomised trial. Lancet Neurol 2009; 8:326-333.
 6.  Sandercock PA, Counsell C, Gubitz GJ et al. Antiplatelet therapy for acute ischaemic stroke. Co-
chrane Database Syst Rev 2008; 3:CD000029.
 7.  Amarenco P, Bogousslavsky J, Caplan LR et al. Classification of stroke subtypes. Cerebrovasc Dis 
2009; 27:493-501.
 8.  Bousser MG, Amarenco P, Chamorro A et al. Rationale and design of a randomized, double-blind, 
parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the 
prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in pa-
tients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc 
Dis 2009; 27:509-518.
 9.  Warlow C, van Gijn J, Sandercock P. Stroke, practical managment. 2008. 
 10.  Heiss WD. Flow thresholds of functional and morphological damage of brain tissue. Stroke 1983; 
14:329-331.
 11.  Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab 
Brain Dis 2004; 19:151-167.
 12.  Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 
2000; 20:1276-1293.
 13.  Kidwell CS, Alger JR, Saver JL. Evolving paradigms in neuroimaging of the ischemic penumbra. 
Stroke 2004; 35:2662-2665.
 14.  Wintermark M, Reichhart M, Thiran JP et al. Prognostic accuracy of cerebral blood flow measure-
ment by perfusion computed tomography, at the time of emergency room admission, in acute 
stroke patients. Ann Neurol 2002; 51:417-432.
 15. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel thera-
peutics. J Cereb Blood Flow Metab 1999; 19:819-834.
 16.  Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184:53-
68.
 17.  Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response 
in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 
139:93-101.
 18.  del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? Arch Neurol 2001; 
58:669-672.
 19. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hem-
orrhage. N Engl J Med 2005; 352:777-785.
 20.  Zazulia AR, Diringer MN, Derdeyn CP et al. Progression of mass effect after intracerebral hemor-
rhage. Stroke 1999; 30:1167-1173.
18
1
 21.  Yang GY, Betz AL, Chenevert TL et al. Experimental intracerebral hemorrhage: relationship be-
tween brain edema, blood flow, and blood-brain barrier permeability in rats. J Neurosurg 1994; 
81:93-102.
 22.  Siddique MS, Fernandes HM, Wooldridge TD et al. Reversible ischemia around intracerebral hemor-
rhage: a single-photon emission computerized tomography study. J Neurosurg 2002; 96:736-741.
 23.  Mayer SA, Lignelli A, Fink ME et al. Perilesional blood flow and edema formation in acute intrace-
rebral hemorrhage: a SPECT study. Stroke 1998; 29:1791-1798.
 24.  Zhang X, Li H, Hu S et al. Brain edema after intracerebral hemorrhage in rats: the role of inflamma-
tion. Neurol India 2006; 54:402-407.
 25. Xi G, Wagner KR, Keep RF et al. Role of blood clot formation on early edema development after 
experimental intracerebral hemorrhage. Stroke 1998; 29:2580-2586.
 26.  Huang FP, Xi G, Keep RF et al. Brain edema after experimental intracerebral hemorrhage: role of 
hemoglobin degradation products. J Neurosurg 2002; 96:287-293.
 27.  Wang J, Dore S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 
27:894-908.
 28.  Yang S, Nakamura T, Hua Y et al. The role of complement C3 in intracerebral hemorrhage-induced 
brain injury. J Cereb Blood Flow Metab 2006; 26:1490-1495.
 29.  Dennis MS, Burn JP, Sandercock PA et al. Long-term survival after first-ever stroke: the Oxfordshire 
Community Stroke Project. Stroke 1993; 24:796-800.
 30.  Hardie K, Hankey GJ, Jamrozik K et al. Ten-year survival after first-ever stroke in the perth com-
munity stroke study. Stroke 2003; 34:1842-1846.
 31.  Hardie K, Hankey GJ, Jamrozik K et al. Ten-year risk of first recurrent stroke and disability after 
first-ever stroke in the Perth Community Stroke Study. Stroke 2004; 35:731-735.
 32.  Hankey GJ, Jamrozik K, Broadhurst RJ et al. Long-term disability after first-ever stroke and related 
prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002; 33:1034-1040.
 33.  Hankey GJ, Spiesser J, Hakimi Z et al. Rate, degree, and predictors of recovery from disability fol-
lowing ischemic stroke. Neurology 2007; 68:1583-1587.
 34.  Lewis SC, Sandercock PA, Dennis MS. Predicting outcome in hyper-acute stroke: validation of a 
prognostic model in the Third International Stroke Trial (IST3). J Neurol Neurosurg Psychiatry 2008; 
79:397-400.
 35.  Aslanyan S, Weir CJ, Diener HC et al. Pneumonia and urinary tract infection after acute ischaemic 
stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 2004; 11:49-53.
 36.  Andre C, de Freitas GR, Fukujima MM. Prevention of deep venous thrombosis and pulmonary 
embolism following stroke: a systematic review of published articles. Eur J Neurol 2007; 14:21-32.
 37.  Baird TA, Parsons MW, Phanh T et al. Persistent poststroke hyperglycemia is independently associ-
ated with infarct expansion and worse clinical outcome. Stroke 2003; 34:2208-2214.
 38. Leonardi-Bee J, Bath PM, Phillips SJ et al. Blood pressure and clinical outcomes in the International 
Stroke Trial. Stroke 2002; 33:1315-1320.
 39.  Rowat AM, Dennis MS, Wardlaw JM. Hypoxaemia in acute stroke is frequent and worsens outcome. 
Cerebrovasc Dis 2006; 21:166-172.
 40.  Kolominsky-Rabas PL, Weber M, Gefeller O et al. Epidemiology of ischemic stroke subtypes accord-
ing to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a 
population-based study. Stroke 2001; 32:2735-2740.
 41.  Petty GW, Brown RD, Whisnant JP et al. Ischemic stroke subtypes : a population-based study of 
functional outcome, survival, and recurrence. Stroke 2000; 31:1062-1068.
 42.  van Swieten JC, Koudstaal PJ, Visser MC et al. Interobserver agreement for the assessment of 
handicap in stroke patients. Stroke 1988; 19:604-607.
19
 G
eneral introduction 
1
 43.  Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J 1965; 14:61-65.
 44. Bath PM, Gray LJ, Collier T et al. Can we improve the statistical analysis of stroke trials? Statistical 
reanalysis of functional outcomes in stroke trials. Stroke 2007; 38:1911-1915.
 45.  Joffe MM, Greenland S. Standardized estimates from categorical regression models. Stat Med 1995; 
14:2131-2141.
 46. Murray GD, Barer D, Choi S et al. Design and analysis of phase III trials with ordered outcome scales: 
the concept of the sliding dichotomy. J Neurotrauma 2005; 22:511-517.
 47.  Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in 
acute stroke trials. Neurology 2009; 72:1310-1315.
 48.  Whitehead J. Sample sizes calculations for ordered categorical data. Stat Med 1996;15:1065-1066.
 49.  Castillo J, Davalos A, Marrugat et al. Timing for fever-related brain damage in acute ischemic 
stroke. Stroke 1998; 29:2455-2460.
 50.  Reith J, Jorgensen HS, Pedersen PM et al. Body temperature in acute stroke: relation to stroke 
severity, infarct size, mortality, and outcome. Lancet 1996; 347:422-425.
 51.  Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. 
Stroke 1998; 29:529-534.
 52.  Azzimondi G, Bassein L, Nonino F et al. Fever in acute stroke worsens prognosis. A prospective 
study. Stroke 1995; 26:2040-2043.
 53.  Boysen G, Christensen H. Stroke Severity Determines Body Temperature in Acute Stroke. Stroke 
2001; 32:413-417.
 54.  Ernon L, Schrooten M, Thijs V. Body temperature and outcome after stroke thrombolysis. Acta 
Neurol Scand 2006; 114:23-28.
 55.  Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome : a meta-analysis of 
studies in patients. Stroke 2000; 31:410-414.
 56.  Hindfelt B. The prognostic significance of subfebrility and fever in ischaemic cerebral infarction. 
Acta Neurol Scand 1976; 53:72-79.
 57.  Jorgensen HS, Reith J, Pedersen PM et al. Body temperature and outcome in stroke patients. Lancet 
1996; 348:193.
 58.  Schwarz S, Hafner K, Aschoff A et al. Incidence and prognostic significance of fever following 
intracerebral hemorrhage. Neurology 2000; 54:354-361.
 59.  Wang Y, Lim LL, Levi C et al. Influence of admission body temperature on stroke mortality. Stroke 
2000; 31:404-409.
 60.  den Hertog HM, van der Worp HB, van Gemert HM et al. The Paracetamol (Acetaminophen) In 
Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 
2009; 8:434-440.

Chapter 2
Introduction to 
temperature-
lowering therapy

Temperature-lowering 
therapy in acute 
ischemic stroke
Background, feasibility, 
and effectiveness
 
 
 
Based on Expert Rev Neurotherapeutics 2007; 7:155-164
Heleen M den Hertog¹, H Bart van 
der Worp², H Maarten A van Gemert³, 
Diederik WJ Dippel¹
¹Department of Neurology, Erasmus MC 
University Medical Center, Rotterdam, 
The Netherlands 
²Department of Neurology, Rudolph 
Magnus institute of Neuroscience, 
University Medical Center Utrecht, Utrecht, 
The Netherlands
³Department of Neurology, Meander 
Medical Center, Amersfoort, 
The Netherlands
abstract
ABSTRACT
Increased body temperatures are common in the acute phase of stroke. Experimental 
and clinical studies have suggested that increased body temperatures are related to poor 
outcome. In animal studies of focal cerebral ischemia, early hypothermia consistently 
reduced infarct volume. Based on these findings, several phase II clinical trials have been 
performed to study physical methods to reduce body temperature in patients with acute 
stroke. The feasibility and safety of these methods have not yet been established with 
sufficient certainty. Pharmacological lowering of body temperature may be an attractive 
alternative approach. In guidelines for the treatment of acute stroke, antipyretics are 
generally recommended to reduce fever, although their effect on functional outcome 
is unknown. There is currently no evidence from randomized trials to support routine 
use of physical or pharmacological strategies to lower body temperature in acute stroke. 
Large randomized clinical trials are needed to study the effect of both physical and phar-
macological temperature-lowering therapy on functional outcome after stroke.
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INTRODUCTION 
The incidence of stroke in Europe and North America ranges from 200 to 300 per 
100.000 inhabitants.1 As the world’s population continues to age, stroke will become 
an increasingly important health problem. The large numbers of affected patients call 
for effective treatments that are easy to administer, cost-effective, and do not exceed 
health care budgets. Unfortunately, treatment of acute ischemic stroke and intracerebral 
hemorrhage has remained unsatisfactory. Aspirin, administered within 48 hours of stroke 
onset, is available for almost all patients but reduces the risk of disability or death by only 
1%.2 Intravenous thrombolysis with recombinant tissue-plasminogen activator (rt-PA) 
administered within three hours increases the probability of a good outcome by 10%, 
but only a limited number of patients will benefit from this treatment because of the 
small therapeutic time window and various contra-indications for treatment. No other 
treatment strategies have been proven effective in acute ischemic stroke.3
One approach to investigate new treatment concepts is to influence physiologic pa-
rameters that are known to be associated with outcome after stroke, including serum 
glucose levels4 blood pressure5, oxygen saturation6, and body temperature.7-12.  
Body temperature is increased in many patients with acute ischemic stroke. In this 
Chapter, I will explore the evidence from experimental and observational studies 
that higher body temperatures in the first hours after stroke are associated with poor 
functional outcome. Increased body temperature may be a direct consequence of brain 
infarction or a result of accompanying infections. Animal studies have suggested that 
elevated body temperatures increase the damage induced by cerebral ischemia and 
that hypothermia improves histological and functional outcome. For this reason, early 
temperature-lowering therapy may protect brain tissue from damage incurred by cere-
bral ischemia. This is a concept that holds promise for neurotherapeutic interventions. 
In this Chapter, I will summarize the results of both animal and clinical studies of 
temperature-lowering therapy in acute ischemic stroke. I will provide a critical analysis 
of the conflicting results of trials of hypothermia in patients after cardiac arrest and in 
patients with severe traumatic brain injury. 
One of the challenges is to find an intervention that is safe and easy to administer. 
This may not necessarily be physical temperature reduction. Pharmacological lowering 
of body temperature may be an attractive alternative approach. However, most known 
agents, such as antipyretics, have a rather small effect on body temperature and it may 
be questioned whether this could translate into a worthwhile effect on outcome. Stud-
ies that evaluate the effect of temperature-lowering therapy on functional outcome in 
acute ischemic stroke are scarce. In the last 10 years, experimental studies and clinical 
observations have shown an association between increased body temperature and poor 
outcome in acute stroke. Has the evidence in favor of a causal relationship between body 
temperature and outcome become strong enough to provide a rationale for phase III 
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studies? Or is the evidence as it stands a sufficient argument to combat fever and el-
evated body temperature on a regular basis, without further data from clinical trials?
INCREASED BODY TEMPERATURE AND STROKE SEVERITY: CAUSE, 
CONSEQUENCE, OR BOTH?
Increased body temperature after ischemic stroke may be a direct consequence of the 
brain damage inflicted by the stroke. Some animal experiments have indeed shown a 
spontaneous increase in body temperature following cerebral ischemia.13,14 In the early 
phase of ischemia and reperfusion, inflammation processes ensue in the ischemic core 
and in the penumbra, where perfusion is compromised but tissue is still viable.15,16 
Numerous pro-inflammatory genes are upregulated, including those for transcription 
factors, heat shock proteins, cytokines, chemokines and adhesion molecules. The classic 
pro-inflammatory cytokines interleukin-1b (IL-b), interleukin-6 (IL-6), and Tumor Necrosis 
Factor (TNF) produced by microglia, astrocytes, endothelial cells, and neurons, mediate 
these inflammation processes. They activate leucocytes, chemokines are released, and 
complementary adhesion molecules on cerebral microvessels and circulating leucocytes 
are upregulated.8,17 It has been suggested that increased body temperature is a result of 
this inflammatory reaction. In patients with acute ischemic stroke, a positive correlation 
was observed between increased plasma IL-6 levels and body temperature.18,19 
Increased body temperature may not be only a consequence of cerebral ischemia; 
already in 1990, a controlled study with 21 rats first suggested an adverse effect of hy-
perthermia on histopathological outcome after global ischemia.20
It has been suggested that an increased body temperature in the early phase after 
stroke worsens ischemic damage by several mechanisms. First, the imbalance in the 
ischemic tissue between energy supply and demand may increase with higher body 
temperatures, as the metabolic rate of the brain increases.21 In a cat model of global 
cerebral ischemia, an enhanced degree of intracellular acidosis and an impaired recovery 
of cerebral ATP and phosphocreatinine levels was observed when a body temperature 
of 40 °C was induced one hour before ischemia and maintained for 1.5-2 hours.22 After 
global cerebral ischemia, rats with a body temperature of 39°C had a less complete re-
covery of ATP levels and adenylate energy charge in both cortical and subcortical regions 
compared to rats with lower body temperatures.23
Secondly, the release of glutamate increases with rising body temperature, which is 
associated with poor outcome in ischemic stroke. In a microdialysis study of 20-minute 
forebrain ischemia, normothermic rats (37°C) showed a 21-fold increase in glutamate 
levels during ischemia, whereas the increase of glutamate at 39°C was 37-fold.24 In rats 
subjected to 2-hour focal cerebral ischemia at a body temperature of 39°C, glutamate 
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release in the penumbral cortex averaged 31-fold above baseline, compared with 6.5 fold 
elevations in rats with normal body temperatures.25 
Thirdly, increased body temperature may result in an increased production of free 
radicals. In rats, oxygen radical production in the cortex during early recirculation after 
global cerebral ischemia was influenced by brain temperature.26 In rats with brain tem-
peratures of 39°C, free radical production was increased 4 to 5 fold. In rats with brain 
temperatures of 36°C, free radical production was 2 to 3 times increased. In rats with 
brain temperatures of 30°C, free radicals were not elevated at all.
Fourthly, the extent of injuries to the blood brain barrier by ischemia is modulated by 
body and brain temperature. A mild to moderate increase in body temperature leads to 
massive extravasation of protein tracers in ischemic tissue.27-29
It is therefore conceivable that increased body temperatures following stroke are not 
only a consequence of brain infarction, but increase ischemic damage as well. Timely 
temperature-lowering therapy may therefore protect brain tissue from the effects of 
cerebral ischemia.
CLINICAL EFFECTS OF INCREASED BODY TEMPERATURE AFTER STROKE IN 
MAN
Body temperature is increased in a considerable number of patients with acute stroke. 
Within the first six hours after onset, the proportion of patients with elevated body tem-
peratures (over 37.5°C) has been reported to vary from 4 to 25%, but this may increase to 
about 33% at 24 hours (Table 1).
The correlation between body temperature (measured rectally or in the bladder) and 
brain temperature has been studied in 8 patients with traumatic brain injury.30 Deep brain 
temperature was found to be 1-2°C higher than rectal and bladder temperatures. Differ-
ences were greatest when the rectal or bladder temperatures were above 38°C.30 As tem-
peratures in patients with acute stroke are usually assessed with rectal, bladder, or tympanic 
thermometry, the brain temperature in these patients may have been underestimated.
Several studies have investigated the relation between body temperature and out-
come after stroke.7-11 In an early retrospective study of 110 patients admitted within 24 
hours of stroke onset, body temperatures between 37.5°C and 38°C during the first days 
Table 1: Body temperature in patients with acute stroke.
Author (reference) Number of 
patients
Stroke type Body temperature on admission 
> 37.5°C 
Time of admission
Reith et al 390 Isch. / Hem. 25 % < 6 hours
Castillo et al 260 Isch. 3.8 % / 37 % < 6 hours/ <24 hours
Azzimondi et al 183 Isch. / Hem. 15 % < 24 hours
Boysen et al 647 Isch. / Hem. 5.4 % < 6 hours
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after stroke were associated with poor outcome.9 However, potential confounders, such 
as age, infarct size, and infection were not taken into account. In a prospective study 
of 260 patients with ischemic stroke, body temperatures over 37,5°C within the first 72 
hours were associated with increased mortality, and similar temperatures within the first 
24 hours were associated with poor outcome and larger infarct volume independent of 
age and infections.8 In a prospective study of 183 patients with ischemic stroke admitted 
within 6 hours of stroke onset, a relation between body temperatures over 37,5°C within 
7 days after admission and mortality at 30 days or 3 months was found.7 This relation was 
independent of age, level of consciousness, and blood glucose levels. A retrospective 
study of 509 patients with ischemic or hemorrhagic stroke showed a significant relation 
between increased body temperatures on admission and mortality in ischemic stroke 
patients only.11 This relation was independent of clinical variables associated with stroke 
severity, such as incontinence and level of consciousness. In a retrospective study of 
251 patients with supratentorial intracerebral hemorrhage, almost every patient (91%) 
had increased body temperature (>37.5°C) within the first 72 hours.12 The duration of 
increased body temperatures was associated with poor outcome. This association was 
independent of the initial score on the Glasgow Coma scale and hematoma volume. In 
a prospective study of 390 unselected patients with ischemic and hemorrhagic stroke 
admitted within 6 hours of onset, a highly significant association between body tem-
perature and outcome was observed (Figure 1). The association was independent of 
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Figure 1: Relationship between poor outcome and body temperature on admission in patients with acute 
stroke, for different initial stroke severities. Data from Reith et al.10
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initial stroke severity, age, gender, and the stroke risk profile (Figure 1).10 For each degree 
Celsius increase in body temperature the relative risk of poor outcome rose by a fac-
tor of 2.2. This association was still present after 5 years of follow-up.10 This implies that 
temperature-lowering therapy may have long-term effects on outcome in patients with 
acute stroke. The relation between body temperature on admission and poor outcome 
declined with time from stroke onset to admission, but was still significant and clinically 
relevant in patients admitted between 6 and 12 hours from stroke onset.31 A 1°C increase 
in body temperature doubled the mortality risk. A similar trend was observed with regard 
to functional outcome in survivors, but this did not reach statistical significance.
In contrast to the studies above, no association between body temperature on admis-
sion and outcome was found in a prospective study of 725 patients with ischemic or 
hemorrhagic stroke admitted within 6 hours of stroke onset.32 However, body tempera-
ture at 10 to 12 hours after stroke onset was related to poor outcome, despite treatment 
with paracetamol in all patients with temperatures above 37°C. The lack of an association 
between admission body temperatures and outcome may be explained by the fact that 
rather insensitive methods of statistical analysis were used (Spearman correlation and 
comparison of median modified Rankin Scale (mRS) scores with a non-parametric test). 
To summarize, body temperature may be a strong independent prognostic factor of 
outcome in acute stroke. The time window of this association may be limited to the first 
12 to 24 hours from stroke onset. This suggests that the relationship with poor outcome 
is not confounded by the occurrence of secondary infections, such as pneumonia or 
urinary tract infection, because these usually appear later in the course of the disease.
EFFECT OF THERAPEUTIC HYPOTHERMIA IN ACUTE STROKE: ANIMAL MODELS
Since the 1950’s, hypothermia has been tested as a protective strategy in animal models 
of focal cerebral ischemia. Rosomoff first demonstrated the efficacy of profound hypo-
thermia for this condition.33 Several controlled animal studies suggested a protective ef-
fect of mild to moderate hypothermia (30-35°C) in rat focal cerebral ischemia models.34,35 
These studies showed that mild hypothermia resulted in a decrease in infarct volume in 
comparison with normothermia, provided that treatment was started within one hour 
after the induced cerebral ischemia.34,35 The effect of hypothermia was larger in animal 
models with transient middle cerebral artery occlusion than in animal models with 
permanent occlusion. Furthermore, the protective effect was influenced by the duration 
of hypothermia.34 A study in rats with embolic middle artery occlusion showed that 
trombolytic therapy following 2 hours of mild hypothermia could not improve the effect 
of hypothermia alone.36
For deep hypothermia (<30°C) the results are conflicting. Three studies with rats showed 
a reduction in infarct volume without adverse effects when the body temperature was 
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lowered below 30°C.37-39 In contrast, two studies in monkeys, cats, and dogs reported an 
increase in infarct volume when body temperature was lowered below 30°C.40,41 
As far as we know, only one animal study has been performed to test the effect of 
paracetamol on body temperature and infarct volume in rats. Treatment with paracetamol 
(250 mg/kg i.p.) significantly reduced body temperature (38.2 °C ± 0.4°C) compared with 
vehicle-treated animals (39.3 °C ± 0.3 °C), but only a trend towards a reduction in infarct 
volume was observed (Figure 2).42
EFFECT OF TEMPERATURE-LOWERING THERAPY: CLINICAL STUDIES 
Based on the beneficial effects of hypothermia demonstrated in animal models, clinical 
studies of physical and chemical cooling were started. These studies were not only con-
ducted in patients with acute ischemic stroke, but also in patients with severe traumatic 
brain injury, and in patients with global cerebral ischemia after cardiac arrest. 
Temperature lowering therapy after traumatic brain injury and cardiac arrest
Encouraging results from large randomized trials of hypothermia in patients with cardiac 
arrest are now available. Two randomized trials showed that lowering body temperature 
to 32-34°C for 12-24 hours in comatose survivors of cardiac arrest improved neurologi-
cal outcome. In one of the trials, survival with a good outcome was nearly doubled and 
in the other it was increased by 40%.43-45 A recent meta-analysis concluded that mild 
therapeutic hypothermia improves short-term neurological recovery and survival in 
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Figure 2: Effects of aspirin and paracetamol on infarct volume in rats. Data from Legos et al.42
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patients resuscitated after cardiac arrest of presumed cardiac origin.45 Further research 
to determine the long-term prognosis, quality of life, and the feasibility of the cooling 
methods was considered warranted.
Mild hypothermia has been used in traumatic brain injury for over 50 years. Several 
experimental studies were promising.46-48 No clinical randomized clinical trials were per-
formed until the last two decades. Although small randomized studies reported encour-
aging results,49-56 the pivotal larger trial could not confirm the benefit of hypothermia.57 
A recent Cochrane review of 12 randomized controlled trials with a total of 1061 patients 
found no evidence for a beneficial effect of hypothermia in patients with traumatic brain 
injury.58 Hypothermia increased the risk of pneumonia and other potentially harmful 
side effects such as hypotension and cardiac arrhythmia in patients with traumatic brain 
injury; hypothermia in traumatic brain injury should therefore not be used outside con-
trolled trials. 
In the largest published trial with 392 patients with traumatic brain injury, hypother-
mia (33°C) did not improve outcome measured by disability, vegetative state or death.52 
However, a subgroup analysis revealed that younger patients (<45 years) who had hypo-
thermia on admission and were assigned to treatment had significantly better outcome 
then patients with normothermia on admission and assigned treatment. A recent pub-
lished multi-center trial focusing on this subgroup randomized 215 patients with severe 
traumatic brain injury to long-term hypothermia (5 days) or short-time hypothermia (2 
days).59 The target temperature was 33°C. Long-term hypothermia significantly improved 
outcome compared to short-time hypothermia. However, the results of this study should 
be interpreted with caution, as this study used a pseudo-randomization procedure 
(alternate day), and the study did not incorporate a control group without hypothermia. 
Another study focusing on this subgroup is underway.58
An interesting question is why cooling is efficacious in patients with cardiac arrest, but 
not in patients with major traumatic brain injury. One obvious explanation is the amount 
of non-ischemic damage that plays a role in the latter condition. Furthermore, earlier 
studies in patients with major head trauma were very small single center studies. It is 
possible that the intervention was applied differently in different centers. Differences in 
time from trauma to start of treatment and differences in the duration of treatment and 
rewarming may also account for the discrepancy in the response to hypothermia.
Temperature-lowering therapy in acute stroke: physical temperature reduction 
Several uncontrolled phase II studies and one randomized controlled phase II study have 
been performed to study the feasibility and the safety of different physical methods to 
reduce body temperature in patients with acute stroke.
In an open study in patients with acute ischemic stroke treated with trombolysis, 
cooling to 32°C for 12-72 hours with cooling blankets appeared feasible and safe.60 In an 
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uncontrolled study of 50 patients with a severe middle cerebral artery infarct, body tem-
perature could be reduced to 32 to 33°C with the use of cooling blankets, alcohol, and ice 
bags under complete anesthesia.61 The most frequent complications were thrombocyto-
penia (70%), bradycardia (62%), and pneumonia (48%). The high frequency of complica-
tions may be explained by the severity of infarction. Because of the uncontrolled design 
of this study, one cannot draw firm conclusions about the complication rate on the one 
hand and effectiveness of the intervention on the other. An uncontrolled study with 25 
patients with middle artery infarction with elevated intracranial pressure showed that 
hypothermia (33°C) for 48-72 hours significantly reduced intracranial pressure.62 In a case 
series 25 patients with middle cerebral artery infarction and elevated intracranial pres-
sure were treated with hypothermia (33°C). The authors observed a subsequent decrease 
in intracranial pressure. Whether this could be attributed to the hypothermic treatment 
remains to be investigated in controlled studies. The COOL-AID study, a randomized con-
trolled study, used endovascular cooling instead of surface cooling.63 Reduction in body 
temperature to 33°C was compared to standard medical treatment in 40 patients with 
acute ischemic stroke. The target temperature was reached in a mean of 77± 44 minutes. 
Shivering was suppressed by warming blankets and sedatives. Only 5 of 18 patients did 
not reach their target temperature. 
The target body temperature in all of these studies was 32-33°C. In all of these stud-
ies, patients had to be sedated and intubated for artificial ventilation. This reduces 
the number of patients suitable for this way of treatment. The large reduction in body 
temperature increases the risk of complications, such as low blood pressure, pulmonary 
complications, infections, cardiac arrhythmia, and coagulation disturbances. The many 
complications that occurred in the study of Schwab may be explained by the fact that 
these patients all had severe middle cerebral artery infarcts. In the other studies safety 
concerns were less prominent.61 
Three uncontrolled phase II studies have been performed with less extreme target 
temperatures. In a study with 73 patients with acute ischemic or hemorrhagic stroke, 
target temperature was 35,5°C.64 Anesthesia was not required. Shivering in this study 
was treated with intravenous pethidine. In another study, temperature reductions of 1°C 
were maintained until 24 hours after onset of ischemic stroke.65  The escalating treatment 
consisted of paracetamol, cooling blankets and sponging with 70 % alcohol. Shivering 
was prevented with continuous infusion of low dose midazolam (1-3 mg / hour). In a 
third study, a 1-2°C body temperature reduction was reached within 3.3 hours with a 
water-perfused cooling matrass in 16 of the 18 patients with ischemic or hemorrhagic 
stroke.66 The patients received pethidine to avoid shivering.
In the Nordic Cooling Stroke Study67, a multicenter randomized controlled trial in pa-
tients with ischemic or hemorrhagic stroke, surface cooling was started within 6 hours of 
stroke onset and continued for 9 hours. The target temperature was 35°C. Unfortunately, 
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the trial was terminated because of slow recruitment after the inclusion of 48 patients 
against a target recruitment of 1000 patients (U.J. Weber, personal communication).
In most physical temperature reduction studies, the nadir was reached within one to 
six hours from start of treatment. Taking into account the development of the ischemic 
penumbra15, this may not be sufficient. However, some studies have shown a relation 
between body temperature after 12 hours of stroke onset and outcome, suggesting that 
even hypothermia reached within 24 hours after onset could be beneficial. At this mo-
ment there are no completed randomized controlled phase III trials of physical tempera-
ture reduction in acute stroke. Well-designed, controlled studies of several intensities of 
hypothermia, aimed to assess feasibility and safety, are still warranted. On the other hand 
the risk of complications and the high cost of this mode of treatment imply that there 
is a need for a simple medical intervention that may reduce body temperature to lesser 
extent, but is cheap and safe.
In studies of physical temperature reduction, shivering is a serious problem that in-
terferes with treatment. Shivering is a physiological reaction that consists of repetitive 
contractions of muscles, in order to generate heat. The effect of pethidine to reduce 
shivering is not unambiguous.68 Meperidine, buspirone69 and dexmedetomidine have 
been shown to reduce the shivering threshold through unknown mechanisms.70
Temperature-lowering therapy in acute stroke: antipyretic drugs 
Pharmacological lowering of body temperature may be an effective and safer alternative 
approach to cooling. In guidelines for acute stroke treatment antipyretics are generally 
recommended to reduce fever.71 However, the effect on of antipyretic therapy on func-
tional outcome after stroke is still unknown. 
Paracetamol: mechanism of action
Paracetamol is one of the most commonly used antipyretic drugs. It is usually well toler-
ated and has almost no side effects. In spite of its wide use, the mechanism of action of 
paracetamol has not fully been elucidated. Paracetamol is a potent inhibitor of prosta-
glandin production within the central nervous system. Evidence has accumulated that 
prostaglandins are the proximal mediators of fever. They are synthesized in the brain by 
cyclooxygenases (COXs). There are two isoforms of COX, named COX-1 and COX-272, which 
differ in their expression patterns. COX-1 is expressed in all tissues and is not affected by 
inflammation mediators, whereas COX-2 is expressed in brain, kidney, testicles and lung 
tissue and is up-regulated by pro-inflammation mediators.73,74 Recently, a new isoform of 
COX has been postulated, provisionally named COX-3, which is mainly produced in the 
brain. It has been suggested that this isoform, and not COX-2, plays a major role in the 
brain in fever production.
34
2
Paracetamol easily penetrates the brain. The reduction of prostaglandin synthesis by 
paracetamol can be explained by its competitive inhibition of arachidonic acid for the ac-
tive site on COX.75 This presumably accounts for its antipyretic properties. The properties 
of paracetamol are different from those of typical NSAIDs, as it potently reduces pain and 
fever but has very little effect on inflammation. This is one to the reasons the existence 
of COX-3 has been postulated76, supported by experimental studies showing a very low 
sensitivity of COX-1 and COX-2 to paracetamol.77 
Paracetamol: phase II studies
Five phase II studies have been performed to study the effect of paracetamol on lower-
ing body temperature in patients with acute stroke. In two of these studies this effect 
was also compared with that of other antipyretic drugs. A randomized pilot study in 42 
patients showed that treatment with paracetamol in a daily dose of 4000 mg resulted in 
a substantial reduction in the number of patients with a body temperature over 37.5°C. 
The size of the temperature reduction was not reported.78 In a partly blinded randomized 
study of 39 patients, a daily dose of 3900 mg paracetamol lowered body temperature 
by 0.2°C. No effect on functional outcome was observed.79 Our group conducted two 
pilot studies. Both studies were double-blind, randomized, placebo-controlled trials to 
study the effect of paracetamol on body temperature in patients with acute ischemic 
stroke confined to the carotid territory. In a first trial, 76 patients were treated with either 
3000 mg or 6000 mg paracetamol or placebo.80 Treatment with high-dose paracetamol 
resulted in a reduction in body temperature of 0.4°C at 24 hours even in normothermic 
and subfebrile patients. This effect was confirmed in a second trial.81 In this study, patients 
with acute ischemic anterior circulation stroke were treated with daily doses of 2400 mg 
ibuprofen, 6000 mg paracetamol, or placebo for 5 days. Ibuprofen had no significantly 
effect on body temperature. Treatment with paracetamol resulted in a 0.3°C reduction in 
body temperature at 24 hours compared to placebo.81 A pooled analysis of the data from 
both studies showed that a significant decrease of body temperature occurred within 4 
hours after start of treatment with high-dose of paracetamol.82 We did not observe an 
increased rate of (masked) infections in with paracetamol-treated patients in both trials.
In an uncontrolled study, 132 patients admitted with acute ischemic stroke were 
treated with either 1000 mg paracetamol as a suppository or 500 mg intravenous ace-
tylsalicylic acid when body temperature rose above 37.5°C.83 In case body temperature 
was still above 37.5°C at six hours, treatment was continued with 4000 mg paracetamol a 
day. Patients who were treated with paracetamol tended to be more often hypothermic 
(<36.5°C) and less often hyperthermic compared to patients who received acetylsalicylic 
acid, but these results were not statistically significant. In this study, a one-third lower 
daily dose of paracetamol was used than in our studies [80;81]. Secondly, the effect of 
antipyretic agents on body temperature was dichotomized as normal or elevated, which 
results in loss of power. Thirdly, the study did not incorporate a control group.84
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In summary, treatment with a daily dose of 6000 mg paracetamol results in a small, but 
potentially worthwhile reduction in body temperature in patients with acute ischemic 
stroke. Ibuprofen had no significant effect on lowering body temperature. In studies with 
high-dose paracetamol, the nadir was reached within 4 hours from start of treatment. 
As mentioned earlier, this may be too late to be beneficial.15 However, several studies 
have shown a relation between body temperature and outcome after 12 hours of stroke 
onset. Further large randomized clinical trials are needed to investigate whether the 
temperature reduction by this dose of paracetamol improves outcome in acute stroke. 
In May 2003, we started with a large double-blind, randomized, placebo–controlled, 
multicenter trial of a high dose paracetamol in patients with acute stroke.85 In total, 2500 
patients with acute ischemic or hemorrhagic stroke will be included. Treatment with 
high-dose paracetamol (6 g/day) or placebo will be started within 12 hours after the onset 
of symptoms and continued for 3 days. Exclusion criteria are a body temperature lower 
than 36°C or higher than 39°C, a history of liver disease, alcohol abuse, liver enzymes 
increased above twice the upper limit of normal, allergy to paracetamol, and significant 
pre-stroke impairment. The primary outcome measure is a dichotomized score on the 
mRS (0-2: good outcome, 3-6: poor outcome) at 3 months. 
Other antipyretic drugs
In 1998, a randomized placebo controlled trial of metamizol has been started.86 Treat-
ment with metamizol (6000mg intravenous) or placebo was started within 48 hours after 
the onset of symptoms, and continued for 3 days. Metamizol is a pyrazolon derivative 
and considered a non-steroidal anti-inflammatory drug. The results of this trial have not 
been published.
EXPERT OPINION
Body temperature is a predictor of outcome in acute stroke. The period in which an 
increased body temperature is associated with poor outcome may be limited to the first 
12 to 24 hours from stroke onset. Animal studies of focal cerebral ischemia have shown 
promising results of interventions aimed at lowering body temperature. Mild hypother-
mia is associated with a more favorable neurological outcome in patients resuscitated 
after cardiac arrest. However, no therapeutic effect of hypothermia was observed in 
patients with severe traumatic brain injury. The uncontrolled studies in acute ischemic 
stroke that have been conducted so far have not provided sufficient evidence of safety 
and feasibility of physical cooling. We need randomized phase II studies with several cool-
ing devices. These studies should explore the relation between intensity of treatment, 
temperature reduction, and adverse events, such as arterial hypotension, infections, and 
cardiac arrhythmias. 
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Pharmacological lowering of body temperature may be a safe alternative to physical 
temperature reduction. Although antipyretics are widely recommended for the treatment 
of elevated body temperatures in stroke patients, there is insufficient or no evidence of 
any effect on outcome. Treatment with a daily dose of 6000 mg paracetamol resulted in 
a 0.3°C reduction in body temperature in patients with acute ischemic stroke. This small 
effect of paracetamol on body temperature may seem insignificant at first sight, but may 
prove to be clinically relevant. In the Copenhagen Stroke Study, the relative risk of poor 
outcome rose by a factor of 2.2 (95% CI 1.4 to 3.5) with each degree Celcius increase in 
body temperature. Based on these data, a decrease of 0.3°C induced by paracetamol may 
lead to a 10% relative risk reduction of poor outcome in patients with acute stroke.
FIVE YEAR VIEW
Physical temperature reduction 
Although the potential benefit of physical temperature reduction in acute stroke has 
been pointed out by many experts, more rigorous phase II studies need to be launched, 
followed by phase III randomized controlled trials. 
Pharmacological temperature reduction
Within five years the PAIS study will have been completed. This study will provide evi-
dence on the effect of pharmacological reduction of body temperature with high dose 
paracetamol on functional outcome in patients with acute stroke. If such an effect can 
be ascertained, a simple and cheap treatment will be readily available for patients with 
acute stroke.
KEY ISSUES
•	 In animal models, mild hypothermia started shortly after the onset of focal cerebral 
ischemia resulted in smaller infarct size. 
•	 In patients with acute stroke, increased baseline body temperature is associated with 
poor outcome. This association may be limited to the first 12 to 24 hours from stroke 
onset. 
•	 Mild therapeutic hypothermia improves short-term neurological recovery and sur-
vival in patients resuscitated after cardiac arrest. There is no evidence of a beneficial 
effect of hypothermia after traumatic brain injury.
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•	 No phase III randomized controlled trials of physical cooling in acute stroke have been 
completed. Feasibility and safety are not sufficiently established and serious side ef-
fects such as hypotension, infections, and cardiac arrhythmias have been reported. 
More randomized phase II studies with various cooling devices are needed.
•	 Treatment with a daily dose of 6000 mg paracetamol results in a small but potentially 
worthwhile reduction in body temperature in patients with acute ischemic stroke. 
Further large randomized clinical trials are needed to study whether this reduction in 
body temperature leads to improved functional outcome.
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BACKGROUND  
Body temperatures over 37.5˚C have been observed in 4 to 25% of patients within the 
first 24 to 36 hours after stroke onset and are associated with poor long-term outcome. 
In the observational Copenhagen Stroke study, a 1°C increase in body temperature mea-
sured within 12 hours after stroke onset doubled the odds of poor outcome.
In animal models of focal cerebral ischemia, cooling reduces infarct volume. Hypother-
mia is successfully used in cardiac surgery and has been associated with a more favorable 
neurological outcome in patients who were resuscitated after cardiac arrest.
These observations suggest that reduction of body temperature and prevention of fever 
may improve functional outcome after stroke. However, the potentially beneficial effects 
of temperature-lowering therapy might be offset by side effects such as infections, cardiac 
arrhythmias, hemorrhagic transformation of infarcts, and deep venous thrombosis.
OBJECTIVES
The aim of this review was to assess the relation between interventions to reduce body 
or brain temperature and functional outcome or death in patients with acute stroke, and 
to determine whether there is any clear evidence that temperature reduction of any kind 
is beneficial, or whether the intervention is sufficiently promising to merit further trials.
SEARCH STRATEGY
We updated the 1999 Cochrane review “Cooling therapy for acute stroke”. Relevant trials 
were identified in the Specialised Register of Controlled Trials (last search, December 
2007). Additional searches were performed in MEDLINE and EMBASE (January 1998 to 
December 2007). We scanned references and contacted authors of included trials. 
SELECTION CRITERIA  
We considered all completed randomized or non-randomized controlled clinical trials, 
published or unpublished, where pharmacological and/or physical strategies to reduce 
body or brain temperature were applied in patients with acute ischemic stroke or intra-
cerebral hemorrhage and the effect on clinical outcome was reported.
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DATA COLLECTION AND ANALYSIS
Two reviewers independently selected trials for inclusion. Thereafter, two of three re-
viewers assessed the methodological quality of each identified trial and extracted the 
data. Outcome measures were death or dependency (modified Rankin Scale score >2) 
and death at the end of follow-up, and adverse effects.
MAIN RESULTS
Five pharmacological temperature reduction trials and three physical temperature re-
duction trials involving a total of 423 patients were included. We found no statistically 
significant effect of pharmacological or physical temperature-lowering therapy in reduc-
ing the risk of death or dependency (OR 0.9, 95% CI 0.6-1.4) (Figure 1) or death (OR 0.9, 
95% CI 0.5-1.5). Both interventions were associated with a non-significant increase in the 
occurrence of infections (OR 1.5, 95% CI 0.8-2.6).
Death or dependency
(mRS>2)
Dippel 2001* 17/26 6/12
Dippel_2 2001* 13/25 6/12
Koennecke 2001 5/20 10/22
Kassner 2002 14/20 13/19
Castillo 2003 15/31 14/29
Dippel 2003* 13/26 6/13
Dippel_2 2003* 9/24 6/12
Subtotal 86/172 61/119
Krieger 2001 13/18 13/22
De Georgia 2004 5/10 8/9
Subtotal 18/28 21/31
Total 104/200 82/150
OR (95%CI)
Favors temperature-lowering                   Favors control
therapy
1.9   [0.5-7.6]
1.1   [0.3-4.3]
0.4   [0.1-1.5]
1.1   [0.3-4.2]
1.0   [0.4-2.8]
1.2   [0.3-4.4]
0.6   [0.2-2.4]
0.9   [0.6-1.5]
0.1   [0.01-1.4]
1.8   [0.5-6.9]
0.9   [0.3-2.5]
0.9   [0.6-1.4]
1 100.1
Temperature           Control
-lowering  therapy
(n/N) (n/N)
Figure 1: Effect of temperature-lowering therapy on death or dependency (score on the modified Rankin 
Scale >2) at final follow up.
*Two intervention groups; the number of patients with poor outcome and the total number of patients 
in the control group were divided by 2, in order to avoid multiple comparisons using the same subset of 
patients.
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IMPLICATIONS FOR PRACTICE AND FUTURE RESEARCH
There is currently no evidence from randomized trials to support routine use of physical 
or pharmacological strategies to reduce temperature in patients with acute stroke. 
Large randomized clinical trials are needed to study the safety, optimal duration 
and the effectiveness of both physical and pharmacological temperature reduction in 
patients with acute stroke. Attention should be paid to trial quality issues such as ran-
domization, blinded outcome assessment, relevant intervention contrast and relevant 
outcome measures and to the occurrence of infections. 
REFERENCES
The full text, data tables, analyses, results and reference list of this article are available in the Cochrane 
Library.1 
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TO THE EDITOR:
We read the review by Hemmen and Lyden on induced hypothermia for acute ischemic 
stroke1 with interest. The review focuses on physical cooling methods in acute stroke. 
Some points however, deserve in our opinion a more extensive discussion.
The authors state that controlling body temperature below 36.5 °C has been proven to 
correlate with good clinical outcome. They do not cite controlled clinical trials to support 
their point, but refer to two observational studies instead. 
Indeed, well-designed studies have shown a consistent relationship between increased 
body temperature measured within 12 to 24 hours after stroke onset, and outcome, but 
not beyond that interval.2 These studies suggest that reductions in body temperature 
of 0.5 degrees Celsius might lead to a relative risk reduction in poor outcome of 10%. 
Reductions in body temperature of this magnitude have been proven feasible in two 
pilot studies of high-dose paracetamol.3,4
In our view, the uncontrolled studies and small randomized trials in acute ischemic 
stroke that have been conducted so far have not provided sufficient evidence of safety 
and feasibility of physical cooling methods. We need more randomized phase II studies 
with several cooling devices. These studies should explore the relation between intensity 
of treatment, temperature reduction, and adverse events, such as arterial hypotension, 
infections, and cardiac arrhythmias. On the other hand, the risk of complications, the 
high costs of this mode of treatment, and other logistical barriers imply that there is 
a need for a simple medical intervention that may reduce body temperature to lesser 
extent, but is cheap and safe.
Although several national and international guidelines recommend the use of 
paracetamol in patients with fever after stroke, it is recognized that there is no evidence 
available of a therapeutic effect.5 Moreover, most patients develop fever after the first 24 
hours, and it appears unlikely that late treatment will have an effect on outcome.
Why not treat all patients early with high-dose paracetamol? The main reason is that 
this treatment strategy has not yet been proven to improve functional outcome after 
stroke. In addition, paracetamol can be dangerous in high doses and cause liver failure. 
Use of paracetamol may delay the recognition of pneumonia and urinary tract infections, 
and thus lead to delayed treatment and poor outcome.
We conclude that a large pragmatic placebo-controlled randomized clinical trial of 
paracetamol in acute ischemic stroke is needed. Exactly such a trial is underway in the 
Netherlands, PAIS: Paracetamol (Acetaminophen) In Stroke. More than 1200 patients 
have been included in the trial as of January 2007. We expect to be able to present the 
trial’s results in 2008.6
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abstract
ABSTRACT
Background The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III 
multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose 
paracetamol in patients with acute stroke. The trial compares treatment with a daily dose 
of 6 g paracetamol, started within 12 hours of symptom onset, with matched placebo. 
The purpose of this study is to assess whether treatment with paracetamol for 3 days will 
result in improved functional outcome through a modest reduction in body temperature 
or prevention of fever.
The previously planned statistical analysis based on a dichotomization of the scores 
on the modified Rankin Scale (mRS) may not make the most efficient use of the available 
baseline information. Therefore, the planned primary analysis of the PAIS study has been 
changed from fixed dichotomization of the mRS to a sliding dichotomy analysis. 
Methods Instead of taking a single definition of good outcome for all patients, the defi-
nition is tailored to each individual patient’s baseline prognosis on entry into the trial. 
Conclusion The protocol change was initiated because of both advances in statistical 
approaches and to increase the efficiency of the trial by improving statistical power.
Trial registration: Current Controlled Trials [ISRCTN74418480]
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INTRODUCTION
The Paracetamol (Acetaminophen) In Stroke (PAIS) Study is a phase III multicenter, double 
blind, randomized, placebo-controlled clinical trial of high-dose paracetamol in patients 
with acute stroke. The trial compares treatment with a daily dose of 6 g paracetamol, 
started within 12 hours after symptom onset, with matched placebo. The purpose of 
this study is to assess whether early treatment with paracetamol will result in improved 
long-term functional outcome through a modest reduction in body temperature or 
prevention of fever.1
In the original protocol, the primary outcome measure is a dichotomized score on the 
modified Rankin Scale (mRS)2 assessed at 3 months from onset of symptoms, with good 
functional outcome defined as a score of 0-2 and poor functional outcome as a score of 
3-death.
The common approach of dichotomizing the mRS, an ordinal outcome scale, has several 
disadvantages. First, it may not correspond with everyday clinical practice. Dichotomized 
outcome analyses convert ordinal scales into binary outcome measures. Most treatment 
strategies tested in acute stroke trials are not expected to be completely curative, but 
to lead to improvement. Therefore, it is also informative to show that treatment moves 
patients from severe to moderate disability or from moderate disability to recovery, and 
not only to demonstrate differences in the numbers of patients with a good or poor 
functional outcome. Secondly, dichotomization may limit statistical power. The sample 
size calculation used for the PAIS study assumes that each patient in the placebo group 
has a 50% probability of poor outcome at 3 months.1 In practice, there will be substantial 
prognostic heterogeneity because of differences in baseline variables between patients. 
If this is not taken into account, the chance of finding a true treatment effect may be 
reduced. Thirdly, by assessing only a single health state transition, investigators may be 
forced to discard a substantial amount of outcome information. This may lead to under-
estimation of treatment benefit or harm. 
Because of these disadvantages of dichotomization, new approaches to outcome 
analysis have been proposed and tested in acute stroke trials.2-7 These novel outcome 
analyses consider the full range of the ordinal outcome scale and lead to a single and 
meaningful estimate of the treatment effect. One of these new approaches is the so-
called “sliding dichotomy”.5 Other approaches are shift analysis and analyses that make 
use of ordinal logistic regression.3,4,7
For the PAIS study, we decided to change the planned analysis for the primary outcome 
measure from a fixed dichotomy to a sliding dichotomy analysis. This protocol change 
was initiated because of both advances in statistical approaches and to increase the ef-
ficiency of the trial by improving statistical power.
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METHODS 
Instead of taking a single definition of good outcome for all patients, the definition is tai-
lored to each individual patient’s baseline prognosis on entry into the trial. The outcome 
of an individual patient is thus regarded as good or poor depending on what would have 
been expected based on the severity of stroke and other prognostic factors. 
Blinded data from the PAIS study1 were used to illustrate this procedure of the sliding 
dichotomy analysis (Figure 1). A prognostic index was derived from a logistic regression 
model for favorable outcome (defined as mRS ≤2), which was generated on the basis of 
blinded observations in the trial. The prognostic index included age, sex, stroke severity 
(according to the NIHSS), previous stroke, stroke type (ischemic stroke versus intracere-
bral hemorrhage), and diabetes mellitus. 
The study population was then divided into 20 quantiles (vingtiles) of the baseline 
prognostic index. For each vingtile, the distribution of outcomes on the mRS was com-
puted (Figure 1). Thereafter, 6 bands (clusters of vingtiles) were defined in such a way that 
the median of the mRS in that band would be closest to one of the six grades of the mRS 
(1-6). Cut-off points would thus be taken between vingtiles 7 and 8, 11 and 12, 14 and 15, 
17 and 18, and 19 and 20. Patients are considered to have improved beyond expectation 
when their score on the mRS is lower than the median grade of patients with a similar 
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Figure 1: Distribution of predicted outcome scores on the modified Rankin Scale2 at three months over 
ordered vingtiles of a prognostic index for good outcome in the PAIS trial.1 Six bands were defined in such 
a way that the median of the mRS in that band was equal to the next score on the mRS (1-6). Cut-off points 
were taken between quantile 7 and 8, 11 and 12, 14 and 15, 17 and 18, and 19 and 20.
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prognostic index. The primary effect estimate will be the odds ratio for improvement. 
For example, for a patient of whom the prognostic risk is in the 12th vingtile, the median 
predicted outcome mRS is 3 and an outcome mRS <3 would be taken as favorable out-
come (Figure 1). This varying bandwidth makes more efficient use of the data than an 
approach based on tertiles or quartiles, as originally proposed.5 Note that the choice of 
cut-off point is completely independent of the treatment effect, as the data are blinded. 
Although the definition of the new primary outcome is based on prognostic indicators 
at baseline, imbalances in these and other prognostic factors between the treatment 
groups may still confound the assessment of treatment effect. Adjustments will therefore 
be made with a multiple logistic regression model that includes time to treatment, base-
line body temperature, stroke severity (as assessed with the NIHSS), stroke type (ischemic 
stroke versus intracerbral hemorrhage versus), ischemic stroke subtype (lacunar versus 
non-lacunar) and thrombolytic therapy, as proposed previously1, as well as for age, sex, 
previous stroke and diabetes mellitus.
Secondary effect measures will include an estimate of the odds ratio for improvement, 
estimated by means of ordinal logistic regression analysis. 
We will also estimate the adjusted odds ratio for the former primary outcome, i.e. favor-
able functional outcome, as defined as a score < 3, and alternative dichotomizations of 
the mRS (0 to 3 versus 4 to 6). As reported before1, the score on the Barthel index at 3 
months, body temperature at 24 hours from start of treatment, and quality of life at three 
months as assessed with the EuroQol-5D will also be assessed. 
DISCUSSION
Several approaches to outcome analysis have recently been applied in acute stroke trials, 
including shift analysis6, a rank test of original ordinal data, ordinal logistic regression3, 
and the concept of a sliding dichotomy5.
Analyzing the full range of ordinal data for functional outcome has shown to be 
more statistically efficient than collapsing data.3 A recent study compared statistical 
approaches to the analysis of differences in functional outcome as measured on ordinal 
scales. The authors concluded that methods that made use of the full range of ordinal 
outcomes were more sensitive to treatment effects. However, in this study methods that 
incorporate baseline prognostic information, such as the sliding dichotomy, could not 
be evaluated.3
Shift analysis6 is not a formal test, but a calculus to estimate the proportion of patients 
moving from one category on the ordinal scale to the next. This can be a useful measure 
to gain insight in the size of a treatment effect. A disadvantage of shift analysis is that the 
uncertainty concerning the effect estimate cannot be quantified, as in statistical effect 
estimation.
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The term ‘shift test’ is used to designate the Mantel-Haenszel (CMH) test that compares 
two ordered outcome distributions after adjusting for one or more baseline variables. 
The test provides a p-value, but not an effect estimate. The van Elteren variant of the test 
was employed in the analysis of the results of the GAIN trial8 and in a post-hoc analysis of 
NINDS and ECASS-2 trials9 Ordinal logistic regression was used to estimate an effect size 
with its corresponding 95% confidence interval.
Classic statistical methods to compare distributions on an ordinal scale require rank 
tests. Translation of the results of a rank test (a p-value) to an estimate of the treatment 
effect is not straightforward; this may be done either by shift analysis (with the afore-
mentioned drawbacks) or by ordinal logistic regression. This analysis does not make use 
of the available baseline information. Ordinal logistic regression may be used to estimate 
treatment effects in studies with ordered outcomes. The relative risk of a transition is 
estimated as an odds ratio. An assumption is that any treatment effect is similar across 
outcome levels, i.e. the odds of moving from mRS level 3 to 2 are similar to the odds of 
moving from level 5 to 4. In the Optimizing Analysis of Stroke Trials (OAST) study, a study 
to assess which statistical approaches are most efficient in analyzing outcomes from 
stroke trials, the assumption of proportional odds was not met in 8 of the 55 datasets 
according to the authors, but they did not specify how they tested for this assumption.3 
Furthermore, this method might be inefficient when treatment effects cluster at one 
transition. When this approach was tested in a large dataset of patients with severe head 
injury, it did not perform better than the sliding dichotomy.5 Effect estimates should 
be meaningful from a clinical point of view. In ordinal logistic regression, meaningful 
interpretation is hampered by the point that moving one category up on the mRS may 
have a different clinical interpretation when it concerns low mRS scores, compared to 
high mRS scores. 
In our view, these are important arguments for not using ordinal regression in the 
primary outcome analysis. 
An advantage of the sliding dichotomy approach is that it makes the least assumptions 
about the type of patients who will be included in the study, the type of outcome they 
will experience, and the treatment effect pattern the treatment strategy under study 
will exert. It provides a simple outcome measure that is relatively easy to interpret, i.e. 
the relative risk of improvement beyond the level that could be expected from baseline 
prognostic information.5 To our opinion, this approach is to be preferred in the analysis of 
treatment effects employing the full range of outcomes on the mRS. With the concept of 
sliding dichotomy, each individual patient’s baseline prognosis is taken into account. This 
approach may be more relevant for clinical practice and may improve statistical power, 
as patients at the prognostic extremes have the potential to contribute to the estimation 
of the treatment effect. 
An exact, parametric approach to sample size estimation for studies that make use 
of the sliding dichotomy approach for ordered categorical outcome variables is not 
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available. Simulation studies of randomized clinical trials in traumatic brain injury that 
made use of the Glasgow Outcome Scale10, suggest that “.. substantial gains in statistical 
efficiency can be made”. Either of these approaches along with adjustment for baseline 
covariates gave efficiency gains equivalent to reducing the required sample size by up 
to 50%.5,11
We realize that this approach may also have disadvantages. Patients, care givers, and 
clinicians may consider the results of this way of analysis more difficult to interpret than 
collapsing data into a binary outcome. We wonder whether this is really the case. Taken 
at face value, a transition across the boundary between mRS 2 and mRS 3 does not tell 
us much at all about the real health benefit of a treatment, and a common odds ratio 
based on sliding dichotomy, may be in fact more informative for those who have become 
familiar with this type of analysis. 
CONCLUSION
In summary, because of the drawbacks of dichotomization, the primary outcome analysis 
of the multicenter acute stroke trial PAIS has been changed from fixed dichotomy of the 
mRS to the sliding dichotomy analysis. It has been approved by the PAIS steering com-
mittee on April 1, 2008, before inclusion into the trial was completed. This approach may 
be more relevant for clinical practice and is expected to increase the efficiency of the trial 
by improving statistical power.
62
3
REFERENCES
 1. van Breda EJ, van der Worp HB, van Gemert HM et al. PAIS: paracetamol (acetaminophen) in stroke; 
protocol for a randomized, double blind clinical trial [ISCRTN 74418480]. BMC Cardiovasc Disord 
2005; 5:24.
 2.  van Swieten JC, Koudstaal PJ, Visser MC et al. Interobserver agreement for the assessment of 
handicap in stroke patients. Stroke 1988; 19:604-607.
 3.  Bath PM, Gray LJ, Collier T et al. Can we improve the statistical analysis of stroke trials? Statistical 
reanalysis of functional outcomes in stroke trials. Stroke 2007; 38:1911-1915.
 4. Joffe MM, Greenland S. Standardized estimates from categorical regression models. Stat Med 1995; 
14:2131-2141.
 5. Murray GD, Barer D, Choi S et al. Design and analysis of phase III trials with ordered outcome scales: 
the concept of the sliding dichotomy. J Neurotrauma 2005; 22:511-517.
 6.  Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of 
outcome scales in acute stroke trials. Stroke 2007; 38:3055-3062.
 7.  Whitehead J. Sample size calculations for ordered categorical data. Stat Med 1993; 12:2257-2271.
 8.  Lees KR, Zivin JA, Ashwood T et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354:588-
600.
 9.  Savitz SI, Lew R, Bluhmki E et al. Shift analysis versus dichotomization of the modified Rankin scale 
outcome scores in the NINDS and ECASS-II trials. Stroke 2007; 38:3205-3212.
 10.  Jennett B, Bond M. Assessment of outcome after severe brain damage Lancet 1975; 1:480-484.
 11.  Murray GD, on behalf of the IMPACT investigators. Approaches to outcome analysis in traumatic 
brain injury trials. Abstract for the 8th International Neurotrauma Symposium 2006, Rotterdam, 
The Netherlands. J Neurotrauma 2006: 735.
High-dose paracetamol 
in acute stroke: 
the Paracetamol 
(Acetaminophen) In 
Stroke trial (PAIS)
Lancet Neurol 2009; 8:434-440
Heleen M den Hertog1, H Bart van 
der Worp2, H Maarten A van Gemert3, 
Ale Algra2,4, L Jaap Kappelle2, Jan van 
Gijn2, Peter J Koudstaal1, Diederik 
WJ Dippel1, on behalf of the PAIS 
investigators
1Department of Neurology, Erasmus MC 
University Medical Center, Rotterdam, 
The Netherlands
2Department of Neurology, Rudolf 
Magnus Institute of Neuroscience, 
University Medical Center Utrecht, Utrecht, 
The Netherlands 
3Department of Neurology, Meander 
Medical Center, Amersfoort, 
The Netherlands 
4Julius Center for Health Sciences and 
Primary care, University Medical Center 
Utrecht, Utrecht and Department of Clinical 
Epidemiology, Leiden University Medical 
Center, Leiden, The Netherlands
abstract
ABSTRACT
Background High body temperature in the first 12 to 24 hours after stroke onset is asso-
ciated with poor functional outcome. The Paracetamol (Acetaminophen) In Stroke (PAIS) 
trial aimed to assess whether early treatment with paracetamol improves functional out-
come in patients with acute stroke by reducing body temperature and preventing fever.
Methods In a multicenter, randomized, double-blind placebo-controlled trial, patients 
with ischemic stroke or intracerebral hemorrhage and body temperature between 36˚C 
and 39˚C were randomly assigned with paracetamol (6 g daily) or placebo within 12 
hours from symptom onset. Treatment allocation was based on a computer-generated 
list of random numbers with varying block size. The primary outcome was the odds ratio 
for improvement beyond expectation on the modified Rankin scale at 3 months, accord-
ing to the sliding dichotomy approach. This trial is registered, number ISRCTN74418480.
Findings Between March 2003, and May 2008, 1400 patients were randomly allocated 
treatment. 260 of 697 (37%) patients receiving paracetamol and 232 of 703 (33%) receiv-
ing placebo improved beyond expectation (adjusted OR 1.20; 95% CI 0.96 to 1.50). In a 
post-hoc analysis of patients with baseline body temperature between 37ºC and 39ºC, 
treatment with paracetamol was associated with improved outcome (adjusted OR 1.43; 
95% CI 1.02 to 1.97). There were 55 serious adverse events in the paracetamol group (8%) 
and 70 in the placebo group (10%).
Interpretation These results do not provide routine use of high-dose paracetamol in 
patients with acute stroke. Paracetamol may have a beneficial effect on functional out-
come in patients admitted with a body temperature between 37.0ºC and 39.0ºC, but this 
post-hoc finding needs further study.
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INTRODUCTION
Many patients admitted with stroke have fever or subfebrile body temperatures, which 
are associated with case fatality and poor functional outcome. About a third of patients 
have temperatures greater than 37.5˚C within the first hours after stroke onset.1-4 The 
odds of poor outcome were doubled for every degree increase in body temperature, 
measured within 12 hours of stroke onset.4 This association was independent of initial 
stroke severity, lesion volume, age, sex, and stroke type. The relation with clinical out-
come is probably limited to body temperatures measured in the first 12 to 24 hours of 
stroke onset.3-5
High body temperature may be a direct consequence of stroke or a result of accom-
panying infections. Studies in animals have suggested that high body temperature in-
creases damage caused by cerebral ischemia through increased metabolic demands, an 
increased release of neurotransmitters, increased free-radical production, breakdown of 
the blood-brain barrier, and increased proteolysis.6 Mitigation of even mild spontaneous 
hyperthermia conferred neuroprotection in animal models6, and induced hypothermia 
reduced infarct volume and improved functional outcome.7 Therefore, reduction of body 
temperature and prevention of fever may form a promising approach in treatment to 
improve functional outcome after stroke.
Guidelines for the treatment of patients with acute ischemic stroke8,9 or intracerebral 
hemorrhage10 recommend antipyretic drugs in patients with fever or body temperature 
above 37.5˚C, and most European stroke specialists view the monitoring of body tem-
perature as an essential component of care in stroke units.11 However, no evidence from 
randomized trials has shown that strategies to prevent or treat high body temperature 
reduce case fatality and improve functional outcome after stroke. 
Paracetamol (acetaminophen) is one of the most commonly used antipyretic drugs. 
Potent inhibition of prostaglandin production in the central nervous system presumably 
confers its antipyretic properties.12 Paracetamol is usually well tolerated by patients with 
acute stroke and has almost no side effects in doses up to 6 g per day.13-16 In patients with 
acute ischemic stroke, paracetamol at a daily dose of 6 g reduces body temperature by 
about 0.3˚C within 4 hours from start of treatment.14
In the Paracetamol (Acetaminophen) In Stroke (PAIS) trial, we aimed to assess whether 
early treatment with paracetamol improves functional outcome in patients with acute 
stroke. 
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METHODS
Patients
PAIS was a multi-center, randomized, double-blind, placebo-controlled, clinical trial in 
which patients were enrolled between March 2003, and May 2008. The study protocol 
has been published previously.17 In brief, patients were eligible for inclusion if they were 
18 years or older, had a clinical diagnosis of ischemic stroke or intracerebral hemorrhage, 
and were able to receive the study drug within 12 hours of symptom onset. In patients 
who noticed symptoms after waking from sleep, the time they were last seen well was 
taken as the time of symptom onset. The clinical diagnosis was confirmed with computed 
tomography or magnetic resonance imaging. Patients were excluded if they had a body 
temperature below 36˚C or over 39˚C, a history of liver disease or alcohol abuse, high 
concentrations of liver enzymes (alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, or gamma-glutamyl transferase increased to more than twice the 
upper limit of normal), hypersensitivity to paracetamol, or impairment before stroke 
that had led to dependency (modified Rankin scale (mRS) >2)18, or if death appeared 
imminent. 
The trial was approved by national and local institutional review boards, and written 
informed consent was obtained from all patients or from their legal representatives.
Randomization and masking
Patients were randomly allocated to paracetamol or an identical placebo given orally 
or rectally. Patients treated with paracetamol received a daily dose of 6 times 1 g for 3 
days consecutively. The study drug was provided in white paper boxes, with ascending 
numbers. Treatment allocation was based on a computer-generated list of random num-
bers with varying block size and linked to a unique treatment number. An independent 
statistician, who was otherwise not involved in the study, provided the list. The pharma-
cist of each center received a confidential list that indicated the treatment allocation for 
each randomized patient. Treatment assignment was masked for all investigators, study 
personnel, and patients were blind to the treatment assignments throughout the trial. In 
the first 3 days after enrollment, concurrent treatment with open-label paracetamol was 
not allowed.
Procedures
The patients were assessed at enrollment and at 14 days (or at discharge, if earlier) and 3 
months after enrollment. The initial assessment included cardiovascular risk factors and 
a quantification of stroke severity according to the National Institutes of Health Stroke 
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Scale (NIHSS), a 15-item scale in which scores can range from 0 to 42, with higher values 
indicating increasing severity.19 Body temperature (tympanic or rectal) was measured at 
enrollment and 24 hours later. For each individual patient, the same method of thermom-
etry was used at baseline and after 24 hours. After 14 days (or at discharge, if earlier), 
functional status was assessed by means of the Barthel Index (BI), which ranges from 
0 to 20, with 20 indicating no disability and 0 indicating complete dependence.20 At 3 
months, scores on the mRS, BI, and European Quality of Life-5 Dimensions (EuroQol-5D)21 
were assessed by telephone interview. Scores on the mRS range from 0 (no symptoms at 
all) to 5 (severe disability)18; for statistical purposes, death is assigned a score of 6. 
Trial conduct was monitored by a steering committee. An independent data monitor-
ing committee (DMC) did five interim safety and effectiveness analyses after intervals of 
one year. 
Serious adverse events were reported by local investigators to the PAIS trial office; 
these included any infection that led to prolonged hospital stay or was life threatening, 
death from any cause, liver failure, and gastro-intestinal hemorrhage that occurred dur-
ing hospitalisation and within the first 14 days after randomization.
Statistical analysis
Analyses were by intention-to-treat and all patients who were randomly assigned treat-
ment were included in the prespecified analyses. The primary outcome measure was the 
score on the mRS at 3 months. The original primary effect measure was the odds ratio 
for unfavorable outcome defined as a score on the mRS of 3 to 6. With this primary effect 
measure, we estimated that 2500 participants would have provided 80% power to detect 
a statistically significant (p<0.05) benefit, assuming a 6% absolute or 12% relative reduc-
tion of unfavorable outcome with paracetamol treatment. During the study, we realised 
that the target of 2500 patients could not be achieved within a reasonable time frame 
with the available financial resources and recruitment rate. As a result, the steering com-
mittee stopped inclusion on May 1, 2008 with final patient follow-up on August 1, 2008.
Early stopping of the trial at 1400 patients would lead to a reduction of power to 60%. 
For this reason, and because of advances in statistical methods during the course of the 
study22-24, the steering committee decided to change the primary effect estimate to the 
odds ratio for “improvement beyond expectation”, according to the sliding dichotomy 
approach.23 This decision was made on April 10, 2008, before data were unmasked, and 
the protocol change was subsequently published.25  Improvement beyond expectation 
(in short, improvement) was defined as a score on the mRS lower than the median grade 
of patients with a similar prognostic index.25 
We also analyzed the effect of treatment in patients who completed at least the first 24 
hours of treatment (on-treatment analysis). 
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Secondary effect estimates were the odds ratio for improvement of at least one cat-
egory on the mRS assessed by ordinal logistic regression and furthermore the odds ratio 
for favorable outcome defined as a score on the mRS of 2 or less, a score on the mRS of 3 
or less, and a score on the BI of 20.
Adjustments were made with a multiple logistic regression model that included the 
following factors: age, sex, time to treatment, baseline body temperature, stroke severity, 
stroke type (ischemic stoke versus intracerebral hemorrhage), ischemic stroke subtype 
(lacunar versus non-lacunar), treatment with rt-PA, previous stroke, atrial fibrillation, and 
diabetes mellitus. 
Quality of life was assessed by means of the EuroQol-5D.21 A utility score was calculated 
with population-based preference weights for combined health scores.26 A utility score of 
1 represents perfect health, a score of 0 represents death and negative scores represent 
health states considered worse than death. 
The mean absolute difference in body temperature between the two treatment groups 
was calculated with adjustment for baseline body temperature by means of multiple 
linear regression. The relation between improvement on the one hand and baseline body 
temperature and body temperature 24 hours after start of treatment on the other was 
expressed as an odds ratio per 1.0˚C increase in body temperature with a correspond-
ing 95% confidence interval, through logistic regression. An adjustment for the impact 
of age, sex, NIHSS score, stroke type, and ischemic stroke subtype was made by use of 
multiple logistic regression. 
Planned subgroup analyses were based on the time from stroke onset to start of 
treatment (dichotomized at the median), stroke type (intracerebral hemorrhage versus 
ischemic stroke), and ischemic stroke subtype (non-lacunar versus lacunar infarction). 
Post-hoc subgroup analyses were done according to baseline body temperature, di-
chotomized at the median, and treatment with rt-PA. 
We also updated our previous meta-analysis of pharmacological temperature-lowering 
therapy in acute stroke.27
All analyses were performed with Stata/SE 9.2 for Windows (Statacorp, College Station, 
Texas). This trial is registered as an International Standard Randomized Controlled trial 
[ISRCTN74418480].
Role of the funding source
The funding sources had no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. The study steering committee had full access to 
all data and had final responsibility for the decision to submit for publication.
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RESULTS
In 29 participating centers in the Netherlands, 697 patients were randomly assigned to 
treatment with paracetamol and 703 to placebo. 21 patients assigned paracetamol (3%) 
and 34 assigned placebo (5%) discontinued treatment within the first 24 hours of treat-
ment, and about 30% of all patients did not complete the 3-day treatment period. Early 
discharge (41%) or death (20%) were the most common reasons for not completing the 
full treatment period. One patient was lost to follow-up (Figure 1).
Baseline characteristics were well balanced (Table 1), except for atrial fibrillation, which 
was more common in patients allocated placebo (Table 1). In the total study population, 
the mean age was 69.8 years (SD 13.0), 56% were men, and 88% had ischemic stroke. 
Eligibility was determined by clinical diagnosis on admission; in 3 patients (0.2%), the 
final diagnosis turned out not to be stroke. The median score on the NIHSS was 6 (range 
0-30). The mean baseline body temperature was 36.9°C (SD 0.6). Median time from stroke 
onset to treatment was about 6 hours. 
Figure 1: Enrolment and follow-up.
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More patients in the paracetamol group than in the placebo group improved beyond 
expectation (Figure 2), but this effect was not statistically significant (adjusted OR 1.20; 
95% CI, 0.96 to 1.50) (Table 2). In the on-treatment analysis, the effect on improvement 
was much the same (1.20 (95% CI, 0.90 to 1.59). No analyses of secondary measures 
showed positive effects of treatment with paracetamol (Table 2). Quality of life according 
to the EuroQol-5D measurement was much the same in both groups, with a negligible 
difference of 0.004 (95% CI: -0.029 to 0.034). 
Mean body temperature at 24 hours from the start of treatment was 0.26°C (95% CI, 
0.18 to 0.31) lower with paracetamol than with placebo. After adjustment for age, sex, 
Table 1:  Baseline characteristics of the patients.
Paracetamol
(n=697)
Placebo
(n=703)
Demographics
Mean (SD) age (years)
Men
69.6 (13.0)
374 (54%)
70.1 (13.0) 
410 (58%)
Cardiovascular risk factors
Hypertension
Atrial fibrillation
Diabetes mellitus
Current smoking
Hypercholesterolemia
343 (49%)
88 (13%)
99 (14%)
197 (29%)
169 (24%)
346 (49%)
123 (18%)
110 (16%)
209 (30%)
177 (26%)
Medical history
Stroke
Myocardial infarction
Peripheral vascular disease
147 (21%)
77 (11%)
64 (9%)
133 (19%)
85 (12%)
68 (10%)
Stroke type
Ischemic stroke 610 (87%) 617 (89%)
Ischemic stroke subtype*
Large vessel disease (≥50% stenosis)
Cardiac source of embolism
Small vessel occlusion
Other determined etiology
Undetermined / negative evaluation 
Missing information
66 (11%) 
109 (18%)
108 (18%)
49 (8%)
251 (41%)
27 (4%)
84 (14%)
124 (20%)
90 (15%)
49 (8%)
241 (39%)
29 (5%)
Stroke severity 
Median (range) NIHSS$ score 6 (0-28) 7 (0-30)
Physical examination
Mean (SD) body temperature (°C) 36.9 (0.6) 36.9 (0.6)
Treatment
Median (IQR) time from stroke onset to start of 
treatment (minutes)
Treated within 12 hours of onset 
Treatment with rt-PA
345 (240-540)
661 (95%)
150 (22%)
360 (240-525)
673 (96%)
147 (21%)
*Based on the definitions of the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria.
$Scores on the National Institutes of Health Stroke Scale (NIHSS), range from 0 to 42, with higher values 
indicating more severe stroke.
71
 H
igh-dose paracetam
ol in acute stroke: the PA
IS trial 
3
NIHSS score, stroke type, and ischemic stroke subtype, baseline body temperature was 
not related to improvement (adjusted OR 0.95; 95 % CI: 0.79 to 1.14). Increased body 
temperature at 24 hours from the start of treatment was associated with a lower likeli-
hood of improvement (adjusted OR 0.83; 95% CI, 0.69 to 0.99).
We found no evidence of benefit of paracetamol in any of the predefined subgroups 
(Figure 3). In post-hoc subgroupanalysis of patients with a baseline body temperature 
between 37.0˚C and 39.0˚C, 131 of 326 patients (40%) in the paracetamol group improved 
beyond expectation compared with 106 of 335 (31%) in the placebo group (106/229) 
(adjusted OR 1.43; 95% CI, 1.02 to 1.97), but a stratified Mantel-Haenszel test did not 
formally indicate heterogeneity in the effect of paracetamol (p=0.12). The absolute risk 
reduction of 9% relates to a number of patients needed to treat of 11. Also, paracetamol 
resulted in a larger reduction in body temperature (0.30˚C; 95% CI, 0.20 to 0.40) in this 
subgroup than in patients with a baseline body temperature between 36.0˚C and 37.0˚C 
(0.19; 95% CI: 0.10 to 0.30). In a post-hoc subgroupanalysis of patients who were not 
treated with rt-PA, treatment with paracetamol was also associated with improvement 
(adjusted OR 1.29; 95% CI: 1.00 to 1.66) (Figure 3).
Table 2: Primary and secondary outcome measures.
Paracetamol
(n=697)
Placebo
(n=703)
OR (95% CI) aOR (95% CI)*
Improvement (sliding dichotomy) 
Improvement (ordinal regression)
Flavorable outcome (mRS ≤2)
Favorable outcome (mRS ≤3)
Favorable outcome (BI = 20)
260 (37%)
355 (51%)
463 (66%)
436 (63%)
232 (33%)
344 (50%)
451 (64%)
446 (63%)
1.21 (0.97-1.50)
1.10 (0.91-1.32)
1.09 (0.88-1.33)
1.11 (0.88-1.39)
0.96 (0.78-1.20)
1.20 (0.96-1.50)
1.03 (0.85-1.25)
1.02 (0.78-1.32)
1.00 (0.76-1.32)
1.09 (0.81-1.49)
*Adjusted for age, sex, NIHSS score, stroke type, ischemic stroke subtype, baseline body temperature, time 
to treatment, previous stroke, diabetes mellitus, treatment with rt-PA, and atrial fibrillation.
Figure 2: Distribution of grades on the modified Rankin Scale at 3 months.
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The number of serious adverse events was similar in both treatment groups (Table 3). 
In particular, there was no increased rate of infections or liver enzyme disturbances in 
patients treated with paracetamol. Fewer patients treated with paracetamol died within 
the first 14 days than did those treated with placebo (OR 0.60; 95% CI: 0.36 to 0.90). How-
ever, no difference in case fatality was found at 3 months (OR 0.90; 95% CI: 0.68 to 1.18). 
DISCUSSION
In the PAIS trial, more patients allocated to paracetamol improved beyond expectation 
than did patients treated with placebo, although the difference was not statistically 
significant. Paracetamol did not affect secondary outcome measures in predefined sub-
groups. However, in patients with a baseline body temperature between 37.0˚C and 
39.0˚C, treatment with paracetamol was associated with improved outcome.
Stroke type Ischemic
Hemorrhagic
Ischemic stroke          Lacunar
Non-lacunar
Time to treatment ≤ 6hrs
> 6hrs
Treatment with rt-PA    yes
no
Baseline body temperature       < 37°C
≥ 37°C
0.5 1.0                     1.5                 2.0
aOR (95% CI)
favors paracetamolfavors placebo
Figure 3: Subgroup analyses for the primary effect measure (improvement).
Table 3: Serious adverse events.
Paracetamol
(n=697)
Placebo 
(n=703)
Pneumonia
Urinary tract infection
Other infection
Sepsis
Liver function disturbance
Liver failure
Gastrointestinal hemorrhage
Death within 14 days
17
7
0
0
2
0
1
28
16
3
1
1
0
0
2
47
Total 55 (8%) 70 (9%)
73
 H
igh-dose paracetam
ol in acute stroke: the PA
IS trial 
3
Two-phase II trials in patients with acute ischemic stroke showed that high-dose 
paracetamol lowered temperature 0.30°C, which was confirmed in the present study. In 
a recent Cochrane review on temperature-lowering therapy for acute stroke, 5 studies of 
pharmacological temperature reduction were identified.27 These studies did not provide 
evidence that temperature reduction decreases the risk of death or dependency. How-
ever, the studies were small, were designed to test safety and feasibility, and long time 
periods were allowed between stroke onset and start of treatment. PAIS addressed the 
question whether temperature reduction by paracetamol improves outcome in patients 
with acute stroke in a large randomized phase III trial. 
We updated our previous meta-analysis of temperature-lowering therapy27  in acute 
stroke. The meta-analysis is now based on the data of six pharmacological temperature-
lowering trials (Figure 4). A pooled analysis shows no significant difference between ac-
tive treatment and control in the proportion of patients who were alive and independent 
(score on the mRS ≤2) at final follow-up (OR 1.1; 95% CI: 0.9 to 1.3).
There are some controversial features in the design of our study. The analysis plan for 
PAIS was changed from a fixed dichotomy of the mRS to the sliding dichotomy analysis 
during the trial. Neither the original primary nor the sliding dichotomy showed an effect 
of paracetamol on functional outcome. The protocol change was prompted by advances 
in statistical methods22-24 and the need to increase the efficiency of the trial. Analysis of 
sliding dichotomy allows each patient’s baseline prognosis to be taken into account and 
Dippel 2001* 9/26 6/12
Dippel_2 2001* 12/25 6/12
Koennecke 2001 15/20 12/22
Kassner 2002 6/20 6/19
Castillo 2003 16/31 15/29
Dippel 2003* 13/26 7/13
Dippel_2 2003* 15/24 6/12
Den Hertog 2008 355/697 344/703
Total 441/869 402/820
OR (95% CI)
Favors control Favors temperature-lowering therapy
0.5 [0.1-2.0]
0.9 [0.2-3.3]
2.5 [0.7-9.0]
0.9 [0.2-3.3]
1.0  [0.4-2.5]
0.8 [0.6-2.5]
1.7 [0.4-6.0]
1.1 [0.8-1.7]
1.1 [0.9-1.3]
1 100.1
Favorable outcome (mRS ≤2)Temperature-lowering  Control
therapy  
(n/N)                           (n/N)
Figure 4: Update of the meta-analysis of pharmacological temperature-lowering therapy in acute stroke.27
*Two intervention groups: the number of patients with favorable outcome and the total number of 
patients in the control group were divided by 2, in order to avoid multiple comparisons with the same 
subset of patients.
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seems more relevant for clinical practice, because even those at the prognostic extremes 
contribute to the estimation of the treatment effect, which may increase statistical power. 
Enrollment in the trial was stopped after inclusion of 1400 patients despite a target 
of 2500, because of lack of funding. This reduced the power of the study to detect a 
statistically significant effect for the original primary outcome measure of poor outcome 
defined as a score on the mRS of 3 to 6. However, the effect of adopting the sliding di-
chotomy approach might be almost the same as a doubling the sample size.23 
Although 95% of patients completed the first 24 hours of treatment, only 70% com-
pleted the full treatment period of three days. Early discharge, because of a complete 
or almost complete recovery or because of death, were the most common reasons for 
not completing the 3-day treatment period. Because overall benefit in the on-treatment 
analysis and intention-to-treat analysis was similar, we think that the suboptimal treat-
ment adherence will not have had a large effect on the results of the trial. Moreover, as 
the rise in temperature occurs mainly within the first 24 hours after stroke onset2,28, the 
first 24 hours might be the most important treatment period. In addition, most observa-
tional studies showed that the relation between body temperature and clinical outcome 
is probably limited to the first 12 to 24 hours after stroke onset.3-5 
Few patients with severe stroke were included in the PAIS trial, possibly because we did 
not specify a lower NIHSS limit in the eligibility criteria of the trial. Underrepresentation 
of patients with severe strokes might affect generalizability if the effect of treatment 
would be less in these patients. This is a point of concern for subsequent clinical trials 
with antipyretic drugs. 
Contrary to most observational studies1,3,4,30, we found no relation between body 
temperature on admission and functional outcome at 3 months. However, patients with 
increased body temperatures at 24 hours from the start of treatment did have a lower 
likelihood of improvement. This disparity suggests that an early rise in body temperature 
is more important in predicting clinical outcome after stroke than the body temperature 
itself.
Post-hoc subgroup analysis indicated a beneficial baseline of paracetamol on improve-
ment in patients with a baseline body temperature between 37.0˚C and 39.0˚C. Treat-
ment with high-dose paracetamol also induced a larger reduction in body temperature 
in this group of patients than in others, because paracetamol leads to larger temperature 
reductions when the initial body temperature is higher.31 
Any possible explanations for this finding should be interpreted with caution, because 
this subgroup was not defined in advance. Post-hoc subgroup analysis also indicated a 
beneficial effect of paracetamol in patients who were not treated with rt-PA. This might 
be explained by a higher recovery rate in the patients treated with rt-PA than in those not 
treated with thrombolysis. 
With organized care on a specialized stroke unit, patients are more likely to survive, 
regain independence, and return home than with a less well-organized stroke service. 
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The features of organized stroke care that confers benefits are unclear.32 Monitoring and 
early treatment of physiological variables, such as glucose levels, blood pressure and 
body temperature, probably contribute to the advantages.32 
Although the PAIS trial does not provide sufficient evidence to support the routine 
use of high-dose paracetamol in patients with acute stroke, its results are promising. In 
the subgroup of patients with a baseline body temperature between 37.0˚C and 39.0˚C, 
treatment with paracetamol resulted in a 9% absolute increase in the number of patients 
who improved beyond expectation, corresponding with a number needed to treat of 
only 11. This observation requires confirmation in an independent study. If such an ef-
fect can be confirmed, a simple, safe, and cheap treatment with a long time window for 
start of therapy will be available for patients with acute ischemic stroke or intracerebral 
hemorrhage.
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abstract
ABSTRACT 
Background and purpose Subfebrile temperature or fever is present in about a third of 
patients on the first day after stroke onset and is associated with poor outcome. How-
ever, the temporal profile of this association is not well established. We aimed to assess 
the relationship between body temperature, on admission as well as the change in body 
temperature from admission to 24 hours thereafter and functional outcome and death. 
Methods We analyzed data of 1332 patients admitted within 12 hours of stroke onset. 
The relation between body temperature on admission or the change in body temperature 
from admission to 24 hours thereafter (adjusted for body temperature on admission) on 
the one hand and poor outcome (death, or a modified Rankin Scale score>2) at 3 months 
on the other were expressed as odds ratio per 1.0˚C increase in body temperature. Adjust-
ments for potential confounders were made with a multiple logistic regression model. 
Results No relation was found between admission body temperature and poor outcome 
(aOR 1.06; 95% CI 0.85 to 1.33) and death (aOR 1.26; 95% CI 0.97-1.64). In contrast, in-
creased body temperature in the first 24 hours after stroke onset was associated with 
poor outcome (aOR 1.29; 95% CI 1.03 to 1.60) and death (aOR 1.48; 95% CI 1.13 to 1.93).
Conclusion An early rise in body temperature rather than elevated body temperature 
on admission is a risk factor for poor functional outcome in patients with acute stroke.
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BACKGROUND
Subfebrile temperature or fever is common in patients with acute stroke. Body tem-
peratures over 37.5°C have been reported in up to a quarter of patients within the first 
six hours1, and in about a third at 24 hours after stroke onset.2 This elevation of body 
temperature may be a direct consequence of brain damage inflicted by stroke, or a result 
of an associated infection.3
Increased body temperature markedly exacerbates neuronal injury in experimental 
models of cerebral ischemia.4 An association between increased body temperature and 
poor outcome has also been shown in patients with acute stroke.1,  2,  5-12 However, the 
temporal profile of this relation is not well established. Several prospective studies found 
that body temperature on admission was associated with poor outcome.1, 2, 5, 9, 11 Others 
found that an increased body temperature in the first 24 hours after admission was a 
prognostic factor for clinical outcome.6, 7, 10 
The aim of our study was to asses the relationship between body temperature within 
the first 12 hours after symptom onset, and the change in body temperature from admis-
sion to 24 hours thereafter on the one hand, and functional outcome and death on the 
other in a large sample of stroke patients.
METHODS
All patients participated in the Paracetamol (Acetaminophen) In Stroke (PAIS) trial. The 
PAIS trial was a multicenter, randomized, placebo-controlled clinical trial of high-dose 
paracetamol in patients with acute stroke.13 In short, patients with ischemic stroke or 
intracerebral hemorrhage with no history of liver disease or significant pre-stroke impair-
ment (grade on the modified Rankin Scale (mRS) ≥ 2)14 were included within 12 hours of 
symptom onset and treated with high-dose paracetamol (6g daily) or placebo for the 
next three days. 
The PAIS trial was approved by national and institutional review boards, and written 
informed consent was obtained from all patients or from their legal representatives.
Clinical characteristics
Baseline clinical information included stroke severity assessed by means of the NIH Stroke 
Scale (NIHSS), a 15-item scale with scores that range from 0 to 42 and higher values indi-
cating greater severity15, ischemic stroke subtype according to the TOAST classification16, 
and cardiovascular risk factors. In addition, any infection that led to prolonged hospital 
stay or was life threatening was recorded. The diagnosis of infection was left with the 
treating physician.
82
3
Body temperature
Body temperature was measured with a tympanic or rectal thermometer within 12 hours 
from stroke onset and 24 hours later. In each patient, a similar method of thermometry 
was used at these two points in time.
Outcome measures
Poor outcome was defined as a grade of more than 2 on the mRS at 3 months from stroke 
onset. Scores on the mRS range from 0 (no symptoms at all) to 5 (severe disability); for 
statistical purposes, death has a score of 6.
A secondary outcome measure was death at 3 months. Outcome assessment was 
blinded for body temperature.
Statistical analysis
Statistical analyses were performed with Stata/SE 9.2 for Windows (Statacorp, College 
Station, Texas). Changes in body temperature from baseline to 24 hours thereafter and 
corresponding 95% confidence intervals (CIs) were calculated with linear regression 
analysis. The relation between body temperature within 12 hours from stroke onset 
and the change in body temperature from admission to 24 hours thereafter (adjusted 
for admission body temperature) on the one hand and poor outcome or death on the 
other was expressed as an odds ratio per 1.0˚C increase in body temperature with a cor-
responding 95% confidence interval (CI), as estimated with logistic regression.
Adjustments were made with a multiple logistic regression model that included the 
following factors: age, sex, baseline NIHSS score, stroke type (ischemic stroke versus 
intracerebral hemorrhage), ischemic stroke subtype (lacunar versus non-lacunar infarc-
tion), and the occurrence of infections. We performed additional analyses to account for 
the potential modifying effect of antipyretic treatment by stratifying for treatment with 
paracetamol, which was the experimental drug treatment in the PAIS trial.
Furthermore, we assessed the relation between several clinical variables including 
stroke type, ischemic stroke subtype, and stroke severity (expressed in quartiles of the 
baseline NIHSS score) and the change in body temperature from baseline to 24 hours 
thereafter, adjusted for baseline body temperature, with multiple linear regression. 
RESULTS
Fourteen hundred patients with a clinical diagnosis of ischemic stroke or intracerebral 
hemorrhage were included in the PAIS trial. Of these patients, 68 were excluded from the 
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present study either because the final diagnosis was not a stroke (n=3) or because body 
temperature at 24 hours was not recorded (n=65).
In the remaining 1332 patients, mean age was 70 years (SD 13), 56% of the patients 
were male, and 88% had an ischemic stroke (Table 1). The infarction was of the lacunar 
type in 193 patients (17%). The median score on the NIHSS scale was 6 (range 0-30). 
Median time from stroke onset to measurement of the admission body temperature was 
360 minutes (IQR 240-540). A total of 660 patients (50%) was treated with paracetamol.
Table 1: Baseline clinical characteristics of the patients (n=1332).
Demographics
Mean (SD) age (years)
Sex (male)
70 (13)
749 (56%)
Cardiovascular risk factors
Hypertension
Atrial fibrillation
Diabetes mellitus
Current cigarette smoking
Hypercholesterolemia
652 (49%)
198 (15%)
195 (15%)
390 (29%)
332 (25%)
Medical history
Stroke
Myocardial infarction
Peripheral vascular disease
267 (20%)
155 (12%)
128 (10%)
Stroke type
Ischemic stroke 1169 (88%)
Ischemic stroke subtype*
Large vessel disease (≥50% stenosis)
Cardiac source of embolism
Small vessel occlusion
Other determined etiology
Undetermined 
Missing information
146 (12%) 
216 (18%)
193 (17%)
90 (8%)
477 (41%)
47 (4%)
Stroke severity 
Median (range) NIHSS score$  6 (0-30)
Physical examination
Mean (SD) body temperature (°C)
Median (IQR) time from stroke onset to measurement of baseline 
body temperature (minutes)
36.9 (0.6)
360 (240-540)
Treatment
Paracetamol
Intravenous alteplase
660 (50%)
281 (21%)
*Based on the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria.16 
$Scores on the National Institutes of Health Stroke Scale (NIHSS).15
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The mean body temperature was 36.9°C (SD 0.6) on admission, and 37.1°C (SD 0.7) 24 
hours later. Body temperature over 37.5˚C was observed in 160 patients (12%) on admis-
sion, and in 298 (22%) 24 hours later. The increase in body temperature from baseline 
to 24 hours thereafter was larger in patients with body temperatures of 37.0˚C or less 
than in those with body temperatures over 37.0˚C (Figure 1). After 24 hours, 96 of 660 
patients (15%) treated with paracetamol and 202 of 672 patients (30%) on placebo had 
a body temperature over 37.5˚C (difference 15%; 95% CI 11% to 19%). Treatment with 
paracetamol was associated with a 0.26°C (95% CI, 0.18 to 0.31) reduction in mean body 
temperature measured 24 hours after admission.
Four of the 160 patients (3%) with baseline body temperatures over 37.5°C and 24 
of 298 patients (8%) with body temperatures over 37.5°C 24 hours later developed an 
infection during hospitalization.
The proportion of patients with admission body temperatures over 37.5˚C was similar in 
patients with ischemic stroke (145/1169 (12%)) and in those with intracerebral hemorrhage 
(16/163 (10%)) and also in patients with non-lacunar infarction (136/1139 (10%) and lacu-
nar infarction (24/193 (12%)). However, the increase in body temperature from admission 
to 24 hours thereafter was 0.24°C larger (95% CI, 0.14 to 0.33) in patients with non-lacunar 
infarction than in those with lacunar infarction and also 0.33°C (95% CI, 0.23 to 0.44) larger 
in patients with intracerebral hemorrhage than in patients with ischemic stroke. 
We did not observe a proportional increase in the association between stroke severity 
and body temperature on admission. In the highest quartile of the NIHSS score (NIHSS 
Figure 1: The change in body temperature in the first 24 hours from admission to 24 hours thereafter (ºC) 
as a function of body temperature on admission (ºC).
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score ³ 13), baseline body temperature was 0.20°C (95% CI, 0.12 to 0.27) lower than body 
temperature in the lower quartiles of the NIHSS score (NIHSS<13) (Figure 2). Body tem-
perature 24 hours later was associated with baseline stroke severity. For every quartile of 
the NIHSS score, body temperature at 24 hours rose on average with 0.16°C (95% CI, 0.13 
to 0.19) (Figure 2).
Body temperature on admission was not related to poor outcome or death (Table 2). 
An increased body temperature in the first 24 hours after admission, however, was as-
sociated with poor outcome or death at 3 months (Table 2). Adjustment for potential 
confounders slightly attenuated this association (Table 2). An additional stratified analy-
sis to account for the potentially modifying effect of treatment with paracetamol did not 
affect the association (Table 2). 
Figure 2: Stroke severity (quartiles) and body temperature within 12 hours from stroke onset, (grey bars) 
and 24 hours later (black bars).
Table 2: Association of body temperature with poor outcome or death at 3 months.
Poor outcome Overall
OR (95% CI)*
Overall
aOR (95% CI)*$
Paracetamol   Placebo
aOR (95% CI)*$
Within 12 hrs 
from stroke 
onset
Change from 
admission to 
24 hours#
mRS>2 (n=663)
Death   (n=218)
mRS>2 (n=663)
Death   (n=218)
0.82 (0.68-0.98)
0.87 (0.68-1.12)
1.98 (1.65-2.39)
2.36 (1.86-2.99)
1.06 (0.85-1.33)
1.26 (0.97-1.64)
1.28 (1.03-1.60)
1.49 (1.13-1.94)
0.90 (0.65 to 1.24)   1.22 (0.89 to 1.68) 
1.15 (0.77 to 1.72)   1.39 (0.96 to 2.02)
1.22 (0.86 to 1.72)    1.31 (0.97 to 1.77)
1.50 (0.96 to 2.32)    1.57 (1.10 to 2.26)
*Per 1.0 degree Celsius increase of body temperature
$Adjusted for age, sex, NIHSS score, stroke type, ischemic stroke subtype, and occurrence of infections
#Adjusted for body temperature on admission
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After exclusion of patients who developed an infection during the first two weeks after 
stroke onset, the adjusted odds ratio for poor outcome was 1.27 (95% CI 1.02 to 1.59), 
and for death 1.47 (95% CI 1.10 to 1.96).
Figure 3 illustrates the strength of the association between the change in body 
temperature from admission to 24 hours thereafter and poor outcome. The absolute 
difference in the risk of poor outcome between patients in the lowest and patients in the 
highest body temperature category is more than 20%.
DISCUSSION
Our results do not confirm the previously reported association between body tempera-
ture on admission and poor outcome in patients with acute stroke. However, patients 
with increased body temperatures in the first 24 hours after admission did have an 
increased risk of poor functional outcome or death at 3 months. 
Before these results can be interpreted, some methodological issues have to be dis-
cussed. First, one of the strengths of our study is its large sample size. Other strengths 
include robust outcome measures and detailed information on confounders. Second, 
PAIS was a randomized double-blind placebo controlled trial that addressed the 
question whether temperature reduction by paracetamol would improve outcome in 
patients with acute stroke.13 Half of the study population was treated with paracetamol 
in a daily dose of 6 g for 3 consecutive days. As a result, body temperature at 24 hours 
after admission was lowered and fewer patients may have experienced a poor outcome, 
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Figure 3: Probability of poor outcome (mRS>2) at 3 months in relation to change in body temperature 
from baseline to 24 hours thereafter (sixtiles) (°C).
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although the overall effect of paracetamol on outcome was not statistically significant. 
We did separate regression analyses in the patients treated with paracetamol and those 
allocated to placebo. The estimates of the association between the change in body 
temperature from admission to 24 hours thereafter and outcome were similar in the two 
groups, suggesting that the study population could be analyzed as one group. 
A second issue is that we only recorded body temperature at two points in time, i.e. 
within 12 hours from symptom onset and 24 hours later and did not repeated measure-
ments of body temperature. As a consequence, it might be more difficult to compare our 
results with the results of previous studies.
Finally, relatively few patients with very severe stroke were included, possibly because 
we did not specify a lower NIHSS score limit in the eligibility criteria of the PAIS trial. 
However, our results showed that patients with more severe strokes had higher body 
temperatures at 24 hours after admission, and thereby underrepresentation of patients 
with severe strokes potentially weakens rather than exaggerates the observed relation 
between body temperature at 24 hours after admission and poor outcome.
Previous studies have found that increased body temperature within 6 hours up to 
at least 24 hours after stroke onset is an independent prognostic factor for poor out-
come.1, 2, 5-12 However, the temporal profile of this association is still under debate. Several 
studies showed that high body temperature on admission was associated with poor out-
come. In three of these, no adjustments were made for baseline stroke severity assessed 
with validated stroke scales.2, 5, 8 A retrospective study of 509 patients with ischemic stroke 
or intracerebral hemorrhage found an association between elevated admission body 
temperature and poor outcome only in patients with ischemic stroke.11 In a prospective 
study of 390 patients with either ischemic stroke or intracerebral hemorrhage admitted 
within 6 hours of symptom onset, the odds of poor outcome doubled for every degree of 
Celsius increase in baseline body temperature.1
A prospective study of 725 patients admitted within 6 hours of symptom onset did 
find a relation between increased body temperature at 10 to 12 hours after stroke onset 
and poor outcome, but no relationship between body temperature on admission and 
poor outcome was found.6 Although these results seem contradictory to our findings, 
our results indeed suggest that increased body temperature in the first 24 hours after 
admission rather than body temperature on admission is an important prognostic factor 
for clinical outcome after stroke. We found that patients with severe stroke had relatively 
low body temperatures at baseline, possibly because of a faster loss of body temperature 
before hospital admission as a result of less muscle activity. This finding might explain 
in part that body temperature on admission was not associated with clinical outcome.
In line with our results, two studies showed that increased body temperature relative 
to baseline in the first 24 to 72 hours after stroke onset was associated with unfavorable 
outcome.7,  10 These studies included only patients with intracerebral hemorrhage10 or 
patients with ischemic stroke treated with intravenous thrombolysis.7
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Increased body temperature may be attributed to a systemic inflammatory response 
following ischemic stroke or to accompanying infections. In addition, it has been sug-
gested that increased body temperature indicates hypothalamic damage following 
stroke.17 The mechanisms of the association between an early rise in body temperature 
and poor outcome remain speculative. Secondary infections are common in the first 
week of stroke and are associated with poor outcome, but they usually occur more than 
12 hours after stroke onset.18 In our study, only three percent of patients with baseline 
body temperatures over 37.5°C and eight percent of patients with body temperatures 
over 37.5°C, 24 hours later developed an infection during hospitalization. Besides, the 
relationship between body temperature at 24 hours after admission and poor outcome 
was independent of the occurrence of infections. Furthermore, exclusion of patients de-
veloping an early infection during hospitalization did not substantially affect the relation 
between body temperature and poor functional outcome or death. Therefore, infections 
cannot account for the observed relation between temperature and outcome.
The change in body temperature from admission was associated with baseline stroke 
severity. One may argue that increased body temperature does not accelerate the 
ischemic cascade, but merely reflects extensive cerebral damage and, thereby, of poor 
outcome. However, the relation between increased body temperature and poor outcome 
was independent of baseline stroke severity. 
Our results provide a rationale for the hypothesis that prevention of an early rise in 
body temperature could reduce death and improve functional outcome. Guidelines for 
the treatment of patients with acute ischemic stroke19 or intracerebral hemorrhage20 rec-
ommend the administration of antipyretic medication in case of fever or a temperature 
above 37.5˚C. This might be too late, as the rise in body temperature has already occurred, 
and the time period in which the brain lesion is most vulnerable has subsided. On the 
other hand, there is still no convincing evidence from randomized trials that strategies to 
prevent or treat elevated body temperature reduce case fatality and improve functional 
outcome after stroke.13, 21
Conflict of interest 
The authors declare no conflict of interest.
Acknowledgement
The PAIS trial was sponsored by the Netherlands Heart Foundation, grant number 
2002B148. We are grateful to all patients, nurses, secretaries, and neurologists who 
contributed to this study. 
Participating centers with names of investigators
Meander MC Amersfoort (HMA van Gemert), Erasmus MC Rotterdam (DWJ Dippel), UMC 
Utrecht (HB van der Worp), Sint Fransicus Gasthuis Rotterdam (FH Vermeij), Slotervaart 
89
 A
n early rise in body tem
perature is related to unfavorable outcom
e after stroke 
3
Ziekenhuis Amsterdam (VIH Kwa), Gelre ziekenhuizen Apeldoorn (HP Bienfait), TweeSt-
eden ziekenhuis Tilburg (BPW Jansen), Sint Elisabeth Ziekenhuis Tilburg (PLM de Kort), 
Westfriesgasthuis Hoorn (TC van der Ree), Maasstad ziekenhuis Rotterdam (R Saxena), 
Ziekenhuis Bethesda Hoogeveen (PG Oomes), Dirksland Ziekenhuis Dirksland (UW Huis-
man), Sint Lucas Andreas Ziekenhuis Amsterdam (EJ Wouda), Martini Ziekenhuis Gronin-
gen (C Bouwsma), Catharina Ziekenhuis Eindhoven (K Keizer) Albert Schweitzer ziekenhuis 
Dordrecht (RP Kleyweg/H Kerkhoff), Amphia Ziekenhuis Breda (HBC Verbiest/SLM Bak-
ker), Rijnland Ziekenhuis Leiderdorp (ELLM De Schryver), Diakonessenhuis Utrecht (RCJM 
Donders), Slingeland Ziekenhuis Doetinchem (RA van der Kruijk), IJsselland Ziekenhuis 
Capelle aan den Ijssel (J Heerema), Jeroen Bosch Ziekenhuis Den Bosch (RAJAM Bernsen), 
Ziekenhuis Hilversum Hilversum (D Herderschêe), Diaconessenhuis Meppel (EJW Keuter), 
Vlietlandziekenhuis Schiedam (WC Baart), Spaarne Ziekenhuis Hoofddorp (RJ Meijer), 
Beatrixziekenhuis Gorinchem (RB Alting van Geusau), Streekziekenhuis Koningin Beatrix 
Winterswijk (JP de Ruiter), Wilhelmina Ziekenhuis Assen (JN Wessel/AE Bollen).
90
3
REFERENCES
 1.  Reith J, Jorgensen HS, Pedersen PM et al. Body temperature in acute stroke: relation to stroke 
severity, infarct size, mortality, and outcome. Lancet 1996; 347:422-425.
 2.  Castillo J, Davalos A, Marrugat J et al. Timing for fever-related brain damage in acute ischemic 
stroke. Stroke 1998; 29:2455-2460.
 3.  den Hertog H, van der Worp B, van Gemert M et al. Therapeutic hypothermia in acute ischemic 
stroke. Expert Rev Neurother 2007; 7:155-164.
 4.  Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. 
Stroke 1998; 29:529-34.
 5.  Azzimondi G, Bassein L, Nonino F et al. Fever in acute stroke worsens prognosis. A prospective 
study. Stroke 1995; 26:2040-2043.
 6.  Boysen G, Christensen H. Stroke Severity Determines Body Temperature in Acute Stroke. Stroke 
2001; 32:413-417.
 7.  Ernon L, Schrooten M, Thijs V. Body temperature and outcome after stroke thrombolysis. Acta 
Neurol Scand 2006; 114:23-28.
 8.  Hindfelt B. The prognostic significance of subfebrility and fever in ischaemic cerebral infarction. 
Acta Neurol Scand 1976; 53:72-9.
  9.  Jorgensen HS, Reith J, Pedersen PM et al. Body temperature and outcome in stroke patients. 
Lancet 1996; 348:193.
 10.  Schwarz S, Hafner K, Aschoff A et al. Incidence and prognostic significance of fever following 
intracerebral hemorrhage. Neurology 2000; 54:354-361.
 11.  Wang Y, Lim LL, Levi C, et al. Influence of admission body temperature on stroke mortality. Stroke 
2000; 31:404-409.
 12.  Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome : a meta-analysis of 
studies in patients. Stroke 2000; 31:410-414.
 13.  den Hertog HM, van der Worp HB, van Gemert HM et al. The Paracetamol (Acetaminophen) In 
Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 
2009; 8:434-440
 14.  van Swieten JC, Koudstaal PJ, Visser MC et al. Interobserver agreement for the assessment of 
handicap in stroke patients. Stroke 1988; 19:604-607.
 15.  Brott T, Adams HP, Olinger CP et al. Measurements of acute cerebral infarction: a clinical examina-
tion scale. Stroke. 1989; 20:864-870.
 16.  Adams HPJ, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Defi-
nitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. 
Stroke 1993; 24:35-41.
 17.  Przelomski MM, Roth RM, Gleckman RA et al. Fever in the wake of a stroke. Neurology 1986; 
36:427-429.
 18.  Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: recent and emerging concepts. 
Lancet Neurol 2008; 7:341-53.
 19.  Adams HP, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with 
ischemic stroke: a guideline from the American Heart Association/American Stroke Association 
Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, 
and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research 
Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this 
guideline as an educational tool for neurologists. Circulation 2007; 115:e478-e534.
91
 H
igh-dose paracetam
ol reduces systolic blood pressure in acute stroke 
3
 20.  Broderick JP, Adams HP, Barsan W et al. Guidelines for the management of spontaneous intrace-
rebral hemorrhage: A statement for healthcare professionals from a special writing group of the 
Stroke Council, American Heart Association. Stroke 1999; 30:905-915.
 21.  den Hertog HM, van der Worp HB, Tseng MC et al. Cooling therapy for acute stroke. Cochrane 
Database Syst Rev 2009; 1:CD001247.

High-dose 
paracetamol 
reduces systolic 
blood pressure 
in acute stroke
Heleen M den Hertog1, H Bart van 
der Worp2, H Maarten A van Gemert3, 
Jan van Gijn2, Peter J Koudstaal1, 
Diederik WJ Dippel1
1Department of Neurology, Erasmus MC 
University Medical Center, Rotterdam, 
The Netherlands
2Department of Neurology, Rudolf 
Magnus Institute of Neuroscience, 
University Medical Center Utrecht, Utrecht, 
The Netherlands 
3Department of Neurology, Meander 
Medical Center, Amersfoort, The 
Netherlands Submitted
abstract
ABSTRACT
Background Early administration of paracetamol may improve outcome of patients 
with acute stroke and a baseline body temperature of 37ºC or above by lowering body 
temperature and preventing fever. Besides its antipyretic effects, paracetamol may also 
reduce blood pressure through cyclooxygenase-2 inhibition. We therefore aimed to as-
sess the effect of high-dose paracetamol on blood pressure in patients with acute stroke. 
Methods We analyzed data of 540 patients admitted within 24 hours of stroke onset 
who were randomized to treatment with either paracetamol (6 g daily) or placebo. Blood 
pressures were measured at 12, 24, and 48 hours from the start of treatment. Changes 
in blood pressure from baseline in the two treatment groups and corresponding 95% 
confidence intervals (CI) were calculated with linear regression analysis. Adjustments for 
potential confounders were made with a multiple linear regression model.
Results Treatment with high-dose paracetamol was associated with a significant reduc-
tion in systolic blood pressure of 4.7 mm Hg (95% CI 0.7 to 8.6) at 12 hours from the start 
of treatment. This effect was no longer present after 24 and 48 hours.
Conclusion High-dose paracetamol reduces not only body temperature, but also blood 
pressure in patients with acute stroke. Both effects may improve functional outcome 
after stroke, but this needs further study.
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BACKGROUND
Guidelines for the treatment of acute ischemic stroke or intracerebral hemorrhage 
recommend administration of antipyretic medication in patients with subfebrile 
temperatures or fever, on the assumption that this will improve functional outcome.1, 2 
We have recently reported that in a large randomized trial, treatment with high-dose 
paracetamol improved functional outcome in patients with acute stroke and a baseline 
body temperature of 37°C or above, although this was a post-hoc finding that requires 
confirmation.3 
Despite its widespread use, the mechanism of action of paracetamol has not been fully 
clarified. Paracetamol is a potent inhibitor of cyclooxygenase (COX)-1 and COX-2-mediat-
ed prostaglandin production in the central nervous system.4, 5 This presumably accounts 
for its antipyretic and analgesic properties. A different effect of paracetamol may be a 
COX-2-mediated change in blood pressure. Two small observational studies suggested 
that in patients admitted to an intensive care unit, administration of paracetamol reduces 
systolic arterial pressure and mean arterial pressure.6,  7 On the other hand, long-term 
use of some COX-2 inhibitors may be associated with an increase in blood pressure by 
inhibiting the synthesis of vasodilatory prostaglandins, sodium retention, or increased 
endothelin 1 production.8 
Most patients with acute stroke initially have an elevated blood pressure, which spon-
taneously normalizes over the first few days.9, 10 High blood pressure in the acute phase of 
stroke is associated with increased case fatality and dependency, and moderate lowering 
of blood pressure may therefore improve outcome.11, 12 
We aimed to assess the effect of high-dose paracetamol on blood pressure in patients 
with acute stroke.
METHODS
Study design
The study population was derived from the Paracetamol (Acetaminophen) in Patients 
with Acute Stroke (PAPAS) trial13, the Paracetamol (Acetaminophen) and Ibuprofen in 
Acute Stroke (PISA) trial14, and the Paracetamol (Acetaminophen) In Stroke (PAIS) trial.3
In the first study (PAPAS)13, 76 patients with ischemic stroke admitted within 24 hours 
of symptom onset were treated with either 3 g or 6 g paracetamol or placebo for 5 days. 
Study medication was provided as suppositories. The second study (PISA)14 compared 
high-dose paracetamol (6 g daily) and ibuprofen (2.4 g daily) with placebo in 75 patients 
with ischemic stroke, admitted within 24 hours of symptom onset. The first dose of the 
study medication was provided as a suppository and the remainder as tablets. In the 
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third study (PAIS)3, patients with ischemic stroke or intracerebral hemorrhage admitted 
within 12 hours of symptom onset were treated with paracetamol in a daily dose of 6 g 
for 3 consecutive days. The study medication was administered orally, except for the first 
four gifts that could be administered as a suppository. In all three studies, patients were 
eligible for inclusion if they had a body temperature between 36°C and 39°C and had 
no history of liver failure or alcohol abuse. All three trials were randomized and double-
blind; detailed protocols have been published.13-16 
For the purpose of the present study, we included patients from PAPAS and PISA who 
were treated with either 6 g paracetamol or placebo and patients from PAIS who were 
enrolled in the two largest recruiting centers (Erasmus Medical Center, Rotterdam, and 
Meander Medical Center, Amersfoort, the Netherlands). Patients were excluded in case of 
missing data on blood pressure at 12 hours of stroke onset. 
National and institutional review boards approved all trials, and written informed 
consent was obtained from all patients or from their legal representatives. 
Baseline data
Baseline clinical information included stroke severity assessed by means of the NIH 
Stroke Scale (NIHSS)17, ischemic stroke subtype according to the TOAST classification18, 
and cardiovascular risk factors. Additionally, the use of antihypertensive drugs and COX-1 
and COX-2 inhibitors was recorded. 
Blood pressure
According to local protocols, systolic blood pressure, diastolic blood pressure and heart 
rate were measured on admission, every 2 hours within the first 24 hours, and every 4 
hours thereafter, up to 48 hours after hospitalization. We collected data on systolic and 
diastolic blood pressure levels and heart rate on admission and at 12, 24, and 48 hours 
from the start of treatment. 
Outcome measures
The primary outcome measures of the present study were the systolic and diastolic 
blood pressure at 12 hours from the start of treatment. Secondary outcome measures 
were systolic and diastolic blood pressure at 24 and 48 hours from the start of treatment. 
Outcome assessment was blinded for treatment with the study drug.
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Statistical analyses
Statistical analyses were performed with Stata/SE 9.2 for Windows (Statacorp, College 
Station, Texas). 
The differences between the baseline blood pressure and the blood pressures on 
follow-up were compared between patients allocated to paracetamol and those on 
placebo. Linear regression analysis was performed to estimate differences between the 
changes in blood pressure in the two treatment groups and corresponding 95% confi-
dence intervals (CI). Adjustments were made with a multiple linear regression model that 
included the following factors: age, sex, stroke severity, time to treatment, stroke type 
(ischemic stroke versus intracerebral hemorrhage), ischemic stroke subtype (lacunar 
versus non-lacunar), diabetes mellitus, hypertension, use of other COX inhibitors, and 
use of antihypertensive drugs. Between-study effects and between-hospital effects were 
explored. We also analyzed the effect of treatment in patients who completed at least the 
first 48 hours of treatment (on-treatment analysis), to evaluate the full pharmacological 
effect of paracetamol on blood pressure.
RESULTS
Of the 151 patients included in the PAPAS en PISA trial, 52 were treated with high-dose 
paracetamol and 50 with placebo. Of the 543 patients in the PAIS trial who were enrolled 
at the Erasmus Medical Center or the Meander Medical Center, 105 patients were ex-
cluded from the present study, because of insufficient data on blood pressure 12 hours 
after the start of treatment. No significant differences in baseline characteristics or case 
fatality were found between included patients (n=540) and excluded patients (n=105) 
(data not shown). 
Blood pressure levels were available for 502 of the 540 patients at 24 hours from the 
start of treatment, and for 423 patients at 48 hours. Early discharge (n = 87) and death 
(n = 13) were the most common reasons for missing blood pressure levels at these two 
points in time.
Of the 540 included patients, 60% were male, mean age was 68 years (SD 14), and 86% 
percent had an ischemic stroke (Table 1). The infarction was of the lacunar type in 56 
patients (12%). Forty-seven percent of patients had a history of hypertension and about 
half of the patients received one or more antihypertensive drugs. The median score on 
the NIHSS scale was 6 (range, 0-40). Median time from stroke onset to start of treatment 
was 6.5 hours (IQR, 4.6 to 10.0).
The mean systolic/diastolic blood pressure on admission was 157/86 mm Hg in the 
paracetamol group and 160/81 mm Hg in patients on placebo. 
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At 12 hours from the start of treatment, the mean systolic blood pressure had dropped 
15.7 mm Hg (95% CI, 12.7 to 18.6) in the paracetamol group and 12.2 mm Hg (95% CI, 8.6 
to 15.6) in patients on placebo (difference 3.5 mm Hg; 95% CI, 0.5 to 8.4 ) (Table 2 and 
Figure 1). The mean diastolic blood pressure had dropped 5.8 mm Hg (95% CI, 3.7 to 8.2) 
in patients on paracetamol, and 4.4 mm Hg (95% CI, 1.7 to 8.6) in patients on placebo (dif-
ference 1.4; 95% CI -1.5 to 4.3) (Table 2 and Figure1). Adjustment for confounding factors 
increased the effect of paracetamol on systolic blood pressure after 12 hours to 4.7 mm 
Table 1: Baseline characteristics of the patients (n=540).
Paracetamol
(N=281)
Placebo
(N=259)
Demographics
Mean (SD) age (years)
Sex (male)
  69 (14)
158 (56%)
  68 (14)
163 (63%)
Cardiovascular risk factors
Hypertension
Atrial fibrillation
Diabetes mellitus
Current cigarette smoking
Hypercholesterolemia
132 (47%)
  36 (13%)
  37 (13%)
  90 (32%)
  58 (21%)
122 (47%)
  36 (14%)
  35 (14%)
  91 (35%)
  59 (23%)
Medical history
Previous stroke
Previous myocardial infarction
Peripheral vascular disease
  56 (20%)
  34 (12%)
  18 (6%)
  55 (21%)
  27 (10%)
  20 (8%)
Stroke type
Ischemic stroke 247 (88%) 218 (84%)
Ischemic stroke subtype*
Large vessel disease (≥50% stenosis)
Cardiac source of embolism
Small vessel occlusion
Other determined etiology
Undetermined 
Missing information
   32 (13%)
   44 (18%)
   32 (13%)
   20 (8%)
 109 (44%)
   10 (4%)
37 (17%)
39 (18%)
24 (11%)
13 (6%)
94 (43%)
11 (5%)
Stroke severity 
Median (range) NIHSS score$  6 (0-42) 7 (0-40)
Physical examination
Mean (SD) systolic blood pressure (mm Hg)
Mean (SD) diagnostic blood pressure (mm Hg)
Mean (SD) heart rate (beats per minute)
157 (29)
  78 (19)
  82 (20)
160 (29)
  81 (18)
  81 (22)
Treatment
Median (IQR) time from stroke onset to start of 
treatment (hours)
Antihypertensive drugs
Other Cox-1 and 2 inhibitors
Intravenous alteplase
6.5 (4.6 to 9.3)
134 (48%)
  51 (18%)
  57 (20%)
7.0 (4.6 to 10.6)
112 (43%)
  35 (14%)
  49 (19%)
*Based on the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria.18
$Scores on the National Institutes of Health Stroke Scale (NIHSS).17
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Figure 1: Systolic and diastolic blood pressures in patients on paracetamol (black dots) and in patients on 
placebo (grey dots).
Table 2: Mean difference in decrease in blood pressure (mm Hg) between patients treated with 
paracetamol and those who received placebo during the treatment period of 48hrs.
Time from 
the start of 
treatment
Difference* 
(95% CI)
Adjusted difference*# 
(95% CI)
Adjusted difference for 
on-treatment analysis*#
(95% CI)
12 hours 
24 hours
48 hours
SBP
DBP
SBP
DBP
SBP
DBP
 3.5 (0.5 to 8.4)
 1.4 (-1.5 to 4.3)
-1.4 (-5.4 to 2.5)
-1.0 (-3.6 to 1.7)
-1.8 (-6.2 to 2.7)
-0.1 (-3.1 to 3.1)
 4.7 (0.7 to 8.6)
 1.2 (-1.7 to 4.1)
-0.9 (-4.8 to 3.1)
-0.5 (-3.2 to 2.3)
-1.1 (-5.5 to 3.4)
-0.1 (-3.1 to 3.1)
 5.3 (1.1 to 9.5)
 1.6 (-1.4 to 4.7)
-0.7 (-4.5 to 3.5)
-1.1 (-3.8 to 1.7)
-0.8 (-5.4 to 3.8)
-0.1 (–3.2 to 3.2)
 SBP, systolic blood pressure; DBP, diastolic blood pressure
*Adjusted for baseline systolic or diastolic blood pressure
#Adjusted for age, sex, NIHSS score, time to treatment, hypertension, diabetes mellitus, stroke type, 
ischemic stroke subtype, use of antihypertensive drugs, and use of other COX inhibitors.
100
3
Hg (95% CI 0.7 to 8.6) (Table 2). Furthermore, paracetamol was associated with a decrease 
in heart rate of 4.2 beats per minute (95% CI, 0.5 to 8.5) as compared with placebo.
At 24 and 48 hours from the start of treatment, no effect of paracetamol was observed 
on either systolic or diastolic blood pressure (Table 2 and Figure1), or on heart rate.
There was no hospital effect. The direction of the effect of paracetamol was consistent 
across the trials. However, the decrease in systolic blood pressure by paracetamol at 12 
hours from the start of treatment was larger in PAPAS (11.4 mm Hg; 95% CI, -6.8 to 29.6) 
than in PISA (2.7 mm Hg; 95% CI -9.2 to 14.6) than in PAIS (3.8 mm Hg; 95% CI, -0.5 to 8.1).
In the on-treatment analysis, the effect of paracetamol on systolic blood pressure 12 
hours from start of treatment increased to 5.3 mm Hg (95% CI, 1.1 to 9.5) (Table 2).
DISCUSSION
We showed that treatment with high-dose paracetamol, started within 24 hours after 
stroke onset, was associated with a significant reduction in systolic blood pressure of 4.7 
mm Hg at 12 hours from the start of treatment. This effect was no longer present after 
24 and 48 hours.
Several methodological issues need to be discussed. First, this study was not designed 
to evaluate the effect of high-dose paracetamol on blood pressure in acute stroke. As a 
consequence, blood pressure was not measured in a standardized way. However, this 
would more likely result in a random error than in a systematic error. Second, we did not 
compare the effect of different doses of paracetamol on blood pressure. However, only 
in the PAPAS trial two doses of paracetamol were compared, and the number of patients 
included in this trial (76) was far too small for reliable analyses. Third, about a sixth of 
the patients enrolled in the three trials had to be excluded because of missing data on 
blood pressure at 12 hours. On the other hand, comparison of the excluded patients 
with the study population showed no significant differences with regard to baseline 
characteristics or case fatality. Fourth, the study population included patients from three 
different randomized trials. For this reason, we performed separate regression analyses in 
the patients included in either PAPAS or PISA and in those included in the PAIS trial. The 
absence of heterogeneity in the effect of paracetamol across the three studies suggests 
that the study population could indeed be analyzed as a single group. Finally, strengths 
of our study are its large sample size and assessment of blood pressure that was blinded 
for treatment allocation.
To our knowledge, our study is the first that assessed the effect of high-dose paracetamol 
on blood pressure in patients with acute stroke. This effect of paracetamol has been pre-
viously assessed in two small studies, both in patients admitted to an intensive care unit. 
The first study found a reduction in mean arterial pressure of approximately 10 percent 
within 15 minutes after oral administration of 1 g paracetamol, persisting for 90 minutes.6 
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The second study reported a reduction in mean arterial pressure of 6 mm Hg at 2 hours 
after administration of an unspecified dose of paracetamol.7 
On the first day after stroke, blood pressure is elevated in up to 75% of the patients, 
but returns to pre-stroke values over a period of a few days.9, 10 We propose two expla-
nations for the short-term increase in blood pressure after stroke and for the effect of 
paracetamol. 
Elevated blood pressure following acute stroke has been associated with increased 
levels of both urinary catecholamines and salivary cortisol, possibly reflecting a neuro-
endocrine stress response.21 About a fifth of patients with ischemic stroke and more than 
half of patients with intracerebral hemorrhage experience headache.22, 23 Headache can 
lead to an increase in blood pressure by increased sympathetic activity. It may therefore 
be hypothesized that paracetamol decreases blood pressure by pain relief. This might 
also explain why paracetamol affected heart rate and why the effect of paracetamol on 
systolic blood pressure in our study seemed to be limited to the first 36 hours after start 
of treatment. Unfortunately we did not record the presence and severity of headache, 
nor did we measure levels of cortisol or catecholamines.
A more speculative hypothesis is that inflammation might lead to increased blood 
pressure after stroke. High blood pressure has been attributed to elevated levels of C-
reactive protein.24,25 COX-2 may be upregulated as a consequence of the inflammatory 
processes following ischemic stroke.25Paracetamol is a weak COX-1 and COX-2 inhibitor 
4, 5, but at higher doses it may exhibit stronger and nonselective COX inhibitor activity, 
thereby affecting blood pressure.20 This suggests that paracetamol may decrease blood 
pressure by inhibition of COX-2- mediated inflammation. Unfortunately, we did not 
measure inflammatory markers in all patients in this cohort.
The best possible management of blood pressure in patients with acute stroke is un-
certain, as has been pointed out in various guidelines for the management of acute isch-
emic stroke or intracerebral hemorrhage, and in a recent Cochrane meta-analysis.2, 26, 27 
However, longitudinal studies have indicated that stroke patients with systolic blood 
pressures of 10 mm Hg above 150 mm Hg may have a 4% increased risk of recurrent 
stroke and a 4% increased risk of death or dependency.11,  12 Also, preliminary studies 
suggest that antihypertensive treatment lowers blood pressure by 10-15 mm Hg after 
stroke.26, 28-30 The effect of paracetamol on systolic blood pressure, which amounted to 
approximately 5 mm Hg in the present study, may therefore be large enough to be of 
clinical significance. 
In conclusion, early administration of high-dose paracetamol in patients with acute 
stroke does not only reduce body temperature, but systolic blood pressure as well. This 
finding provides an additional argument for further studies of the effect of prophylactic 
high-dose paracetamol on functional outcome in acute stroke.
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abstract
ABSTRACT
Objective Acute ischemic stroke may trigger an inflammatory response that leads to 
increased levels of C-reactive protein (CRP). High levels of CRP may be associated with 
poor outcome either because they reflect an inflammatory reaction or tissue damage. 
We evaluated the prognostic value of CRP within 12 hours of onset of ischemic stroke.
Methods Levels of CRP were routinely obtained within 12 hours of symptom onset in 561 
patients with ischemic stroke. CRP values were dichotomized as <7 mg/L or ≥7 mg/L. The 
full range of CRP values was used to detect a possible level-risk relationship. We studied 
the relation between CRP values and poor outcome (modified Rankin Scale score >2) or 
death at 3 months. A multiple logistic regression model was applied to adjust for age, 
sex, NIHSS score, current cigarette smoking, diabetes mellitus, hypertension, statin use, 
and stroke subtype.
Results After adjustment for potential confounders, patients with CRP levels ≥7 mg/L 
had a significantly increased risk of poor outcome (adjusted OR 1.6, 95% CI 1.1-2.4) or 
death (adjusted OR 1.7, 95% CI 1.0-2.9) at 3 months. In addition, the risk of poor outcome 
or death at 3 months increased with higher levels of CRP.
Conclusion CRP within 12 hours of ischemic stroke is an independent prognostic factor 
of poor outcome at 3 months. 
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BACKGROUND
Elevated serum levels of C-reactive protein (CRP) are found in up to three quarters of 
patients with ischemic stroke.1, 2 Increases in CRP may reflect a systemic inflammatory 
response following ischemic stroke, the extent of tissue injury, or concurrent infections. 
Moreover, in animal models of focal cerebral ischemia, CRP increased secondary brain 
damage through activation of the complement system.3, 4
Several studies have assessed the value of CRP in the very early phase of stroke as 
a prognostic factor of functional outcome. These studies were either small, included a 
selected group of patients, or only tested the relation between CRP and mortality instead 
of functional outcome. The findings were inconclusive as some found a positive associa-
tion5-7, but others not.8, 9 
Verification of the role of CRP as an early prognostic factor of functional outcome after 
ischemic stroke may be of clinical importance, because it is an easy to measure and read-
ily available inflammatory marker. The aim of our study was therefore to determine the 
prognostic value of CRP measured in the very early phase of ischemic stroke for poor 
functional outcome and death in large sample of patients with acute ischemic stroke.
METHODS
Study design 
All patients included in the present study participated in the Paracetamol (Acetamino-
phen) In Stroke (PAIS) trial, a multicenter, randomized, placebo-controlled clinical trial 
of high-dose paracetamol in patients with acute stroke. The study protocol has been 
published earlier.10, 11 In short, patients with ischemic stroke or intracerebral hemorrhage 
within 12 hours of symptom onset with no history of liver disease or pre-stroke impair-
ment (modified Rankin Scale (mRS) score <2)12 were included in this study. Patients with 
ischemic stroke included in the PAIS trial between March 2003 and March 2007 in centers 
where CRP was measured as a part of routine laboratory assessment on admission were 
included in the present study if venous blood sampling for CRP was accomplished within 
12 hours of symptom onset.
Baseline variables
Baseline clinical information was extracted from the trial records. This included body 
temperature on admission and 24 hrs later, stroke subtype according to the TOAST clas-
sification13, stroke severity as assessed with the NIH Stroke Scale (NIHSS)14, and cardio-
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vascular risk factors. In addition, the occurrence of infections during hospitalization was 
assessed. Body temperature was measured with either tympanic or rectal thermometers.
Blood samples and CRP assay
Blood samples for assessment of CRP and white blood cell count were taken on admis-
sion. The time of CRP measurement relative to stroke onset was recorded in all patients.
Levels of CRP were determined with a clinically validated assay. Participating centers 
used different analyzers (Dade Behring, Beckman LX-20, Beckman Synchron, Beckman 
Coulter DXC, Olympus 640, Ortho Vitros, Roche Cobas 6000, Roche Cobas Integra, Roche 
Hitachi 917, Roche Modular) to establish CRP levels. Intra- and inter-assay variation of all 
participating centers was evaluated by means of the external quality control scheme of 
the Dutch Foundation for Quality Assessment in Clinical Laboratories (SKML). If the intra-
assay and/or inter-assay coefficient of variation was higher than 7,5%, patients from these 
centers were excluded from further analysis. All centers were subjected to quality review by 
the Dutch Foundation for Quality Assessment in Clinical Laboratories (SKML (www.skml.nl).
Some centers did not report exact values of CRP below a certain cut-off point, as values 
below these cut-off points were considered “normal” values. These cut-off points varied 
between 1 mg/L and 7 mg/L. 
As extremely high levels of CRP likely reflect an infection at the time of blood sampling, 
patients in whom the level of CRP was higher than 2 SD above the mean, were excluded 
from further analysis.
Outcome measures
Poor outcome was defined as a score of more than 2 on the mRS, including death, at 3 
months from stroke onset. A secondary outcome was death at 3 months. Outcome was 
assessed without knowledge of baseline CRP levels. 
Statistical analysis
Statistical analyses were performed with Stata/SE 8.2 for Windows (Statacorp, College 
Station, Texas). The relation between outcome and dichotomized CRP levels was ex-
pressed as an odds ratio (OR) with a corresponding 95% confidence interval (CI), through 
logistic regression.
CRP values were dichotomized at 7 mg/L. This cut-off point was selected, as this was 
the highest cut-off point below which values were considered normal, and not reported 
as exact values by some centers. In order to study a possible level-risk relationship, all 
CRP values were recoded with 7 mg/L as the lower bound. Odds ratios were expressed 
per unit increase in logarithmically transformed CRP levels. Adjustment for the impact of 
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age, sex, baseline NIHSS score, cigarette smoking status, diabetes mellitus, hypertension, 
statin use, and stroke subtype (cardioembolic stroke versus non-cardioembolic stroke) 
was made with multiple logistic regression. We performed additional analyses to account 
for the potential confounding effect of antipyretic treatment by stratifying for treatment 
with acetaminophen.
RESULTS
Between March 1, 2003 and March 1, 2007, 1187 patients were included in the PAIS trial. 
Sixteen of the 29 participating centers routinely performed CRP measurements on admis-
sion for acute stroke. In these 16 centers, 897 patients where included in the PAIS trial in the 
period under study. Of these patients, 336 were excluded from the present study because 
of hemorrhagic stroke (n=117), CRP measurement not accomplished within 12 hours of 
stroke onset or time of assessment unknown (n=154), CRP measurements with analyzers 
with a variation coefficient >7.5% (n=56), or CRP levels over 110 mg/L (2 SD; n= 9).
The median CRP level was 5 mg/L (IQR 2-8) and 33% of patients had CRP levels of 7 
mg/L or above.
Table 1 shows the baseline characteristics of the patients with CRP levels <7 mg/L or 
≥7 mg/L. Median time from onset of symptoms to CRP measurement was 137 minutes 
(range, 0-696). Patients with CRP ≥7 mg/L were older, had higher scores on the NIHSS, 
had a slightly higher body temperature on admission, were more often smokers, more 
frequently had hypertension, diabetes mellitus, or atrial fibrillation, and less often used 
statins than patients with low CRP levels. Cardioembolic strokes were observed more 
often in patients with CRP ≥7 mg/L. 
Sixteen patients with CRP ≥7 mg/L (9%) and 15 patients (4%) with CRP <7 mg/L devel-
oped an infection during hospitalization. Two patients with CRP ≥7 mg/L had an infection 
(both pneumonia) within 24 hours of stroke onset. No infections within 24 hours were 
reported in patients with CRP <7 mg/L.
No association between CRP levels and the body temperature at 24 hours after study 
enrollment was found.
Patients with CRP levels³ 7 mg/L more often had a poor outcome (57% versus 42%; 
p=0.006) or died (23% versus 13%; p=0.0007) than patients with lower CRP levels (Figure 
1). Adjustment for potential confounders did not change these results (Table 2).
An additional stratified analysis to account for the potential confounding effect of 
treatment with paracetamol did not affect the association.
A level-risk relationship was observed between CRP and poor outcome or death at 3 
months. The relation between CRP and poor outcome was attenuated after adjustment 
for potential confounders (Table 3). 
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After exclusion of patients who developed an infection during the first two weeks after 
stroke onset, the adjusted odds ratio for poor outcome was 1.5 (95% CI 1.0-2.3; p=0.07), 
and for death 1.9 (95% CI 1.1-3.4).
DISCUSSION 
In this study, patients with CRP levels ≥7 mg/L within 12 hours of ischemic stroke onset 
had a significantly increased risk of poor functional outcome or death at 3 months, even 
Table 1: Baseline characteristics of the study population.
CRP<7 mg/L CRP ≥7 mg/L
Demographics
N
Age (years), mean (SD)
Male
377
69.1 (13.4)
226 (60%)
184
70.9 (13.8) 
110 (60%)
Stroke severity$
NIHSS, mean (SD) 7.5 (6.0) 8.9 (6.6)
Risk factors
Arterial hypertension
Atrial fibrillation
Diabetes mellitus
Current cigarette smoking
Hypercholesterolemia
183 (49%)
47 (12%)
50 (13%)
108 (29%)
104 (28%)
107 (58%)
47 (26%)
37 (20%)
70 (38%)
42 (23%)
History
Stroke
Myocardial infarction
Peripheral vascular disease
84 (22%)
47 (12%)
25 (7%)
40 (22%)
25 (14%)
21 (11%)
Physical examination
Systolic blood pressure, mean (SD)
Diastolic blood pressure, mean (SD)
Body temperature, mean (SD)
169 (31)
89 (18)
36.9 (0.6)
171 (34)
89 (21)
37.0 (0.6)
Laboratory assessments
Time until CRP measurement (minutes), median (range)
Leukocytes 109 /L, mean (SD)
140 (2-696)
8.2 (2.6)
129 (0-681)
9.4 (3)
Stroke type (TOAST)*
Undetermined 
Large vessel disease (≥50% stenosis)
Cardiac source of embolism
Small vessel occlusion
Other determined etiology
189 (50%)
38 (10%) 
60 (16%)
49 (13%)
41 (11%)
81 (44%)
28 (15%)
44 (24%)
24 (13%)
7 (4%)
Treatment
RtPA
Ace inhibitor
Statin 
95 (25%)
65 (17%)
101 (27%)
50 (27%)
38 (21%)
36 (20%)
$Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher values 
indicating more severe stroke.5
*Based on the definitions of the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria.1
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after adjustment for potential confounders. In addition, a level-risk relationship was 
found between CRP and poor outcome and death. 
Several studies have found an association between increased CRP levels and clinical 
outcome in the time window between 12 and 72 hours after ischemic stroke.1, 2, 5-9, 15-17 The 
results of previous studies that have aimed to assess the prognostic value of CRP in the 
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Figure 1: Association of CRP levels on admission with poor outcome or death at 3 months.
Table 2: Association between increased CRP (≥7 mg/L) at baseline and outcome after ischemic stroke.
OR (95% CI) Adjusted OR (95% CI)*
Poor outcome (mRS>2) 
Death
1.9 (1.3-2.7)
2.0 (1.3-3.2)
1.6 (1.1-2.4)
1.7 (1.0-2.9)
*Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes mellitus, hypertension, statin use, and 
stroke subtype.
Table 3: Level-risk relationship CRP and outcome.
OR$ (95% CI) Adjusted OR*$ (95% CI)
Poor outcome (mRS>2)
Death
1.6 (1.2-2.2)
2.1 (1.5-3.0)
1.3 (0.9-1.9)
1.9 (1.2-2.8)
$ORs were expressed per 1 unit increase in logarithmically transformed CRP levels.
*Adjusted for age, sex, NIHSS score, cigarette smoking, diabetes mellitus, hypertension, statin use, and 
stroke subtype.
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very early phase of stroke are ambiguous. Two prospective studies did not observe a rela-
tion between CRP levels obtained within 6 or 12 hours after symptom onset and death 
or dependency at follow-up.8, 9 Both studies were rather small (127 and 111 patients) and 
may therefore have lacked the power to detect an association. In addition, one of these 
studies included only patients treated with rt-PA.8
In line with our results, three other studies found an association between CRP and 
outcome. In one of these studies, CRP was measured within 24 hours of stroke onset, 
and 25% of the patients had a TIA instead of a stroke, which may have influenced the 
observed association.5 In addition, only the relation between CRP and mortality, and not 
disability, was studied. Other studies included only patients aged 75 years or older 6, or 
patients who had a middle cerebral artery occlusion and received rt-PA.7 In the latter, an 
association with mortality was found, but functional outcome was not assessed.7
The strengths of the present study are its large sample size, robust outcome measures 
and early CRP measurement, which increase the relevance of our findings. Furthermore, 
detailed information on confounders was available. 
Some methodological limitations should be discussed. First, this study was part of a 
larger clinical trial, and not designed to evaluate the prognostic value of CRP with regard 
to clinical outcome in acute ischemic stroke. As a consequence, a detailed history of 
inflammatory conditions was not recorded. 
Levels were determined with different analyzers, which may have resulted in a system-
atic error. For this reason, measurements performed with analyzers with an inter-assay 
coefficient of variation ≥ 7,5% or that demonstrated bias relative to the other participat-
ing centers were excluded from further analysis. Secondly, the lowest detection limit for 
CRP varied from 1 mg/L to 7 mg/L among the centers. Therefore, CRP levels had to be 
dichotomized. This makes it more difficult to compare our results with previous studies. 
However, in three of the five studies that assessed the relation between CRP levels in the 
very early phase of acute stroke and clinical outcome, a similar cut-off point level was 
selected.20, 27, 30 Furthermore, all CRP values were recoded with 7 as the lower bound, in 
order to study a possible level-risk relationship.
A fourth issue might be that rather few patients with very severe stroke were included, 
which may affect the generalisability of the results. 
In patients with ischemic stroke, increased levels of CRP may reflect the pre-existing 
degree of atherosclerosis or the presence of vascular risk factors. We found that patients 
with higher levels of CRP were more often smokers and more frequently had hyperten-
sion, diabetes mellitus, or atrial fibrillation. Furthermore, cardioembolic strokes were 
observed more often in patients with higher levels of CRP. Moreover, patients with CRP 
≥7 mg/L used statins less often than patients with low CRP levels, suggesting that drugs 
in this class reduce levels of CRP. These findings are supported by previous studies.6, 18-22
Why could CRP concentration be a prognostic factor for poor outcome and death? Early 
after onset of ischemic stroke, increased CRP levels may reflect an accompanying inflam-
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matory reaction. Inflammatory processes play an important role in the pathophysiology 
of ischemic stroke.23 Cerebral ischemia triggers an inflammatory response characterized 
by activation and release of acute phase proteins such as C-reactive protein (CRP) and 
cytokines.23-25 The inflammatory processes may start within 2 hours after stroke onset and 
sustain for days 26, and may contribute to ischemic brain damage even in that early stage.27
Elevated CRP levels may be a reflection of the extent of brain injury. In our study, pa-
tients with CRP levels ≥7 mg/L had higher NIHSS scores on admission. Previous studies 
have shown that patients with increased CRP levels have larger infarctions.26 Although 
patients with CRP levels ≥7 mg/L taken as a group had worse outcomes at 3 months as 
assessed with the mRS, multiple logistic regression modeling indicated that the adverse 
outcome in this group remained even after adjustment for initial stroke severity by NIHSS 
score and multiple other risk factors for poor outcome. This suggests that CRP not only 
reflects the amount of tissue damage, but may also indicates a state of enhanced risk 
due to increased inflammation or cytokine excess. Interestingly, recent experimental 
studies have shown that CRP itself may contribute to secondary brain damage after focal 
cerebral ischemia, possibly via a complement-mediated exacerbation of tissue injury.3, 4 
In rats, treatment with human CRP after middle cerebral artery occlusion resulted in 
larger infarcts.3 Similar results have been observed in experimental models of myocardial 
infarction.28 
It is therefore conceivable that increased levels of CRP following stroke are not only a 
consequence of brain infarction, but contribute to ischemic damage as well.
Increased CRP levels following ischemic stroke may also reflect concurrent infections. 
Secondary infections are common in the first week of stroke and are associated with 
poor outcome27, 29,  30, but they usually occur more than 12 hours after stroke onset. In 
our study, only two clinically overt infections were reported within 24 hours after stroke 
onset. In addition, we excluded patients in whom the CRP level exceeded 2 SD above the 
mean, who may have had an infection before stroke onset. Furthermore, exclusion of 
patients developing an early infection during hospitalization did not substantially affect 
the relation between CRP levels and poor functional outcome or death.
The use of biomarkers as predictors of stroke lesion evolution and prognosis is becom-
ing increasingly important, as they may be valuable tools in the search for an optimal 
management of stroke patients. The present study confirms results from previous stud-
ies that have advocated CRP as a powerful prognostic marker in patients with ischemic 
stroke.1, 5-7, 9, 15-17, 26 It may provide important prognostic information beyond conventional 
clinical parameters. Further studies are needed to assess if CRP is also a predictor of 
outcome after stroke.
Moreover, the fact that animal studies have found that CRP might exacerbate brain 
tissue damage following ischemic stroke, might stimulate research into the underlying 
pathogenetic mechanisms and development of new, more targeted, medical treatments 
for acute ischemic stroke.
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In conclusion, elevated CRP levels in the very early phase of acute ischemic stroke are 
independent prognostic factors for poor outcome at 3 months.
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abstract
ABSTRACT
Background and purpose Elevated levels of C-reactive protein (CRP) are found in up 
to three quarters of patients with acute ischemic stroke and are associated with poor 
outcome. We investigated whether haplotypes representing common variations in the 
CRP gene are associated with levels of CRP in patients with acute ischemic stroke.
Methods We included 185 patients with ischemic stroke in whom CRP was measured 
within 24 hours of symptom onset. Common haplotypes within the CRP gene were 
determined by 3 genotype-tagging single-nucleotide polymorphisms (SNPs). 
Results Four haplotypes with frequencies >5% covered 99.2% of the genetic variation. 
Haplotype 4 (CCG, frequency 8.3%) was associated with a 20.6 mg/L (95% CI, 9.8 to 30.4) 
stronger increase in CRP level as compared with haplotype 1 (CTC, frequency 33.7%). 
Conclusion Variation in the CRP gene is associated with levels of CRP in acute ischemic 
stroke. 
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BACKGROUND
C-reactive protein (CRP) is a strong acute phase reactant. Elevated levels of serum CRP are 
found in up to three quarters of patients with acute ischemic stroke and are associated 
with poor outcome.1-4This leads to interest in the use of CRP as a biomarker of prognosis 
of ischemic stroke. Moreover, CRP may contribute to secondary brain damage after focal 
cerebral ischemia, possibly via a complement-mediated exacerbation of tissue injury.5
The CRP concentrations are under genetic influence. Family and twin studies found 
that additive genetic factors account for 27–40% of the variance in CRP, indicating a 
role of DNA sequence variation in determining serum protein levels.6 Furthermore, there 
is accumulating evidence for an association between single nucleotide polymorphisms 
(SNPs) in the CRP-gene and levels of CRP.7
Only limited and inconsistent data are available on the association between SNPs in 
the CRP gene and CRP concentrations in patients with acute ischemic stroke.3, 8
In the present study, we investigated whether haplotypes representing common varia-
tions in the CRP gene are associated with levels of CRP in patients with acute ischemic 
stroke.
METHODS
Study population 
We evaluated 185 consecutive patients with acute ischemic stroke admitted between 
2005 and 2008 in whom venous blood was collected within 24 hours of symptom onset 
from the Rotterdam Stroke Biobank, a project aimed at collecting clinical information, 
blood samples and DNA of all patients with neurovascular diseases admitted to Erasmus 
University Medical Center. Written informed consent was obtained from all patients, 
signed by the participants or a first degree relative, as approved by the Institutional Eth-
ics Committee.
Baseline characteristics
Baseline clinical information was extracted from the trial records. This included a quan-
tification of stroke severity according to the National Institutes of Health Stroke Scale 
(NIHSS)9, ischemic stroke subtype according to the TOAST classification10, and cardiovas-
cular risk factors. 
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Measurement of CRP
CRP levels were determined by means of the Roche Modular assay. The range of mea-
surement is 1–285 mg/L with a variation coefficient of 4.6%.
CRP polymorphism genotyping
In the Seattle SNPs program for Genomic applications, 31 SNPs were identified in the CRP 
gene on chromosome 1q21 (http://www.pga.gs.washington.edu/data/crp, “visual 
haplotype” option).
In 23 unrelated individuals of European descent, these SNPs formed 4 well-defined 
haplotypes with frequencies of more than 5%. By selecting 3 tagging SNPs, the total 
common variation in the CRP gene is described. We selected the following tagging SNPs: 
1184 C>T (rs1130864), 2042 C>T (rs1205) and 2911C>G (rs3093068).
DNA was extracted according to standard procedures and stored at -20°C. Genotypes 
were determined in genomic DNA of 2 ng with the Taqman allelic discrimination assay 
(Applied Biosystems, Foster City, California) and end-point readings of fluorescence were 
performed on Taqman Prism 7900HT (Applied Biosystems, Foster City, California)
Statistical analysis
SNPs were tested for Hardy Weinberg equilibrium with a Chi square test. The association 
between CRP haplotypes and levels of CRP were assessed with the non-parametric haplo.
score function of Haplo Stats (http://cran-r.project.org/scr/contrib/Descriptions/haplo-
stats). We adjusted for age, sex and stroke severity on admission by means of multiple 
linear regression.
RESULTS
In the total study population, the mean age was 64 years (SD 15), 53% were male and the 
median NIHSS score was 4 (range 0-22) (Table 1). Mean CRP level was 10 mg/L (SD 27). 
Median time from onset of symptoms to CRP measurement was approximately 7 hours.
All SNPs were in Hardy Weinberg equilibrium. The 1184T-allele was present in 25.9%, 
the 2042T-allele was present in 34.5% and the 2911G-allele in 8.6% of 370 chromosomes.
Four common haplotypes were identified (Table 2). The remaining haplotypes (CTG, 
TCG, TTC) were present in less than 5%.
Haplotype 4 (CCG) was associated with a significant stronger increase in CRP level (20.6 
mg/L; 95% CI, 9.8 to 30.4) relative to the reference haplotype 1 (CTC) (Table 2 and Figure 
1). Adjustment for age, sex and NIHSS score did not attenuate this association (Figure 1).
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DISCUSSION
In this study, we found that SNPs in the CRP gene were associated with levels of CRP 
within 24 hours of ischemic stroke onset. Haplotype 4 (CCG) was associated with signifi-
cant higher levels of CRP than haplotype 1 (CTC).
Our results provide further proof that, apart from environmental factors, genetic 
variations may influence levels of CRP. Several studies found an association between 
Table 1: Clinical characteristics of the patients (n=185).
Demographics
Mean (SD) age (years)
Sex (male)
 64 (15)
 98 (53%)
Cardiovascular risk factors
Hypertension
Atrial fibrillation
Diabetes mellitus
Current cigarette smoking
Hypercholesterolemia
 98 (53%)
 22  (12%)
 29  (16%)
 35  (19%)
 85  (46%)
Medical history
Previous stroke
Previous myocardial infarction
Peripheral vascular disease
50 (27%)
31 (17%)
13 (7%)
Stroke subtype*
Large vessel disease (≥50% stenosis)
Cardiac source of embolism
Small vessel occlusion
Other determined etiology
Undetermined / negative evaluation 
28 (15%) 
30 (16%)
27 (15%)
21 (11%)
79 (43%)
Stroke severity 
Median (range) NIHSS score$  4 (0-22)
Physical examination
Mean (SD) systolic blood pressure on admission (mm Hg)
Mean (SD) diastolic blood pressure on admission (mm Hg)
167 (34)
86 (20)
6.6 (3 to 13.9)
Laboratory assessments
Median (IQR) time from stroke onset to measurement of CRP (hrs)
Treatment
Treatment with rt-PA 36 (19%)
*Based on the Trial of ORG 10172 in Acute Stroke Therapy (TOAST) criteria.10
$Scores on the National Institutes of Health Stroke Scale (NIHSS).9 
Table 2: Frequency of haplotypes and association between CRP haplotypes and levels of CRP.
Haplotype Haplotype frequency Haplo-score P-value*
1 (CTC) 33.7% -0.75 0.45
2 (CCC) 31.7% -0.01 0.98
3 (TCC) 25.5% 0.41 0.68
4 (CCG)   8.3% 4.49 <0.01
*P-values were obtained using haplo.score, after 2377 simulations
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CRP haplotypes and levels of CRP in diseases in which inflammation is involved.7, 11, 12 The 
direction of the haplotype-CRP-level associations are also supported by previous studies 
that have used the same polymorphisms to reconstruct the haplotypes.7, 11, 12 Two previ-
ous studies that investigated the association between SNPs in the CRP gene and levels 
of CRP in patients with acute ischemic stroke cannot be compared directly with ours, 
because only single SNPs were studied.3, 8 
The present study has some limitations. The study compromised a small number of 
patients. Furthermore, our results did not include information about ethnicity. Allele 
frequencies have been reported to differ between ethnic groups. However, the haplo-
type structures are similar and therefore the direction and size of changes in CRP levels 
associated with most SNPs might be similar regardless of ethnic group.12
Increases in CRP levels following ischemic stroke may reflect a systemic inflammatory 
response, the extent of tissue injury, or concurrent infections. Interestingly, in animal 
models of focal cerebral ischemia, CRP increased secondary brain damage through 
activation of the complement system.5,  13 These findings suggest that understanding 
genotype–phenotype associations of CRP polymorphisms may provide a genetic basis 
for the future development of tailored therapeutic strategies in ischemic stroke.
In conclusion, variation in the CRP gene is associated with levels of CRP in acute isch-
emic stroke. Further studies are needed to investigate the relation between variation in 
the CRP gene, levels of CRP and clinical outcome after acute ischemic stroke.
Figure 1: Relative effects of CRP gene haplotypes on levels of CRP (mg/L)
*P-value<0.01. Regression coefficients were adjusted for age, sex and
NIHSS score on admission. Coefficients reflect the mean difference in levels
of CRP relative to haplotype 1 (CTC).
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BACKGROUND
The notion that ischemic stroke is not only preventable but also an attractive target 
for acute therapeutic interventions has provided a major impetus to stroke research. 
At present, aspirin, surgical decompression and rt-PA are available proven therapeutic 
options for acute stroke.1-4 Animal experiments help to learn us about the pathogenesis 
of ischemic stroke and are therefore an integral part of research on cerebral ischemia. 
Ideally, an animal model of ischemic stroke meets the following criteria:
1. It should be relevant to human ischemic stroke
2. The ischemic lesion should be reproducible
3. The technique applied to induce cerebral ischemia should be relatively easy to per-
form and minimally invasive
4. Relevant outcome measures
First, I will give a short overview of the different models of ischemic stroke that have 
been used to date, the advantages and disadvantages of these models and the role of 
animals models in relation to stroke research. Next, a first step into further research in 
acute stroke aimed at integrating basic and clinical science will be presented.
ANIMAL SELECTION 
Experimental models of ischemic stroke have been developed in many species, including 
larger mammals such as cats, rabbits and nonhuman primates, as well as small rodents 
such as rats and mice. Rats and mice are most commonly used, since they are relatively 
inexpensive and their physiology and cerebrovascular anatomy closely resemble that of 
humans. The commercially available inbred rats are genetically relatively homogenous5, 
allowing good reproducibility of infarctions. Mice have been of increased interest, be-
cause of availability of transgenic technology, which offers new insights in the molecular 
processes involved in acute ischemic stroke. 
Animal studies typically use young, healthy populations of animals that are homoge-
neous for sex and age, whereas the typical stroke patient is elderly with numerous risk 
factors. Therefore, the influence of age, sex and comorbidities on experimental ischemic 
stroke should also be taken into account.
TECHNIQUES FOR INDUCING FOCAL CEREBRAL ISCHEMIA
Focal cerebral ischemia models usually involve occlusion of the middle cerebral artery 
and can be divided into transient and permanent ischemia models. 
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The intraluminal monofilament model6, 7 
This is the most commonly used model. Briefly, a nylon monofilament is introduced into 
the internal carotid artery and forwarded until the tip occludes the origin of the middle 
cerebral artery . The monofilament can be coated with silicone, a harder or it can be used 
without coating. Both permanent and transient ischemia can be achieved by respectively 
maintaining or withdrawing the monofilament. Advantages of this approach are that 
it is relatively easy to perform, less invasive than other models and is reproducible. A 
disadvantage is that this model is not appropriate for evaluation of treatment with rt-PA. 
Transcranial model8
The middle cerebral artery is surgically dissected, and subsequently occluded by a clip 
or ligation. This technique produces reproducible infarctions. Furthermore, it results into 
smaller infarctions, and hence is appropriate for experiments with long-term survival. 
One of the disadvantages of this approach is that it is difficult and requires more inves-
tigator experience. Furthermore, it is invasive, and is associated with an increased risk of 
subarchnoid hemorrhage. 
The thrombo-embolic model9
This model is of great interest because it resembles human ischemic stroke and because 
of its role in evaluating treatment with rt-PA. The middle cerebral artery is occluded by 
fibrin-rich clots, prepared either by adding thrombin to freshly drawn arterial blood or 
by spontaneous coagulation. The clots are injected via a catheter in the internal carotid 
artery. Disadvantages of this model are that it is less reproducible and that it is associated 
with an increased risk of hemorrhagic stroke.
Photo-thrombosis model10
In this model, ischemic stroke is induced by vascular injection of a photo-active dye in 
combination of irradiation with a light beam. A reaction between the dye and the light 
beam resulted in platelet aggregation and thrombosis. The location and the extent of 
the lesion may be well controlled with this technique. However, it do not mimic human 
stroke very closely. Furthermore, this technique is associated with an increased risk of 
hemorrhagic stroke and is not appropriate for evaluating treatment with rt-PA.
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CHOICE OF ANIMAL MODEL
Since ischemic stroke is a heterogeneous disease, no single animal model can represent 
human stroke. We have opted to set up a “intraluminal monofilament” model, because 
this is one of the most reproducible models and is widely applied.
STAIR CRITERIA
Many animal studies of ischemic stroke have been poorly designed, conducted and ana-
lyzed. Experimental studies have identified numerous targets for therapy. However, the 
translation of these results from bench to bedside has been disappointing. Lessons from 
translational failures led to the Stroke Therapy Academic Industry Roundtable (STAIR) 
recommendations for pre-clinical and clinical studies (see appendix).11, 12 The STAIR crite-
ria aim to improve the methodological quality of preclinical stroke research. 
EVALUATION
The STAIR citeria recommend that at least two outcome measures should be reported, 
namely infarct volume and functional recovery.11, 12
Physiological variables
Rectal temperature, blood pressure and blood gases can be measured during the inter-
vention. These parameters are important for the interpretation of outcome of animals.
Histology: measurement of infarct area
The infarct volume is usually assessed after 24 hours of reperfusion in transient ischemia 
models and after 6 hours of reperfusion in permanent ischemia models. The brain is 
removed, and subsequently 2-mm-thick coronal sections are obtained. Brain infarction 
is determined by a TTC (2,3,5 triphenyltetrazolium chloride) vital staining method. TTC 
is reduced by mitochondrial enzymes to a red compound. As a consequence, the non-
infarcted regions are stained red, whereas the infarcted regions are not stained. Alterna-
tively, the brains can be snap-frozen in isopentane for cryostat sectioning and stained 
with hematoxylin and eosin (HE), a nuclear/cytoplasmatic staining. TTC staining is easier, 
and less expensive than HE staining. However, after 72 hours of reperfusion, TTC stain-
ing may underestimate infarct volume, because various cells infiltrate into the infarcted 
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region, and mitochondria in these cells may react with TTC, resulting in obscuration of 
the borders of the infarct.
Infarct areas are quantitated by use of sigma 4.0 software, and infarct volumes are cal-
culated by summing the volumes of each section directly or indirectly with the following 
formula: contralateral hemisphere (mm3) – undamaged ipsilateral hemisphere (mm3).
A number of other staining methods, including TUNEL staining and Caspase-3 staining 
to detect apoptotic cells can be applied.
Imaging: MRI
In the past, and to a large extent still today, evaluation of the animal experiments of cere-
bral ischemia have been based on invasive techniques, thus permitting only information 
on single time points in the evolution of the ischemic pathology. With the advent of 
noninvasive imaging methods, longitudinal studies on animals have become available, 
thus providing access to information on disease evolution. The non-invasiveness of MRI 
provides the potential to monitor the evolution of physiological changes within the isch-
emic brain and to predict therapeutic effects of new treatments. So far the application of 
imaging with different MR techniques in animal models is just beginning, but will rapidly 
expand in the near future.
Neurological evaluation
Functional impairment can be assessed by the following 4-point scale13: 
1. Spontaneous activity: moving and exploring
0 = moving and exploring, 1 = moving without exploring, 2 = no moving or only when 
pulled by tail
2. Circling to the left/right
0 = none, 1 = when elevated by the tail and pushed or pulled, 2 = spontaneously, 3 = 
circling without displacement
3. Parachute reflex 
0= symmetrical, 1 = asymmetrical, 2 = contralateral forelimb retracted
4. Resistance to left forepaw stretching
0 = stretching not allowed, 1 = stretching allowed, 2 = no resistance
The total score ranges from 0 (no neurological deficits) to 9 (severe neurological deficits).
Other tests for assessment of functional impairment are the Morris water maze test14, the 
paw-placement test15 and the cylinder test.15
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“BEDSIDE TO BENCH AND BACK APPROACH”
Animal studies may help to unravel the biology of stroke and the response to various 
drugs. The contribution of animal studies of acute stroke to clinical practice, however, 
has been poor thus far. This has led to serious doubts about the utility of animal models 
of acute stroke for development of therapy for human stroke. There is clearly a need to 
increase the quality of the design of animal studies and to develop models that more 
closely approximate the clinical situation. 
On the other hand, it becomes clear that a strictly linear bench-to-bedside approach may 
not be optimal for translating findings in animal models of acute stroke into clinically effec-
tive stroke therapies. A clinical study often raises new questions and information should be 
obtained from the positive or negative results of each clinical trial. Animal studies might 
be valuable in helping to elucidate these issues. Furthermore, close communication and 
collaboration between the clinician and the basic stroke scientist is of high importance.
We expect that this `bench to bedside and back” approach will greatly enhance our 
knowledge on ischemic stroke as well as on the response of ischemic stroke to therapies 
and may support our clinical studies. 
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abstract
ABSTRACT
Background and purpose Inflammation plays an important role in the pathophysiology 
of ischemic stroke and may contribute to secondary damage following ischemic stroke. 
Recently, it has been shown that synthetic oligopeptides related to human chorionic 
gonadotropin (hCG) and various other synthetic oligopeptides may have immunomodu-
latory effects.
We aimed to investigate the effects of two promising synthetic anti-inflammatory 
tetrapeptides, namely the hCG-related peptide AQGV and the p53-related peptide EPPE 
on infarct volume and on inflammatory gene expression in an animal model of focal 
cerebral ischemia.
Methods Mice received two injections of either AQGV (30 mg/kg bodyweight) or EPPE 
(30mg/kg bodyweight) or phosphate buffered saline. The first dose was administered 
15 minutes before middle cerebral artery occlusion, and the second dose 45 minutes 
after reperfusion. Infarct volume and gene expression levels of tumor necrosis factor-a, 
interleukin-6, E-selectin and intercellular adhesion molecule-I (ICAM-1) were measured 
24 hours after reperfusion.
Results Neither AQGV nor EPPE showed an effect on infarct volume or on transcription 
levels of adhesion molecules and pro-inflammatory cytokines.
Conclusion AQGV and EPPE did not show any beneficial effects in this mouse model of 
acute ischemic stroke. Further studies are needed to investigate the nature and dynamics 
of the immunomodulatory effects of synthetic oligopeptides in acute ischemic stroke.
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BACKGROUND
Inflammation plays a central role in the pathophysiology of ischemic stroke. In the early 
phase of ischemia and reperfusion, an inflammatory cascade is set off in the ischemic 
core and in the penumbra, where perfusion is compromised but tissue is still viable.1 
Numerous pro-inflammatory genes are upregulated, including those for transcrip-
tion factors, heat shock proteins, cytokines, chemokines and adhesion molecules. The 
classical pro-inflammatory cytokines interleukin-6 (IL-6), and tumor necrosis factor-a 
(TNF-a), produced by microglia, astrocytes, endothelial cells, and neurons, mediate the 
inflammatory processes.2 They activate leucocytes, stimulate the release of chemokines, 
and increase adhesion molecule expression on cerebral microvessels and circulating 
leukocytes, including intercellular adhesion molecule (ICAM-1) and E-selectin.2 The 
early inflammatory phase is followed by a tissue-remodelling phase during which 
tissue-remodelling factors are expressed and are associated with healing of the infarcted 
tissue. The inflammatory processes start within 2 hours after stroke onset and sustain for 
several days.3, 4 Besides its beneficial effect, inflammation may contribute to the second-
ary progression of ischemic brain injury. The acute inflammatory phase is believed to 
be detrimental, while the chronic phase inflammation may be essential for repair and 
regeneration.1, 3, 4 This is a concept that holds promise for new therapeutic interventions. 
The adaptations of the immune system during pregnancy are striking. The maternal 
immune system is under tight control to prevent rejection of the foetal allograft. This sug-
gests that a specific hormonal environment is responsible for modulating the immune 
system during pregnancy. Human chorionic gonadotropin (hCG) is secreted by placental 
syncytiotrophoblasts, but is also produced by the pituitary gland and leucocytes in non-
pregnant females and males.5-7 HCG consists of an a- and a b-chain. In human pregnancy 
urine, hCG occurs in a variety of forms, including oligopeptidic breakdown products of 
the ab-chain.5 HCG preparations have been recognized to exert immunomodulatory 
activities that are not due to the native molecule nor to it’s a- and b-chain, but resided 
in specific peptide fractions.5 Based on known preferential cleavage sites, several oligo-
peptides from b-hCG residues have been synthesized. These oligopeptides including 
AQGV have shown promise in the treatment of ischemia-reperfusion injury such as septic 
shock8, hemorrhagic shock9 and renal ischemia-reperfusion injury10. Several regulatory 
oligopeptides based on the primary sequence of other proteins have also been gener-
ated and proven biologically active in different models tested. One of these regulatory 
oligopeptides is the p53-related tetrapeptide EPPE. 
In this study, as a first step in assessing potential beneficial effects of synthetic anti-
inflammatory tetrapeptides in acute ischemic stroke, we investigated the effects of the 
b-hCG related synthetic tetrapeptide AQGV and the p53-related synthetic tetrapeptide 
EPPE on infarct volume and on inflammatory gene expression in an animal model of focal 
cerebral ischemia.
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MATERIALS AND METHODS
Animals
Experiments were performed in male C57BL/6 mice, weighing 20-30g, in accordance 
with the NIH Guidelines for the Care and Use of Laboratory Animals and with approval of 
the local Animal Care Committee.
Synthetic anti-inflammatory tetrapeptides
The b-hCG-related tetrapeptide AQGV and the p53-related tetrapeptide EPPE were syn-
thesized (Ansynth Service BV Roosendaal, the Netherlands) using the fluorenylmethoxy-
carbonyl (Fmoc)/tert-butyl-based methodology with a 2-chlorotritylchloride resin as the 
solid support and dissolved in 0.9% sodium chloride at a concentration of 30 mg/ml.
Model of focal cerebral ischemia 
Anesthesia was induced by 1.5% halothane and maintained with 1% halothane in 70% 
N2O and 30% O2. Middle cerebral artery occlusion for one hour was induced with a sili-
cone-coated 8.0 nylon monofilament, as described previously.11 A midline neck incision 
was made and the soft tissues were pushed apart. The left common carotid artery (LCCA) 
was dissected free from the surrounding nerves and a node was made with a 6.0 string. 
The left external carotid artery (LECA) was separated and a second node was made. Next, 
the left internal carotid artery (LICA) was isolated and was tied with a 6.0 string. After 
obtaining a good view of the LICA and the left pterygo palatine artery, both arteries 
were clipped. A small hole was cut in the LCCA before it bifurcates to the LECA and the 
LICA. An 8.0 nylon monofilament coated with a mixture of silicone resin and a harder 
was left in the artery. The clipped artery was reopened and the filament was introduced 
into LICA up to the origin of the left middle cerebral artery. The third node on the LICA 
will be closed with the filament inside. After 60 minutes, the third node was opened and 
the filament was withdrawn. The remaining string was cut and the skin was sutured with 
a 4.0 string. The core temperature of the mice during the procedure was maintained at 
36.5ºC using a feedback temperature control unit.
Administration of synthetic anti-inflammatory tetrapeptides
Three groups of mice (10 mice per group) received, in a randomized single- blinded 
fashion, either AQGV (30 mg/kg bodyweight) or EPPE (30mg/kg bodyweight) or 1 ml 
phosphate buffered saline (PBS), which was administered intravenously in two slow in-
jections (1ml over 10 min). Administration of the first dose was started 15 minutes before 
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middle cerebral artery occlusion (MCAO). The second dose was administered 45 minutes 
after reperfusion. 
Measurement of infarct size
The animals were sacrificed 24 hours after reperfusion. The brains were snap-frozen in 
isopentane for cryostat sectioning. Infarct areas were quantitated by use of sigma 4.0 
software (sigmaScan Pro 4.0, Jandel scientific) on 20-μm hematoxylin-and eosin–stained 
cryostat sections without knowledge of treatment. Infarct volumes were calculated by 
summing the volumes of each section directly or indirectly with the following formula: 
contralateral hemisphere (mm3) – undamaged ipsilateral hemisphere (mm3). 
Evaluation of mRNA levels by real-time quantitative polymerase chain reaction
RNA was isolated from 20-μm cryostat sections with a Qiagen RNeasy kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instructions, and reverse transcribed 
into cDNA. We determined gene expression levels of TNF-a, IL-6, E-selectin and ICAM-I 
Applied Biosystems 7700 PCR machine (Foster City, California), as described previously.12 
The expression levels of these genes were quantified by normalization against the mRNA 
levels of the household gene ABL.
Data analysis and presentation
Statistical analyses were performed using SPSS version 11 software (SPSS, inc., Chicago III)
Data are presented as mean values +/- SD of the ten mice per group. Comparisons were 
made by one-way of variance (ANOVA), followed by Duncan’s multiple range test.
RESULTS
Of the total 30 mice entered in the study, two mice in the EPPE group and one mouse in 
the AQGV group died, because of technical failure during surgery.
AQGV and EPPE do not alter infarct volume
The infarct volume was not significantly different between AQGV-treated mice and mice 
treated with PBS (114.9 +/- 23.9 mm3 versus 108.7 +/- 12.1 mm3 versus; P=0.7) and be-
tween EPPE-treated and mice treated with PBS (131.8 +/-12.8 mm3 versus 114.9 +/- 23.9 
mm3; P=0.1) (Figure1). 
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AQGV and EPPE do not influence mRNA transcription levels of TNF-a, IL-6, ICAM-1 and E-selectin 
All three experimental groups displayed comparable mRNA expression levels of TNF-α, 
IL-6, ICAM-1 and E-selectin at 24 hours after the ischemic insult (Figure 2).
0
20
40
60
80
100
120
140
PBS AQGV EPPE
Infarct 
volume
(mm3)
Figure 1: Effects of treatment with AQGV and EPPE versus PBS on mean infarct volume (mm3) +/- SD.
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Figure 2: Relative expression of mRNA transcription levels of pro-inflammatory cytokines TNF-a and IL-6 
(A) and adhesion molecules E-selectin and ICAM-1 (B) in the brain 24 hours after reperfusion. Transcription 
levels are normalized to the expression level of the household gene ABL. Data are presented as the mean 
of per group +/-SD. AQGV nor EPPE caused significant differences in the transcription levels of TNF-a and 
IL-6 as compared with PBS.
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DISCUSSION
In this study, we found that in an established mouse model of ischemic stroke, treatment 
with two synthetic anti-inflammatory tetrapeptides had no effect on infarct volume or on 
mRNA expression levels of adhesion molecules and pro-inflammatory cytokines. 
Our results deviate from the beneficial effects of treatment with synthetic anti-
inflammatory oligopeptides in various other in vivo models of ischemia-reperfusion in-
jury.8-10 Treatment with such synthetic anti-inflammatory oligopeptides has been shown 
to inhibit renal ischemia-reperfusion injury and to increase survival rates by reducing 
systemic inflammation and adhesion molecule expression in the kidney10 These peptides 
also attenuated inflammation and liver damage after hemorrhagic shock9 and decreased 
morbidity and mortality associated with lipopolysaccharide injection8. 
There are several explanations why no such beneficial effects of treatment with syn-
thetic anti-inflammatory oligopeptides were found in our model of acute ischemic stroke. 
First, the role of inflammation in the acute phase of stroke is ambivalent. The inflam-
matory reaction following ischemic stroke triggers the removal of noxious agents and 
supports tissue cleaning and repair. Contrary to these beneficial effects, it may augment 
secondary damage by disruption of the blood-brain barrier, release of cytotoxic agents, 
edema resulting from endothelial cell injury and leucocyte-mediated injury, increased 
body temperature and microvascular thrombosis. Since the underlying mechanisms by 
which the synthetic anti-inflammatory oligopeptides exert their effects are unclear, it 
cannot be excluded that they might also nergate the positive effects of the inflamma-
tory reaction. On the other hand, synthetic anti-inflammatory oligopeptides did show 
beneficial effects in renal ischemia-reperfusion injury and there are many similarities 
in the pathophysiology of acute cerebral ischemia-reperfusion injury and acute renal 
ischemia-reperfusion injury.10 
Furthermore, we did not compare the mRNA expression levels of adhesion molecules 
and pro-inflammatory cytokines with those in brains of sham-operated animals. There-
fore, we do not know whether these pro-inflammatory genes were upregulated in our 
model of ischemic stroke. However, there is substantial evidence from previous studies 
that these genes are upregulated witin the first hours of stroke onset.1-3 
It should also be noted that different synthetic anti-inflammatory oligopeptides might 
have different modes of action. This is supported by previous studies that have identified 
different synthetic anti-inflammatory oligopeptides as the most effective mediator.8-10 
Another explanation of the negative results of our study is that it was not designed to 
investigate different doses of AQGV or EPPE. Therefore, we cannot rule out that there is a 
dose-dependent effect, as was observed in previous studies.8, 10 Also, the two time-points 
of peptide administration chosen for the current study may not have been optimal. 
Neither can we exclude that repeated peptide administrations during the study period 
could have been effective. 
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We have studied only the effects of AQGV and EPPE on infarct volume and mRNA 
transcription levels at 24 hours after reperfusion. As the inflammatory reaction is initi-
ated within a few hours after stroke onset and lasts for several days, it may be worth-
while to monitor the early evolution of brain injury at different points in time with MRI 
scanning.13 The major advantage of MRI over histologic examinations is its potential 
to non-invasively assess changes in the brain in vivo. Finally, since no measurements 
of brain concentrations of the administered tetrapeptides were performed we do not 
know whether the oligopeptides underwent presystemic transformation and actually 
crossed the blood-brain barrier. However, their small size as well as the disruption of the 
blood–brain barrier following ischemic stroke makes it likely that tetrapeptides did cross 
the blood-brain barrier.
HCG is not the only protein source for regulatory oligopeptides. Sequences of other 
proteins such as C-reactive protein Ig heaving chain, phospholipase A2, hemoglobin, 
b-defensins, lactoferrin and granulysin possess anti-inflammatory activities with the 
function being expressed upon the degradation of the parent protein.14-20 So far about 
500 human genes encoding proteases/peptidases have been identified. This might be 
related to regulation of biological processes by peptidases and might imply that virtually 
every protein within the body can serve as a source of regulatory oligopeptides.
Our results do not negate the possibility that anti-inflammatory oligopeptides might 
be useful for acute stroke treatment. Further studies are needed to investigate the nature 
and dynamics of the immunomodulatory effects of synthetic anti-inflammatory oligo-
peptides in acute ischemic stroke.
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abstract
ABSTRACT
Background and purpose There is substantial evidence that inflammation plays an 
important role in the pathophysiology of ischemic stroke and may contribute to the 
secondary damage following ischemic stroke. Complement activation may be one of the 
key pathways in the onset and reinforcement of this inflammation process. 
We aimed to assess whether the complement system is activated in acute ischemic stroke 
by determining the concentration of complement activation products and the remaining 
function of the three pathways of complement activation in peripheral blood of patients 
with acute ischemic stroke. 
Materials and methods Blood samples from 20 patients with ischemic stroke will be col-
lected on admission, and on day 1, 2, 3 and 5 and at 6 weeks. We will analyze plasma for 
components of all three pathways of complement activation and for levels of C1q, CH50, 
C3a, C5a levels by an enzyme-linked immunosorbent assay. Complement levels of each 
time point will be compared with complement levels at 6 weeks. Regression analysis will 
be applied to study the association between complement levels on the one hand and 
stroke severity and functional outcome on the other.
Clinical implications Studying the role of the complement system in the acute ischemic 
stroke might be very interesting as it may be an important novel therapeutic target. 
149
 Com
plem
ent activation follow
ing acute ischem
ic stroke 
5
BACKGROUND 
Stroke is the third leading cause of death and the first cause of disability in developed 
countries. It is to be expected that with an increasing age of the population, the number 
of stroke patients will increase as well. 
Since the advent of Intravenous thrombolysis with recombinant tissue-plasminogen 
activator, important progress in the treatment of acute ischemic stroke has been made.1 
However, only a limited number of patients will benefit from this treatment because of 
the short therapeutic time window and various contra-indications for treatment. There is 
a great need for other therapies in acute stroke.1, 2 
There is growing evidence that inflammation plays an important role in the pathophys-
iology of ischemic stroke. The inflammatory reaction is a defence mechanism against 
invading toxic organism and noxious agents and provides for tissue cleaning and repair. 
Besides its beneficial effect, it may contribute to the secondary progression of ischemic 
brain injury. In the early phase of ischemia and reperfusion, inflammation processes 
ensue in the ischemic core and in the penumbra, where perfusion is compromised, but 
tissue is still viable.3, 4 Numerous pro-inflammatory mediatiors are upregulated, including 
those for transcription factors, heat shock proteins, cytokines, chemokines and adhe-
sion molecules.5 The classic pro-inflammatory cytokines interleukin-b, interleukin-6, and 
tumor necrosis factor, produced by microglia, astrocytes, endothelial cells, and neurons, 
mediate these inflammation processes.6,  7 The inflammation processes start within 2 
hours and sustain for days.5, 6 Complement activation may be one of the key pathways in 
the onset and reinforcement of this inflammation process. 
Besides its important role in innate host defence, complement activation contributes 
to inflammatory and immunological responses in a number of pathological conditions. 
Numerous studies have demonstrated that complement contributes to secondary injury 
after ischemia in other organs such as myocardial tissue8, 9, skeletal muscles10 and kidney11. 
The role of the complement system in acute phase of ischemic stroke is unclear. Evi-
dence for involvement of complement in neural damaging after ischemia comes from 
studies in animal models and patients. Recently, animal studies suggest a crucial role 
for complement in neurological damage after ischemic stroke and show that inhibition 
of complement activation can reduce infarct size.12-14 Complement activation can occur 
via one of the three pathways, the classical, alternative and lectin pathway. Complement 
activation may trigger the inflammatory reaction after ischemia that may aggravate the 
damaging of neuronal cells via attraction of immune competent cells by chemotactic 
activated complement factors including C3a and C5a and by opsonisation of neuronal 
cells by C2b and C5b. Moreover, complement activation may also lead tot the production 
of the membrane attack complex (MAC), which can directly damage opsonized neuronal 
cell membranes. Additionally, this inappropriate inflammatory reaction may lead to 
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restenosis and recurrence of stroke. An activator of the complement cascade might be 
C-reactive protein (CRP).15
Only two small clinical studies on the role of complement in human ischemic stroke are 
available.16, 17 One study with 17 ischemic stroke patients showed that levels of C3b and 
C3a plasma were increased in patients with acute stroke compared to controls, indicating 
that shortly after a stroke there is a strong complement activation which can be mea-
sured in peripheral blood.16The second study with 11 patients with acute ischemic stroke 
showed that MAC plasma levels were increased.17 This increase in MAC was correlated 
with concentrations of CRP suggesting a possible role for CRP in complement activation. 
Neither study investigated all three pathways of complement activation. 
Studying the role of the complement system in the acute phase of ischemic stroke 
might be very interesting as it may be an important novel therapeutic target. Questions 
for future research may include: 
- Is activation of the complement system associated with infarct size and functionale 
outcome in patients with acute ischemic stroke? 
- Is activation of the complement system associated with restenosis after treatment 
with rtPA in patients with acute ischemic stroke? 
- Is activation of the complement system associated with the occurrence of infections?
- Is complement activation also found in patients with hemorrhagic stroke?
HYPOTHESIS
Against this background, our hypothesis will be that brain ischemia induces a strong 
complement activation that is reflected in the peripheral blood and that may contribute 
to the extent of the brain damaging.
AIM
To test this hypothesis by measuring the concentration of complement activation 
products and the remaining function of the three pathways of complement activation in 
peripheral blood from patients with an acute ischemic stroke. 
METHODS
Study population
A cohort of 20 patients with ischemic stroke will be prospectively studied. 
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Inclusion criteria will be a clinical diagnosis of ischemic stroke, the possibility to confirm 
the diagnosis with CT or MRI within 24 hours after inclusion in the study and admission 
within 24 hours of symptom onset. 
Patients with symptoms of an infection, malignant or other underlying inflammatory 
disease and/or currently receiving anti-inflammatory or immunosuppressive medication 
will be excluded. 
In addition, blood samples of ten stroke-free controls will be derived from the Rot-
terdam Stroke Biobank (RSB), a project aimed at collecting clinical information, blood 
samples and DNA of all patients with neurovascular diseases admitted to Erasmus Uni-
versity Medical Center and stroke free controls. Controls will be selected on basis of age 
and sex.
Baseline data
A detailed history of vascular risk factors and time of symptom onset will be collected. 
Neurological examination will be performed on admission and on discharge. Stroke se-
verity, neurological improvement or worsening will be assessed by means of the NIH 
Stroke Scale (NIHSS).18
Blood sampling and laboratory assessment 
Blood samples (25ml) will be collected on admission, and on day 1, 2, 3 and 5 and at 6 
weeks. EDTA tubes will be used to collect blood samples and plasma will be obtained 
by standard methods. After centrifugation, plasma will be stored at -80ºC until analysis. 
Plasma will be analyzed for components of all three pathways of complement activation 
by means of an ELISA. 
Plasma will also be analyzed for levels of C1q, CH50, C3a, C5a by means of ELISA. In 
addition, CRP levels will be measured, using a Roche Modular assay. The range of mea-
surement is 1–285 mg/L with a variation coefficient of 4.6%.
Statistical methods
The analysis will be carried out with STATA 10.0 statistical package (Statacorp, College 
Station, Texas). All data will be presented as mean +/- standard deviation. Concentrations 
of each time point will be compared with concentrations at 6 weeks by Student’s t-test. 
In addition, mean concentrations of patients with ischemic stroke will be compared with 
concentrations of the matched control group. Logarithmic transformation will be made 
for data that are not normally distributed. In addition, we will use linear regression to 
assess the relation between complement levels on the one hand and neurological stroke 
severity (baseline NIHSS score) and functional outcome (NIHSS score on discharge ad-
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justed for baseline NIHSS score) on the other. A multiple regression model will be applied 
to adjust for age and sex.
Sample size
We expect a difference in complement levels of 300 ng/ml between ischemic stroke pa-
tients and controls. Assuming a standard deviation of 200 ng/ml, a group of 20 patients 
and 20 controls will have a power of 80% to detect a significant (α=0.05) difference in 
complement levels. 
Ethical considerations
The study will be conducted according to the principles of the Declaration of Helsinki 
(version, date, see for the most recent version: www.wma.net) and in accordance with 
the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regula-
tions and acts.
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In my thesis, I have focused on body temperature and temperature-lowering therapy in 
acute stroke. Furthermore, I have explored the role of inflammation in relation to prog-
nosis and treatment in acute stroke. 
Over the past years, evidence has accumulated that inflammation plays a role in the 
pathophysiology of acute stroke. Body temperature and classic acute-phase reactants 
are modified by this inflammatory reaction, and both may be useful in the prediction of 
the prognosis after stroke and as therapeutic targets.
BODY TEMPERATURE IN ACUTE STROKE: IMPLICATIONS FOR PROGNOSIS AND 
TREATMENT
Interpretation of the results of the PAIS trial
Lowering body temperature and the prevention of fever may improve functional out-
come after stroke, as discussed in Chapter 2. 
The main aim of this thesis was to assess whether early treatment with high-dose 
paracetamol improves functional outcome in patients with acute stroke by reducing 
body temperature and preventing fever. To answer this question, we performed a large 
randomized placebo-controlled multicenter trial: the PAIS trial.1 We found that more 
patients on high-dose paracetamol than patients treated with placebo improved beyond 
expectation, but the difference was not statistically significant. In a post-hoc subgroup 
analysis, we found that in patients with a baseline body temperature between 37ºC and 
39ºC, treatment with paracetamol was significantly associated with improved outcome.1 
One could comment that the lack of an overall benefit of paracetamol may have been 
caused by the inclusion of 1400 instead of the planned 2500 patients.2 However, the ef-
fect of adopting the sliding dichotomy approach might be almost the same as a doubling 
of sample size.3
Although explanations for this finding should be interpreted with caution, the benefit 
of paracetamol in patients with higher body temperatures is biologically plausible. Two 
phase II trials in patients with acute ischemic stroke showed that high-dose paracetamol 
lowered body temperature by about 0.30ºC4,  5, which was confirmed in the PAIS trial.1 
Paracetamol induces larger temperature reductions if the initial body temperature is high-
er.6 Accordingly, we found that treatment with high-dose paracetamol induced a larger 
reduction in body temperature in patients with a baseline body temperature between 
37ºC and 39ºC than in those with a baseline body temperature between 36ºC and 37ºC.1
Furthermore, we found that an early rise in body temperature rather than an initially el-
evated body temperature was a risk factor for poor functional outcome. (Chapter 3.3) This 
supports the notion that prevention of an early rise in body temperature could reduce 
death and improve functional outcome. These results are in contrast with those of the 
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frequently cited Copenhagen Stroke Study that showed that the odds of poor outcome 
doubled for every degree increase in initial body temperature within 12 hours of stroke 
onset.7 We also found that patients with severe stroke had relatively low body tempera-
tures at baseline (Chapter 3.3), possibly because of a faster decrease in body temperature 
before hospital admission as a result of diminished muscle activity. This finding might 
explain in part that baseline body temperature was not associated with clinical outcome, 
and stresses the importance of considering acute stroke as a dynamic process.
The change in body temperature after onset was associated with initial stroke sever-
ity. (Chapter 3.3) One may argue that increased body temperature does not accelerate 
the ischemic cascade, but merely reflects extensive cerebral damage and, thereby, poor 
outcome. However, the relation between a rise in body temperature and poor outcome 
was independent of baseline stroke severity. Furthermore, the potential benefit of 
paracetamol in patients with higher body temperatures suggests that increased body 
temperatures following stroke are not an innocent consequence of brain infarction, but 
may increase ischemic damage.
Paracetamol is widely known as an antipyretic and analgesic, but may also have 
other effects. We assessed the effect of high-dose paracetamol on blood pressure in 
patients with acute stroke and showed for the first time that treatment with high-dose 
paracetamol is associated with a reduction in systolic blood pressure of approximately 
5 mm Hg within the first two days of stroke onset. (Chapter 3.4) A plausible cause of this 
reduction in systolic pressure by paracetamol is pain relief, but this remains speculative. 
The management of blood pressure in patients with acute stroke is uncertain.8-10 
However, prognostic studies have indicated that patients with systolic blood pressures 
of 10 mmHg above 150 mmHg may have a 4% increased risk of recurrent stroke and a 
4% increased risk of death or dependency.11, 12 Also, preliminary studies suggest that an-
tihypertensive treatment lowers blood pressure by 10-15 mm Hg after stroke.10, 13, 14 The 
effect of paracetamol on systolic blood pressure may therefore be large enough to be of 
clinical significance and provides an additional argument for further studies of high-dose 
paracetamol in acute stroke.
Implications of the PAIS trial 
I do not think that a recommendation for routine use of paracetamol in acute stroke 
can be considered good scientific and clinical practice at this moment. Although the 
benefit of paracetamol in patients with higher temperatures is supported by biological 
plausibility, these results should be interpreted with caution, as they are derived from a 
subgroup analysis. Furthermore, guidelines for the treatment of acute ischemic stroke or 
intracerebral hemorrhage recommend administration of antipyretic medication in case of 
fever or a temperature above 37.5˚C.8, 9 However, paracetamol likely improves functional 
outcome through the prevention of a rise in body temperature, and not through treat-
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ment of high body temperature after it has developed in stroke patients. Finally, a daily 
dose of 6 g of paracetamol used in PAIS is 50% higher than the recommended maximum 
dose. Although high-dose paracetamol was safe in the controlled setting of our trial, it 
may still lead to acute liver failure, especially in patients with chronic liver disease.1 In 
addition, it may mask fever, which could lead to delayed detection of pneumonia, urinary 
tract infections, and sepsis. 
A new trial on high-dose paracetamol in patients with acute stroke and a baseline 
body temperature of 37˚C or above should be the next step. Once this trial proves that 
paracetamol is effective, a cheap and simple therapy will be available for many patients 
with acute stroke. 
Suggestions for additional studies in PAIS II
Further research also needs to focus on the mechanisms of action of paracetamol in acute 
stroke. As I have discussed in Chapters 2 and 3, it has been suggested that COX-2 is in-
volved in inflammation following ischemic stroke and contributes to tissue damage.15 As a 
consequence, the COX-2 inhibitor paracetamol may mediate this inflammatory response. 
Therefore, it would be interesting to collect blood samples for the assessment of inflam-
matory cytokines and acute-phase reactants and analysis of inflammation-related genes. 
As the mechanisms of action of paracetamol have not been fully clarified, animal 
studies may support in expanding our knowledge on the effect of paracetamol in acute 
stroke. To the best of my knowledge, only one animal study has been performed to de-
termine the effect of paracetamol on body temperature and infarct volume in animals.16 
In this study, a trend towards a reduction in infarct volume by paracetamol was observed. 
Further animal studies should focus on prevention of a rise in body temperature by 
paracetamol in acute stroke, and may thereby contribute to better understanding of our 
findings in the post-hoc subgroup analysis of PAIS. 
To further explore the effect of paracetamol on blood pressure, I recommend to mea-
sure blood pressure and serum levels of catecholamines and cortisol, in particular on the 
first day of stroke onset.
Issues concerning temperature reduction and trials on temperature-lowering therapy in acute stroke
Body temperature or brain temperature?
In a study of 8 patients with traumatic brain injury, the correlation between temperatures 
measured rectally or in the bladder and those measured in the brain was investigated.17 
Brain temperature was found to be 1-2°C higher than rectal and bladder temperatures. 
Differences were largest when the rectal or bladder temperatures were higher than 
38°C. As temperatures in all trials of temperature reduction were assessed with rectal, 
bladder, or tympanic thermometry, the brain temperature in these patients may have 
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been underestimated. Magnetic resonance thermometry might be a valuable approach 
for non-invasive monitoring of brain temperature.18, 19 This technique has shown useful 
in an experimental setting, but has to be further explored before it can be applied in the 
clinical setting.18,  19 On the other hand, all clinical prognostic studies and most animal 
experiments that have suggested a benefit of temperature reduction reported body 
temperatures and not brain temperatures. In addition, in another small study of 20 
patients with traumatic brain injury or subarachnoid hemorrhage and fever, the mean 
difference between body and brain temperature was only 0.3°C (SD 0.3°C).20
Is temperature lowering effective in ischemic and hemorrhagic stroke?
In ischemic stroke, temperature-lowering therapy may reduce tissue damage via several 
pathophysiological routes, such as protection of the blood-brain barrier, suppression of 
the release of excitatory amino acids and free radicals, lowering of the cerebral metabolic 
rate, and anti-inflammatory actions.21, 22 The mechanisms underlying a possible benefit of 
temperature-lowering therapy in intracerebral hemorrhage are less clear. In animal stud-
ies, temperature lowering reduced edema, but not lesion volume.23, 24 These findings war-
rant further studies. However, observational studies have shown an association between 
increased body temperatures and poor outcome both in patients with ischemic stroke, as 
well as in patients with intracerebral hemorrhage.21 (Chapter 3.4) Therefore, we included 
both ischemic and hemorrhagic stroke patients in the PAIS trial.1 The subgroup analysis 
based on main stroke subtype did not indicate any differences in treatment effect.1
What is the optimal duration of therapy?
Uncertainty exists on the optimal duration of temperature-lowering therapy. In animal 
models of focal cerebral ischemia, pathophysiological processes exert their deleterious 
effects anywhere between the first minutes and several days after vessel occlusion.25 On 
the other hand, longer duration of treatment was not associated with improved out-
come in a meta-analysis of hypothermia in animal models of focal cerebral ischemia.26 
Moreover, as the rise in temperature occurs mainly within the first 24 hours after stroke 
onset, this period might be regarded as the critical treatment period.27,  28 In addition, 
most observational studies have shown that the relation between body temperature and 
clinical outcome is probably limited to the first 12 to 24 hours after stroke onset.7, 29, 30 
Furthermore, the risk of side effects may increase with longer durations of treatment. 
Is physical temperature-lowering therapy a promising approach to stroke treatment?
Larger temperature reductions by physical cooling methods are an alternative approach 
to antipyretic treatment. In animal studies of focal cerebral ischemia, efficacy was highest 
with temperatures below 32°C, but infarct volume was still reduced by about one-third 
after cooling to 35°C.26 In trials of cardiac arrest, the target temperature was 32 - 34°C.31, 32 
however, because of patient comfort monitoring, and the prevention of shivering, 
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temperature-lowering therapy to such levels generally requires sedation, mechanical 
ventilation, and therefore admission to an intensive care unit. Given the limited avail-
ability of intensive care beds in most countries, cooling to temperatures of about 33°C 
may be impractical. In addition, sedation and mechanical ventilation may increase the 
risk of side effects. Therefore, moderate hypothermia might be a better choice in patients 
with acute stroke. On the other hand, a local approach of selective brain cooling might 
have less systemic complications and might permit larger temperature reductions. Hence, 
further large randomized clinical trials are needed to study the feasibility, safety, optimal 
duration and the effectiveness of physical temperature reduction in patients with acute 
stroke. Two phase II trials on the combination of mild hypothermia and treatment with 
rt-PA are underway.33, 34 
Furthermore, a European collaboration aiming for multi-center randomized trials of 
interventions involving systemic hypothermia in acute ischemic stroke (EURO-COOLS) 
will be launched this year. This project aims to assess the feasibility and safety of surface 
and endovascular cooling to 33ºC, as well as to 35ºC.
The “sliding dichotomy” approach 
Because of the drawbacks of dichotomization of ordinary outcome scales and to increase 
statistical power, as I discussed in Chapter 3.1, we changed the primary effect estimate of 
the PAIS trial to the odds ratio for “improvement beyond expectation”, according to the 
sliding dichotomy approach.3, 35 
This approach appears to be more efficient, as the original primary effect measure did 
not show an effect of paracetamol on functional outcome whereas the sliding dichotomy 
approach did suggest a trend towards a beneficial effect. Furthermore, I believe that this 
approach is more relevant for clinical practice. It is also informative to show whether 
treatment moves patients from any category of disability to a less severe one, and not 
only to demonstrate differences in the numbers of patients on either side of an arbitrary 
cut-off point.
Patient recruitment 
A key to success in any clinical trial is the achievement of a study population of an 
adequate sample size. In the PAIS trial, we did not meet the planned target of 2500 
patients.1 Patient recruitment is one of the greatest barriers in the conduct of random-
ized controlled trials. Lack of eligible patients is an important cause of an inadequate 
inclusion rate in clinical trials, but did not prove to be a major hurdle in the PAIS trial. PAIS 
was an investigator-driven trial, and therefore the success was completely dependent on 
the efforts of the investigators. Although it was designed as a simple trial, the workload, 
small as this has been compared to that of industry-driven trials, may have caused many 
hard-pressed neurologists to gradually lose their enthousiasm for recruiting patients. The 
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low recruitment rate may also have been caused by simultaneous competitive trials, in 
particular if these studies offered attractive financial incentives. 
Various strategies may help to achieve an increase in recruitment rate in future 
investigator-driven trials. One option is to offer small incentives for every patient inclu-
sion. Second, collaboration with other European countries may enhance recruitment. 
However, nowadays funding for trials tends to be granted at the level of an individual 
country and there is limited funding at the European level. Furthermore, the rules and 
requirements for clinical trials may be different in the participating countries. An alterna-
tive approach is to combine the results of similar trials in a meta-analysis. Standardization 
of clinical outcomes and designs in trials could make it easier to compare their results.36, 37
INFLAMMATION IN ACUTE STROKE: IMPLICATIONS FOR PROGNOSIS AND 
TREATMENT
Prognosis
Elevated levels of CRP can be a reflection of the inflammatory reaction following acute 
stroke. We found that an increased level of CRP in the very early phase of acute stroke 
was an independent prognostic factor for poor outcome. (Chapter 4.1) Furthermore, 
common variation in the CRP gene was associated with increased levels of CRP in acute 
stroke. (Chapter 4.2)
The use of biomarkers as predictors of stroke lesion evolution and prognosis is becom-
ing increasingly important, as they may be valuable tools in the search for an optimal 
management of stroke patients. Animal studies may help us to understand the role of bio-
markers in the disease process. Furthermore, biomarkers can also be used to link animal 
studies with human studies. Animal models may not produce clinical symptoms similar to 
humans. In this case, a biomarker may serve as a surrogate endpoint in the animal. 
CRP is an easy to measure and readily available inflammatory marker. It may provide 
important prognostic information beyond conventional clinical parameters. Further 
studies are needed to assess whether CRP is a predictor of outcome also after stroke.
Interestingly, animal studies have found that CRP might exacerbate brain tissue dam-
age following ischemic stroke, possibly via a complement-mediated exacerbation of tis-
sue injury.38 This could stimulate research into the underlying pathogenetic mechanisms 
and the development of new medical treatments for acute ischemic stroke. Furthermore, 
stroke is a heterogeneous disease and more insight in genotype–phenotype associations 
may provide a basis for development of tailored therapeutic strategies in ischemic stroke 
and intracerebral hemorrhage. 
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Inflammation, a target for therapy in patients with acute stroke?
The accumulating evidence that inflammation-mediated damage plays a role in ischemic 
stroke suggests that immunomodulatory agents represent a promising class of drugs. As 
discussed in Chapter 5, the complement system plays an integrated role in the initiation 
and regulation of the inflammatory response and might be a promising target. We have 
recently started a study in 20 patients with ischemic stroke to assess the concentration 
of complement activation products and the remaining function of the three pathways 
of complement activation in peripheral blood. (Chapter 5) If brain ischemia indeed in-
duces a strong complement activation which is reflected in the peripheral blood, further 
research should be aimed at the assessment of the relation between this activation of 
the complement system and infarct size and functional outcome. Other interesting 
research questions are whether activation of the complement system is associated with 
reocclusion after treatment with rt-PA, whether complement activation is also found 
in patients with intracerebral hemorrhage, and whether genetic variants contribute to 
activation of complement in patients with acute stroke. The nature of the substances in 
the infarcted area that start activation of complement system is unknown. CRP could be 
involved as an activator. Further experimental studies are needed to unravel the mecha-
nisms by which the complement system is activated and to further explore the role of the 
complement cascade in tissue damage following acute stroke.
Furthermore, clinical and experimental studies suggest that the inflammatory reac-
tion following stroke induces immunological changes that increase the susceptibility for 
infections. Further research is needed to determine the clinical consequences of these 
immunological changes.39-41
CONCLUSION
Acute stroke is a challenging and heterogeneous disease. A pivotal objective of treat-
ment of acute ischemic stroke is lysis of the clot to restore blood flow to ischemic tissue. 
Reperfusion induced by intravenous administration of rt-PA has shown to be effective 
when initiated up to 4.5 hours of ischemic stroke onset.42 Further research should be 
aimed at increasing the therapeutic window for thrombolysis by identifying patients 
who benefit from rt-PA beyond a 4.5-hour interval by means of diffusion–perfusion MRI 
or perfusion CT techniques and by applying intra-arterial thrombolytic therapy and 
mechanical reperfusion methods.
The studies described in this thesis show that lowering body temperature and the 
prevention of fever is a promising approach to improve functional outcome after stroke 
and provide directions for further research. It is too early for routine use of high-dose 
paracetamol in acute stroke. A new trial on the effect of high-dose paracetamol in patients 
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with body temperatures of 37ºC or above is needed. Moreover, future research should 
focus on larger temperature reductions by physical cooling methods in acute stroke. The 
studies presented in this thesis also suggest that inflammation plays a prognostic role in 
acute stroke, and may further guide therapeutic choices in acute stroke.
Finally, it is quite likely that early recanalization or reperfusion is a prerequisite for 
effectiveness of neuroprotective and anti-inflammatory strategies. Combination of 
thrombolysis with rt-PA and neuroprotective and anti-inflammatory strategies aimed at 
limitation of tissue damage following ischemic stroke might be an attractive therapeutic 
approach. 
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SUMMARY
Stroke ranks second as a cause of death worldwide and is the main cause of disability 
in high-income countries. Treatment of ischemic stroke and intracerebral hemorrhage 
has remained unsatisfactory. Apart from stroke unit care, intravenous thrombolysis with 
recombinant tissue-plasminogen activator (rt-PA) and aspirin are efficacious in patients 
with ischemic stroke, and there is no treatment for intracerebral hemorrhage with proven 
efficacy. Safe, cheap, and broadly applicable therapies for acute stroke are needed.
Inflammation plays a role in the pathophysiology of acute stroke. Body temperature 
and classic acute-phase reactants are modified by this inflammatory reaction, and may 
be useful in the prediction of the prognosis after stroke and as therapeutic targets.
This thesis focused on body temperature and temperature-lowering therapy in acute 
stroke. A secondary aim was to further expand the knowledge on inflammation in rela-
tion to prognosis and treatment in acute stroke. 
Chapter 1, the general introduction, describes the background and the rationale for 
the research described in this thesis.
In Chapter 2, we give a general review of the literature concerning temperature-lower-
ing therapy and discuss the existing evidence in terms of feasibility and effectiveness of 
this treatment strategy in acute stroke. There is currently no evidence from randomized 
trials to support routine use of physical or pharmacological strategies to reduce tempera-
ture or preventing fever in patients with acute stroke. Large randomized clinical trials are 
needed to study the safety and the effectiveness of both physical and pharmacological 
temperature reduction in patients with acute stroke.
Based on the existing evidence, we started the Paracetamol (Acetaminophen) In Stroke 
(PAIS) trial. In this multicenter, randomized, double-blind, placebo-controlled trial, we as-
sessed whether early treatment with high-dose paracetamol (6 g daily) for 3 consecutive 
days improves functional outcome in 1400 patients with acute stroke. 
For the PAIS trial, we decided to change the planned analysis for the primary outcome 
measure from a fixed dichotomy of the modified Rankin Scale (mRS) to a sliding di-
chotomy analysis. Chapter 3.1 describes the protocol change. Instead of taking a single 
definition of good outcome for all patients, the definition was tailored to each individual 
patient’s baseline prognosis on entry into the trial. This protocol change was initiated 
because of both advances in statistical approaches and to increase the efficiency of the 
trial by improving statistical power.
Chapter 3.2 describes the results of the PAIS trial. We found that more patients on 
high-dose paracetamol than patients treated with placebo improved beyond expecta-
tion, but the difference was not statistically significant (adjusted odds ratio 1.20, 95% 
CI 0.96–1.50). In a post-hoc subgroup analysis, we found that in patients with a baseline 
body temperature between 37ºC and 39ºC, treatment with paracetamol was significantly 
associated with improved outcome (adjusted odds ratio 1.43, 95% CI 1.02-1.97). The re-
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sults do not support routine use of high-dose paracetamol in patients with acute stroke. 
Further study is needed to confirm the beneficial effects of paracetamol in patients with 
a baseline body temperature between 37ºC and 39ºC.
Subfebrile temperature or fever is present in about a third of patients on the first day 
after stroke onset and is associated with poor outcome. However, the temporal profile of 
this association is not well established. In Chapter 3.3, we assessed the relationship be-
tween body temperature, on admission as well as the change in body temperature from 
admission to 24 hours thereafter and functional outcome and death in 1332 patients 
included in the PAIS trial. We found that an early rise in body temperature rather than 
elevated body temperature on admission is a risk factor for poor functional outcome in 
patients with acute stroke. This provides a rationale for the hypothesis that prevention of 
an early rise in body temperature could reduce death and improve functional outcome.
Paracetamol is widely known as an antipyretic and analgesic, but may also have other 
effects. In Chapter 3.4, we assessed the effect of high-dose paracetamol on blood pres-
sure in 540 patients with acute stroke. We showed that paracetamol also reduces blood 
pressure at 12 hours from the start of treatment. This finding provides an additional 
argument for further studies of the effect of prophylactic high-dose acetaminophen on 
functional outcome in acute stroke.
Elevated levels of C-reactive protein (CRP) can be a reflection of the inflammatory 
reaction following acute stroke. In Chapter 4.1, we evaluated the prognostic value of 
CRP obtained within 12 hours of symptom onset in 561 patients of ischemic stroke. An 
increased level of CRP in the very early phase of acute stroke was an independent prog-
nostic factor for poor outcome. Furthermore, we found that common variation in the CRP 
gene was associated with increased levels of CRP in 185 patients with acute ischemic 
stroke in Chapter 4.2. Further studies are needed to investigate the relation between 
variation in the CRP gene, levels of CRP and clinical outcome after acute ischemic stroke.
In Chapter 5, a first step into further research in acute stroke aimed at integrating 
basic and clinical science is presented. Chapter 5.1 gives a short overview of the dif-
ferent animal models of ischemic stroke that have been used to date, the advantages 
and disadvantages of these models and the role of animals models in relation to stroke 
research. 
Recently, it has been shown that synthetic oligopeptides related to human chorionic 
gonadotropin (hCG) and various other synthetic oligopeptides may have immunomodu-
latory effects. In Chapter 5.2, a pilot study to assess the effects of two promising synthetic 
anti-inflammatory tetrapeptides on infarct volume and on inflammatory gene expression 
in an animal model of focal cerebral ischemia is described. We found no immunomodula-
tory effects of these synthetic tetrapeptides in a mouse model of ischemic stroke.
Complement activation may be one of the key pathways in the onset and reinforce-
ment of the inflammation process following acute stroke. The protocol of a pilot study on 
complement activation in acute ischemic stroke is presented in Chapter 5.3. 
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The implications of the studies described in this thesis and future research are dis-
cussed in Chapter 6. It is concluded that lowering body temperature and the prevention 
of fever is a promising approach to improve functional outcome after stroke and provides 
directions for further research. It is too early for routine use of high-dose paracetamol 
in acute stroke. A second trial on the effect of high-dose paracetamol in patients with 
body temperatures of 37ºC is needed. Moreover, future research should focus on larger 
temperature reductions by physical cooling methods in acute stroke. Inflammation plays 
a prognostic role in acute stroke, and may further guide therapeutic choices in acute 
stroke.
NEDERLANDSE SAMENVATTING
Een beroerte (herseninfarct of hersenbloeding) is de tweede doodsoorzaak en de be-
langrijkste oorzaak van invaliditeit in de westerse wereld. Hoewel de behandeling van 
het acute herseninfarct de laatste jaren is verbeterd door de komst van stroke units en 
behandeling met aspirine en trombolyse is de functionele uitkomst voor veel patiënten 
nog steeds slecht. Voor de acute hersenbloeding is behoudens de stroke unit geen enkele 
bewezen effectieve therapie beschikbaar. Het is daarom van belang om het onderzoek 
naar nieuwe behandelingen voor beroerte voort te zetten.
De laatste jaren wordt steeds meer duidelijk dat ontsteking een belangrijke rol speelt 
in de pathofysiologie van een beroerte. Naast het gegeven dat ontsteking betrokken is 
bij het herstel van weefselschade draagt het waarschijnlijk ook bij aan de weefselschade. 
De lichaamstemperatuur en acute fase eiwitten worden beïnvloed door deze ontste-
kingsreactie en zouden nuttig kunnen zijn bij het voorspellen van de prognose na een 
beroerte en als aangrijpingpunt voor therapie.
Het in dit proefschrift beschreven onderzoek is gericht op lichaamstemperatuur en 
temperatuurverlagende therapieën bij patiënten met een beroerte. Daarnaast hebben 
we de rol van ontsteking met betrekking tot de prognose en de behandeling van patiën-
ten met een beroerte bestudeerd.
In hoofdstuk 2 wordt de achtergrond geschetst van temperatuurverlaging of het 
voorkómen van koorts bij patiënten met een beroerte en wordt een overzicht gegeven 
van het bewijs van de effectiviteit en veiligheid van deze therapieën. Er zijn twee manie-
ren om de lichaamstemperatuur te verlagen, namelijk medicamenteus met bijvoorbeeld 
paracetamol en door middel van fysiek koelen met bijvoorbeeld koelmatrassen, koude 
infuusvloeistof of koelhelmen. De conclusie is dat er onvoldoende bewijs is voor de ef-
fectiviteit en veiligheid van temperatuurverlagende therapieën bij patiënten met een 
beroerte. Grote gerandomiseerde trials zijn nodig om de veiligheid en effectiviteit van 
zowel temperatuurverlaging of het voorkomen van koorts te bestuderen. 
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Om na te gaan of vroege behandeling met een hoge dosis paracetamol door middel 
van het voorkomen van koorts en het verlagen van de lichaamtemperatuur de functio-
nele uitkomst na een beroerte verbetert, hebben wij de Paracetamol (Acetaminophen) 
In Stroke (PAIS) trial uitgevoerd.
In Hoofdstuk 3.1 wordt een wijziging op het protocol van PAIS beschreven. Voor de 
primaire uitkomstmaat wordt in de meeste trials met patiënten met een beroerte de 
modified Rankin Scale gebruikt. Deze frequent gebruikte schaal om de uitkomst na een 
beroerte te meten wordt vaak in twee categorieën ingedeeld, namelijk een gunstige of 
ongunstige uitkomst. Deze methode heeft als nadeel dat het minder overeenkomt met 
de klinische praktijk en minder efficiënt gebruik maakt van de beschikbare gegevens. 
Om deze redenen hebben wij de primaire uitkomstmaat van de PAIS gewijzigd van deze 
grove tweedeling naar verbetering volgens de zogenoemde “sliding dichotomy analysis”. 
Hierbij wordt rekening gehouden met de verwachte prognose van een patiënt.
In hoofdstuk 3.2 worden de hoofdresultaten van de PAIS besproken. In deze gerando-
miseerde placebo-gecontroleerde dubbelblinde trial werden in 29 Nederlandse centra 
1400 patiënten met een beroerte en een lichaamstemperatuur van 36-39 ºC binnen 12 
uur na aanvang van de symptomen gerandomiseerd voor behandeling met paracetamol 
(6 gram per dag) of placebo gedurende 3 dagen. Meer patiënten die behandeld waren 
met paracetamol verbeterden dan patiënten die een placebo hadden gebruikt, maar dit 
effect was niet statistisch significant (geadjusteerde odds ratio, 1.20; 95% BI, 0.96–1.50). 
In een post-hoc subgroepanalyse had paracetamol wel een significant gunstig effect bij 
patiënten met een lichaamstemperatuur van 37-39ºC (geadjusteerde odds ratio 1.43, 
95% BI 1.02–1.97). De resultaten zijn veelbelovend, maar bieden nog onvoldoende basis 
om een hoge dosis paracetamol routinematig te geven aan patiënten met een acute 
beroerte. Paracetamol verbetert mogelijk het herstel bij patiënten met een lichaamstem-
peratuur van 37ºC of meer. Dit moet worden bevestigd in een onafhankelijke studie. 
Een verhoogde lichaamstemperatuur op de eerste dag na een beroerte komt voor 
bij eenderde van de patiënten en is geassocieerd met slecht functioneel herstel. Het is 
echter onduidelijk wat de meeste voorspellende waarde heeft, de lichaamstemperatuur 
bij opname of de stijging van de lichaamstemperatuur gedurende de eerste 24 uur. In 
hoofdstuk 3.3 zijn we nagegaan bij 1332 patiënten die geïncludeerd waren in PAIS wat 
de prognostische waarde was van de lichaamstemperatuur gemeten op 2 momenten, 
namelijk bij opname en 24 uur later op het functionele herstel en overlijden. We vonden 
dat de stijging in de lichaamstemperatuur en niet een verhoogde lichaamstemperatuur 
bij opname gerelateerd was met een slechter functioneel herstel en overlijden. Dit on-
dersteunt de gedachte dat het belangrijk is om temperatuurstijging te voorkómen bij 
patiënten met een beroerte.
Paracetamol heeft naast een pijnstillende en temperatuurverlagende werking moge-
lijk ook andere effecten. In hoofdstuk 3.4 wordt een onderzoek beschreven waarin we 
bij 540 patiënten met een beroerte het effect van paracetamol op de bloeddruk hebben 
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bestudeerd. We vonden dat paracetamol ook een bloeddrukverlagend effect heeft in de 
eerste 12 uur na het starten van de behandeling. Deze bevinding is een extra onder-
steuning voor nieuwe trials naar het effect van paracetamol bij patiënten met een acute 
beroerte.
Tijdens de acute fase van een herseninfarct worden in het serum van patienten ver-
hoogde concentraties van C-reactive protein (CRP), een acuut fase eiwit, gevonden. Deze 
verhoogde concentraties zijn mogelijk een weerspiegeling van de ontstekingsreactie 
die na het herseninfarct op gang komt. In hoofdstuk 4.1 hebben we bij 561 patiënten 
met een herseninfarct de prognostische waarde van CRPconcentraties op de klinische 
uitkomst onderzocht. Een verhoogde CRP-waarde was een onafhankelijke voorspeller 
voor een ongunstige klinische uitkomst.
De mate van de ontstekingsreactie bij patiënten met een acuut herseninfarct kan sterk 
wisselen, mogelijk op basis van erfelijke eigenschappen. In hoofdstuk 4.2 vonden wij in 
185 patiënten met een herseninfarct dat genetische variatie in het CRP-gen gerelateerd 
is aan hogere CRP-concentraties. Als in toekomstig onderzoek blijkt dat deze genetische 
variatie in het CRP-gen ook gerelateerd is aan de klinische uitkomst zou dit kunnen 
leiden tot een nieuw aangrijpingspunt voor therapie .
In hoofdstuk 5 worden de eerste stappen voor vervolgonderzoek zowel in een 
diermodel als in patiënten gepresenteerd. In hoofdstuk 5.1 worden de verschillende 
diermodellen van het herseninfarct, de voor- en nadelen van deze modellen en de rol 
van het diermodel binnen het onderzoek naar het herseninfarct besproken. 
In hoofdstuk 5.2 beschrijven we een eerste studie die we hebben verricht in een 
muismodel voor het herseninfarct. Eerder onderzoek heeft laten zien dat synthetisch 
verkregen tetrapeptides (moleculen die bestaan uit 4 aminozuren en veelal bouwstenen 
vormen voor eiwitten) die gerelateerd zijn aan het zwangerschapshormoon humaan 
Chorion Gonadotrofine (hCG) en diverse ander synthetisch verkregen tetrapeptides ver-
anderingen in het immuunsysteem ter weeg kunnen brengen. Wij hebben onderzocht 
of deze tetrapetides een gunstige invloed hadden op de grootte van het herseninfarct 
en de ontstekingsreactie die na het herseninfarct op gang komt. We vonden geen 
aanwijzingen voor een gunstig effect van de tetrapeptides in een muismodel van het 
herseninfarct. Vervolgonderzoek is nodig om de rol van deze tetrapeptides op de ontste-
kingsreactie in de acute fase van het herseninfarct nader te bestuderen.
Een belangrijke factor bij de ontstekingsreactie is het complementsysteem. Het com-
plementsysteem kan zorgen voor het initiëren en verergeren van een ontstekingsreactie. 
Hoofdstuk 5.3 beschrijft een protocol van een studie waarin we bij patiënten met een 
acuut herseninfarct willen nagaan of een activatie van het complementsysteem te meten 
is in het serum van deze patiënten. Het is een eerste stap om de rol van het complement-
systeem in de acute fase van het herseninfarct nader te bestuderen.
In hoofdstuk 6 worden de klinische implicaties van de verschillende studies in dit 
proefschrift besproken en worden suggesties gedaan voor toekomstig onderzoek. 
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Temperatuurverlaging of het voorkomen van temperatuurstijging blijft een veelbelo-
vende behandeling, maar het is te vroeg om patiënten met een beroerte routinematig te 
behandelen met een hoge dosis paracetamol. Een nieuwe trial naar het effect van hoge 
dosis paracetamol bij patiënten met een beroerte en een temperatuur van 37ºC of hoger 
is nodig. Ook zouden toekomstige trials zich moeten richten op fysiek koelen. Met deze 
methode kunnen lagere temperaturen worden bereikt. Daarnaast speelt ontsteking een 
rol bij de prognose van patiënten met een beroerte en kan dit een aangrijpingspunt zijn 
voor nieuwe therapieën.
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LIST OF ABBREVIATIONS
AOR  adjusted OR
BI  Barthel Index
CI  confidence interval
COX  cyclooxygenase
CRP  C-reactive protein
DNA  deoxyribonucleic acid
ELISA  Enzyme-Linked Immuno Sorbent Assay
EuroQol-5D European Quality of Life-5 Dimensions
Fmoc  fluorenylmethoxycarbonyl
HCG  human chorionic gonadotropin
HE  hematoxylin and eosin 
ICAM  intercellular adhesion molecule
IQR  interquartil range
IL  interleukin 
LCCA  left common carotid artery
LECA  left external carotid artery
LICA  left internal carotid artery
MAC  membrane attack complex
MCAO  middle cerebral artery occlusion
MRS  modified Rankin Scale
NIHSS  National Institutes of Health Stroke Scale
OR  odds ratio
PAIS  Paracetamol (Acetaminophen) In Stroke 
PAPAS  Paracetamol (Acetaminophen) in Patients with Acute Stroke
PCR  Polymerase Chain Reaction
PISA  Paracetamol (Acetaminophen) and Ibuprofen in Acute Stroke
RNA  ribonucleic acid 
Rt-PA  tissue-plasminogen activator
SD  Standard deviation
SNP  single-nucleotide polymorphism
STAIR  Stroke Therapy Academic Industry Roundtable
TOAST  Trial of ORG 10172 in Acute Stroke Therapy
TNF-a  tumor necrosis factor-a 
TTC  2,3,5 triphenyltetrazolium chloride
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APPENDIX I: THE MODIFIED RANKIN SCALE
Grade Description
0 No symptoms at all
1 No significant disability despite symptoms; able to carry out all usual duties and 
activities
2  Slight disability; unable to carry out all previous activities, but able to look after 
own affairs without assistance 
3 Moderate disability; requiring some help, but able to walk without assistance
4  Moderately severe disability; unable to walk without assistance and unable to at-
tend to own bodily needs without assistance
5  Severe disability; bedridden, incontinent and requiring constant nursing care and 
attention
6  Dead
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APENDIX II: BARTHEL INDEX
FEEDING
0 = unable
1 =  needs help cutting, spreading butter, 
etc., or requires modified diet
2 = independent 
BATHING
0 = dependent
1 = independent (or in shower) 
GROOMING
0 = needs to help with personal care
1 =  independent face/hair/teeth/shaving 
(implements provided) 
DRESSING
0 = dependent
1 =  needs help but can do about half 
unaided
2 =  independent (including buttons, zips, 
laces, etc.) 
BOWELS
0 =  incontinent (or needs to be given 
enemas)
1 = occasional accident
2 = continent 
BLADDER
0 =  incontinent, or catheterized and 
unable to manage alone
1 = occasional accident
2 = continent
TOILET USE
0 = dependent
1 =  needs some help, but can do some-
thing alone
2 =  independent (on and off, dressing, 
wiping) 
TRANSFERS (BED TO CHAIR AND BACK)
0 = unable, no sitting balance
1 =  major help (one or two people, 
physical), can sit
2 = minor help (verbal or physical)
3 = independent
MOBILITY (ON LEVEL SURFACES)
0 = immobile or < 50 yards
1 =  wheelchair independent, including 
corners, > 50 yards
2 =  walks with help of one person (verbal 
or physical) > 50 yards
3 =  independent (but may use any aid; for 
example, stick) > 50 yards 
STAIRS
0 = unable
1 =  needs help (verbal, physical, carrying 
aid)
2 = independent 
183
 A
ppendices 
A
APPENDIX III: THE STAIR RECOMMENDATIONS FOR STANDARDS REGARDING 
PRECLINICAL NEUROPROTECTIVE DRUG DEVELOPMENT
STAIR recommendations
1. Adequate dose-response studies should be conducted with serum concentrations 
measured to define minimally and maximally effective doses
2. Time-window studies to confirm efficacy are required
3. Physiological monitoring should be undertaken
4. Randomized, blinded studies that give reproducible effects should be conducted, 
involving at least one independent laboratory
5. Both infarct volume and functional response should be assessed, including short- 
and long-term assessment
6. Efficacy should be evaluated in both transient and permanent middle cerebral 
artery occlusion rat models 
7. For novel, first-in-class agents, studies in larger species/primates are required to 
confirm efficacy
8. Studies should be published in peer-reviewed journals
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De overige co-auteurs van mijn manuscripten wil ik bedanken voor hun intellectuele 
bijdrage. Een speciaal woord van dank gaat uit naar prof.dr. M.P.M. de Maat, prof.dr. R. 
Benner en dr. B.C. Jacobs. Beste Moniek, bedankt voor je begeleiding van de SNPbepa-
lingen, discussies en je laagdrempeligheid om even langs te kunnen lopen bij vragen. 
Beste professor Benner, bedankt dat u me de mogelijkheid heeft gegeven om een eerste 
onderzoek uit te voeren met het herseninfarctmodel in Berlijn. Beste Bart, bedankt voor 
je belangstelling, goede adviezen en betrokkenheid bij toekomstig onderzoek.
Het trialbureau
Naziha el Ghannouti en Esther van der Heijden
Het includeren van patiënten en het verzamelen van de gegevens uit zoveel ziekenhui-
zen in Nederland is een aanzienlijke klus. Naziha en Esther, zonder jullie hulp was dit 
niet gelukt. Ik heb goede herinneringen aan onze treinreizen naar alle uithoeken van 
Nederland en aan onze autoritten. Door de vele kilometers heb ik ook nog eens mijn 
rijvaardigheid op peil kunnen houden. Daarnaast bedankt voor jullie volhardendheid 
waardoor we uiteindelijk slechts één lost to follow-up hadden in de PAISstudie.
Deelnemende centra PAISstudie
Zonder de neurologen en arts-assistenten uit de 29 deelnemende ziekenhuizen was PAIS 
nooit een succes geworden. Bedankt voor jullie inzet de afgelopen jaren.
Daarnaast wil ik alle onderzoeksassistenten, verpleegkundigen en secretaressen die ons 
hierin hebben bijgestaan bedanken voor hun hulp. 
Verpleging van 6 noord en 6 midden
Bedankt voor jullie bijdrage aan de PAISstudie! Dorien, bedankt voor je samenwerking en 
belangstelling de afgelopen jaren. 
Hester Lingsma
Hester, bedankt voor je bereidheid om me te helpen bij de “sliding dichotomy” analyse 
en de jaarlijkse datacontrole van PAIS.
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Mijn collega’s uit de vasculaire groep, bedankt voor de gezelligheid, steun en de goede 
herinneringen aan onder andere de congressen in Brussel, Glasgow, Nice en Stockholm. 
Maaike en Lonneke, ook heb ik bijzonder goede herinneringen aan de summer school in 
Barcelona. 
Marjolein, bedankt voor je tips bij het geven van mijn presentaties.
Marieke, bedankt voor je kritische blik en het uitpluizen van de tekst op typefouten.
Daarnaast wil ik in het bijzonder de stroketelefoonhouders Annemarie, Maaike, Ewoud, 
Lisette, Lonneke, Mathieu, Mary-Lou en Niels bedanken voor dat jullie door weer en wind 
tijdens weekenden en avonden patiënten in PAIS hebben geïncludeerd.
Minah Ngoredjo
Bedankt voor de samenwerking en het maken van alle onderzoeksafspraken.
Elza van Deel, Monique de Waard, Maaike te Lintel Hekkert, Patricia Specht
Beste Elza, Monique, Maaike en Patricia, bedankt voor jullie ondersteuning in het lab en 
met resultaat; het herseninfarctmodel is er!
Studenten
Joram van Rossum, Evita van den Herik en Arezo Mohamad
Beste Joram, je volhardenheid en enthousiasme hebben geleid tot mooi resultaat. Suc-
ces met je verdere carriere! 
Evita, je altijd goede humeur, enthousiasme en gedrevenheid zijn opvallend.
Inmiddels ben je al bijna weer een jaar promovendus, succes met het vervolg! 
Arezo, bedankt voor je ondersteuning bij het verzamelen van de data in Amersfoort, 
zodat het me toch nog lukte om tijdens de laatste dagen van mijn onderzoek alles nog 
compleet te krijgen.
Patrick Hessels
Beste Patrick, heel erg bedankt voor de mooie omslag!
Vrienden en collega’s
Velen verdienen dank voor het zorgen voor de nodige afleiding tijdens de promotietijd.
Allereerst mijn cordialgenoten en studievrienden. Bedankt voor jullie nooit aflatende 
interesse in mijn werkzaamheden. Het woord stroke is de afgelopen jaren vaak gevallen. 
De vakanties, weekenden weg, uitstapjes en vele etentjes waren een welkome afwisseling.
Ireen, bedankt dat je altijd voor me hebt klaar gestaan en voor je luisterend oor. Je altijd 
goede humeur en je zeer positieve kijk op het leven bewonder ik.
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Maaike, je bent me in dit traject voor gegaan en je wist me altijd op de juiste momenten 
weer op te beuren en zoals jezelf al zei: het gaat echt lukken! 
Ilse, het sporten zorgde voor een goede ontstresser. Bedankt voor je interesse en steun. 
Volgend jaar zul jij hier staan.
Mijn collega’s van de neurologie, dank jullie wel voor jullie steun zowel op de werkvloer 
als bij de borrels. Ik weet dat ik jullie de laatste maanden van dit proefschrift heb ver-
waarloosd, gelukkig heb ik nog voldoende tijd om het goed te maken.
Paranimfen Rosalie Kemps en Janet de Beukelaar
Rosalie, ook al begrijp je mijn voorliefde voor het onderzoek niet helemaal, ik ben super-
blij dat je bereid bent om me naast alle steun van de afgelopen jaren ook in dit laatste 
traject en op de dag van de promotie bij te willen staan.
Janet, je nimmer aflatende enthousiasme en organisatietalent zijn opvallend.
Bedankt voor je steun en relativerende vermogen tijdens de afgelopen jaren. 
Ik prijs me gelukkig met jullie als paranimfen!
Mijn familie
Lieve papa en mama, jullie hebben me altijd volop de ruimte gegeven om me persoonlijk 
te ontwikkelen. Jullie hebben me de kans gegeven om naast de studie geneeskunde ook 
biomedische wetenschappen af te maken. Ik ben jullie dankbaar voor jullie vertrouwen 
en voor alles wat ik van jullie heb meegekregen.
Zusje, lieve Annemieke, bedankt voor je onvoorwaardelijke steun.
Oma en opa Schoemaker, bedankt voor jullie liefde, vertrouwen en interesse in alles wat 
mij bezig houdt. Jullie hebben me altijd gestimuleerd om me te ontwikkelen en door te 
zetten. Helaas kan opa er op deze promotiedag niet bij zijn.
Oma den Hertog bedankt voor uw betrokkenheid en liefde.
Mijn schoonfamilie, bedankt voor jullie belangstelling, liefde en begrip. 
Michiel Proper
Lieve Michiel, ik kan je niet genoeg bedanken. Je was een enorme steun de afgelopen 
jaren. Bedankt voor je altijd luisterend oor, liefde en geduld. Je wist me altijd weer op te 
beuren,”it is not what happens, but what you do that makes the difference”.
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PHD PORTFOLIO-SUMMARY OF PHD TRAINING AND TEACHING ACTIVITIES
Research School: COEUR
Work load Year (ECTS)
Research skills 
Classical methods for data analysis, Nihes, Rotterdam, NL 2005 5.0 
Regression analysis, Nihes, Rotterdam, NL 2007 1.4
Repeated measurements, Nihes, Rotterdam, NL 2008 1.4
Advanced analysis of prognostic studies, Nihes, Rotterdam, NL 2008 1.4
Animal experimentation, Experimental Animal Center, 
Rotterdam, NL
2007 3.0
In-depth courses
Cochrane course, Cochrane Center, Amsterdam, NL 2006 0.4
PhD courses (5x) and seminars (5x) at COEUR, Rotterdam, NL 2005-2009 9.5
Summer school neurovascular diseases, Barcelona, Spain 2007 2.0
Neuroimmunology, Department of immunology, Rotterdam, NL 2008 1.5
SNP Course V, MolMed, Rotterdam, NL 2008 1.5
Animal models for the study of neurological diseases, 2008 2.0
DIMI, Barcelona, Spain
Neurovascular seminar (3x), Utrecht, NL 2005-2008 2.0
Neurovascular meetings (3x) and seminars (2x), Utrecht NL  
Grant applications introduction and advanced course 2008-2009 1.5
MolMed, Rotterdam, NL 
NWO talent class “grant applications” 2009 1.0
NWO talent day, Utrecht, NL 2009 0.4
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(Inter)national conferences: participation and presentations
European Stroke Conferences, Brussel, Belgium; Glasgow, UK; 
Nice, France; poster presentations “Paracetamol 
(Acetaminophen) In Stroke (PAIS study), ongoing trial.”
2006-2008 3.0
COEUR seminar, Erasmus MC, Rotterdam, NL; oral presentation 
“Neuroprotection in acute stroke” 
2007 0.4
International meeting, Charite, Berlin, Germany; oral presenta-
tion “Acute stroke and candidate peptides.”
2007 1.5
COEUR seminar, Erasmus MC, Rotterdam, NL; oral presentation 
“Stroke induced immunodepression: from clinical experiments 
to animal experiments”
2008 0.4
European Stroke Conference, Nice, France; oral presentation 
“Cooling therapy for acute stroke.”
2008 1.0
European Stroke Conference, EURO-COOLS meeting, Nice, 
France;  Oral presentation “Cooling therapy for acute stroke: 
lessons from a cochrane review.”
2008 1.0
European Stroke Conference Nice, France; poster presentation 
“C-reactive protein in acute ischemic stroke: relationship with 
short term outcome.”
2008 1.0
World Stroke Conference, Vienna, Austria; oral presentation 
late breaking news session “Paracetamol (acetaminophen) 
In Stroke (PAIS) trial: A multicenter randomized double blind 
placebo-controlled trial.”
2008 1.5 
European Stroke Conference, Stockholm, Sweden; oral pre-
sentation “An early rise in body temperature rather than initial 
body temperature is related to functional outcome and death 
after stroke.”
2009 1.0
European Stroke Conference, Stockholm, Sweden; poster 
presentation “Safety and feasibility of treatment with metfor-
min in patients with TIA or minor ischemic stroke and impaired 
glucose tolerance: a randomized, open-label phase II trial.” 
2009 1.0
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Research projects abroad
Animal models of ischemic stroke
Research group of prof.dr. M. Endres, Charite, Berlin, Germany  2007 4.0
Research group of dr. A.M. Planas, Hospital clinic, Barcelona, 
Spain 
2008 2.0
Teaching activities
Supervising 
Research projects of medical students at Erasmus MC 
“C-reactive protein acute ischemic stroke: relationship with 
short term outcome.”
2007 6.0
“Hemostatis and inflammation in stroke.” 2007-2008 6.0 
Lecturing
Teaching PhD students at COEUR “Vascular clinical epidemiol-
ogy”, Erasmus MC, Rotterdam, NL
2008 0.4
Other
Organization and coordination of research seminars, Depart-
ment of Neurology, Erasmus MC, Rotterdam, NL 
2009 0.5
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Stroke ranks second as a cause of death worldwide and is a leading cause 
of disability in high-income countries. Treatment of ischemic stroke 
and intracerebral hemorrhage has remained unsatisfactory. Apart 
from stroke unit care, intravenous thrombolysis with recombinant 
tissue-plasminogen activator and aspirin are efficacious in patients 
with ischemic stroke, and there is no treatment for intracerebral 
hemorrhage with proven efficacy. Safe, cheap, and broadly applicable 
therapies for acute stroke are needed.
Over the past years, evidence has accumulated that inflammation plays 
a role in the pathophysiology of acute stroke. Body temperature and 
classic acute-phase reactants are modified by this inflammatory reaction, 
and both may be useful in the prediction of the prognosis after stroke 
and as therapeutic targets. This thesis focuses on body temperature and 
temperature-lowering therapy in acute stroke. A secondary aim is to 
further expand the knowledge on inflammation in relation to prognosis 
and treatment in acute stroke.  
